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Summary 
 
 The main focus of this thesis is the stereoselective funtionalization of cyclopropenes 
mainly via the addition of H-X (hetroatom-hydrogen) moieties across the strained double bond. 
It is broken up into three chapters, each one devoted to different methods all wing for direct 
funtionalization of these uniquely interesting and highly reactive carbocycles. 
 The first chapter is devoted to the palladium catalyzed hydrophosphorylation and 
hydrophosphinylation of cyclopropenes. This methodology allows for the direct r ng retentive 
funtionalization of cyclopropenes with a pronucleophilic entity, which up until now has been 
extremely scarce. Aside from the synthetic value, the methodology also provides access to highly 
funtionalized stereodefined cyclopropylphosphonates which have a proven track record as 
medicinaly relevant substrates. 
 The second chapter focuses on intermolecular formal nucleophilic substitutions of 
bromocyclopropanes. This method aims for the construction of highly functionalized 
cyclopropyl ethers via direct nucleophilic attack of O-based pronucleophiles to in situ generated, 
highly reactive cyclopropene intermediates. The diastereoselectivity of the reaction is controlled 
either by sterics or through directing effects providing highly streo-defined donor-acceptor 
cyclopropanes. 
 Chapter three describes highly efficient and diastereoselective medium ring closures 
occurring upon intramolecular attack of a tethered alkoxide nucleophile at bromocyclopropane.  
The reaction proceeds via initial 1,2-dehydrobromination to produce a cyclopropene 
xxv 
 
 
intermediate, followed by nucleophilic addition  across the strained C=C bond, to produce 
cyclopropane-fused medium heterocycles.   
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Chapter 1. The Diastereoselective Palladium Catalyzed Hydrophosphorylation and 
Hydrophosphinylation of Cyclopropenes 
 
1.1. Introduction 
 
1.1.1. Transition metal assisted additions to cyclopropenes 
 
 The rich and versatile chemistry of cyclopropenes has been extensively explored. These 
three-membered carbocycles are extremely important versatil  bu lding blocks for organic 
chemistry1. Their unique structural and electronic properties give rise to a variety of very 
interesting, characteristic transformations. The increased strain and π-density of its double bond 
makes cyclopropene a very attractive substrate for π-acceptor transition metals and allows for 
reactivity unknown for olefins, allenes and alkynes. Employment of catalysts allows for 
controlling and fine-tuning of the diastereo- and enantioselectivity as well as the efficiency of the 
reaction. Thus, several recent advances have been made in the transition metal-catalyzed 
chemistry of cyclopropenes which is a quickly developing area and is the primary focus of many 
research groups.2 The inherent strain of cyclopropene presents a challenge in the design of 
reaction processes in which the integrity of the strained carbocycle is not sacrificed. Several 
elegant metal assisted additions to cyclopropene have been recently d veloped, in which 
stereodefined densely substituted cyclopropanes are efficiently accessed via hydrometalations, 
2 
 
 
hydroboration, dimetalations, carbometalations, hydroformylation, and hyroacylation      
(Figure 1).  
 
Figure 1. 
 
 
 
 
1.1.2. Carbometalations of cyclopropenes 
 
 In 2000, Nakamura demonstrated that the use of an iron catalyst facilitated 
carbomagnesation of cyclopropenone acetals 1 with a wide range of Grignard reagents, including 
aryl- and alkenylmagnesium halides (Scheme 1.). 
3 
 
 
 Nakamura has also shown catalytic asymmetric carbozincation of cyclopropenone 
acetals in the presence of an iron catalyst and chiral phosphine liga ds. Interestingly, addition of 
TMEDA was necessary for achieving high enantioselectivities, as racemic products were 
obtained in the absence of this additive3. Both cyclopropyl magnesium 2 and cyclopropyl zinc 
species 3 were efficiently trapped with a variety of electrophiles to furnish tetra-substituted 
cyclopropanes. 
 
Scheme 1. 
 
OO
RMgX
cat. FeCl3
OO
R Mg
E+
OO
R E
R2Zn
cat. FeCl3/L
*
OO
R Zn
OO
R E
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56-96% yield
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R = Alk, Ar
E = H, Alk, allyl
1 2
5
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In 2002, Fox reported a directed carbomagnesation of hydroxymethylcyclopropenes 7 in 
the presence of copper catalysts (Scheme 2). Alkyl and vinyl Grignard reagents reacted smoothly 
in this reaction, generally providing very good syn-selectivity. Trapping the 
4 
 
 
cyclopropylmagnesium intermediate with different electrophiles alowed for easy installation of 
various functional groups in the three-membered ring.4 
 
Scheme 2.  
 
 
Later in 2006 Fox demonstrated the diastereo- and enantioselective carbomagnesiation 
reaction of 3-hydroxymethylcyclopropenes 9 in the presence of organic chiral catalyst 10 
(Scheme 3). As opposed to previous studies this method allowed for the addition of a wide 
variety of Grignard reagents. This highly stereoselective transformation permits rapid access to 
non-racemic tri- and tetrasubstituted hydroxymethylcyclopropanes 12.5 
 
Scheme 3. 
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The use of Grignard reagents in carbomagnesiation reactions makes them incompatible 
with cyclopropanes bearing ester functions. In a recent study Fox demonstrated the 
diastereoselective carbozincation of cyclopropenes in which the diastreo electivity is efficiently 
directed through the ester functionality (Scheme 4). Chiral oxazolidin ne functions direct the 
addition of a variety of nucleophiles with excellent facial selectivity. The regioselectivity is also 
high for carbozincation reactions of 2-alkyl-substituted cycloprop-2-ene carboxylate esters 13. 
The resulting cyclopropylzinc species 14 can be intercepted via stereospecific reactions with a 
variety of electrophiles.6 
 
Scheme 4. 
 
 
Lautens very recently showcased a highly enantioselective palladium-catalyzed 
carbozincation of cyclopropenes. The cyclopropyl zinc intermediates were successfully trapped 
with a range of electrophiles (Scheme 5). It was found that trapping of the cyclopropylzinc 
intermediate 17 with carbon electrophiles required transmetalation with copper.7 The flourene 
6 
 
 
derived cyclopropene 16 reacted smoothly to provide tetra-substituted cyclopropanes 18 with 
ee’s up to 93%. However, reactions with other types of cyclopropenes showed only marginal 
efficiency and selectivity. 
 
Scheme 5. 
 
 
 
1.1.3. Hydrometalations/dimetalations of cyclopropenes 
 
Gevorgyan reported on highly stereo- and regioselective transition metal-catalyzed 
hydrostannation of cyclopropenes to produce tri-, tetra-, and pentasubstituted 
cyclopropylstannanes  in very good yields (Scheme 6). This reaction proceeded with high cis-
selectively and with excellent facial selectivity controlled by steric factors. In all cases single 
diastereomers of cyclopropylstannanes were obtained (Scheme 6).8b 
  
7 
 
 
Scheme 6. 
 
 
  
It was also found that hydrosilylation8 of cyclopropene with trichlorosilane proceeds 
smoothly from the less hindered face in the presence of [(π-allyl)PdCl]2 and a bulky electron rich 
ligand, tris(2,6-dimethoxyphenyl)phosphine (TDMPP). Exhaustive alkylation of with MeLi 
afforded the corresponding cyclopropyltrimethylsilane in good overall yield. Efficient 
hydrosilylation and hydrogermylation with triorganometal hydrides proceed in the presence of 
catalytic amounts of PtCl2, affording cyclopropylsilanes and cyclopropylgermanes  in good to 
excellent yields. Steric factors efficiently govern the facial selectivity of this reaction. 
 Gevorgyan also disclosed catalytic asymmetric hydrostannation of 3,3-disubstituted 
cyclopropenes (Scheme 7)  in the presence of the Rh(I) complex bearing a chiral diamide9-based 
phosphine ligand 23.  Good yields, high degrees of diastereo- and enantioselectivity, and 
excellent functional group compatibility are the clear advantages of this approach. This 
methodology marks the first and only example of catalytic asymmetric hydrostannation known to 
date. 
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Scheme 7. 
 
 
 
 It was further shown by Gevorgyan that the rhodium catalyzed asymmetric hydroboration 
of 3,3-disubstituted cyclopropenes 24  affords cis-cyclopropylboronates 25 with perfect 
diastereoselectivity and very high enantioselectivity in contrast to he sterically controlled 
hydrostannation reactions, the enantio- and diastereoselectivities of the hydroboration were 
controlled by the directing effect of an ester or alkoxymethyl substituen s.  
 
Scheme 8. 
 
 
 
 Gevorgyan also demonstrated a highly diastereoselective Pd catalyzed silastannation and 
distannation of cyclopropenes 26 (Scheme 9). Analogous to the Pd catalyzed hydrostannation 
reaction, the facial selectivity of the dimetalation was entirly controlled by steric factors.  
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Remarkably, silastannation of cyclopropenes substituted at C-1 proceeded highly 
regioselectively with the stannyl moiety adding to the most hindered position.8b  
Scheme 9. 
 
 
 
 
1.1.4. Hydroformylation and hydroacylation of cyclopropenes 
 
The first catalytic diastereo- and enantioselective hydroformylation of cyclopropenes was 
demonstrated by Rubin in 2008 (Scheme 10).10 The reaction proceeds efficiently under very mild 
conditions and low catalyst loadings providing high yields of cyclopropylcarboxaldehydes 29. 
The reaction proceeded with good diastereoselectivity controlled throug  steric factors. The 
authors were also able to demonstrate an asymmetric version of this reaction reaching ee’s up to 
89%. Notably, the well known rhodium-catalyzed dimerization of cyclopropene 28 was avoided 
via employment of electron rich-phosphine ligands. This novel methodology represents a 
convenient, atom-economic approach toward optically active cyclopropylcarboxaldehydes 29 
from readily available prochiral cyclopropenes. 
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Scheme 10. 
 
 
 
Dong very recently reported an enantioselective desymmetrization of cyclopropenes via 
intermolecular Rh-catalyzed hydroacylation11 (Scheme 11). Cyclopropylketones 30 bearing 
quaternary stereocenters, are produced with diastereocontrol (up to 20:1) and excellent 
enantiomeric excess (up to 99 %ee). To achieve asymmetric induction, various chiral Josiphos 
ligands 32 were screened and among those tested, the more electron-rich and sterically bulky 
ligands gave better yields and enantioselectivity. The observed trans diastereoselectivity 
suggests that the reaction is sterically controlled analogous to the previously reported 
hydroformylation of cyclopropanes. 
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Scheme 11. 
 
 
 
1.1.5. Pronucleophillic additions to cyclopropenes 
 
While a number of elegant transition metal catalyzed transformations of cyclopropanes 
have been developed, examples involving the addition of a pronucleophilic species have been 
extremely scarce. Even more so are the transition metal catlyzed processes in which the 
integrity of the cycloropyl core is kept intact.  
In 2006, Chisholm reported the addition of alkynes to cyclopropenes utilizing palladium 
acetate and trimethylphosphonium tetrafluoroborate as a catalyst and triethylamine to promote 
both the release of free electron-rich phosphine and formation of alkynylpalladium species. 
These mild and neutral conditions permitted installation of functional groups such as aldehydes, 
carboxylic acids, and alcohols, which are incompatible with basic organ metallic reagents. 
However, the low diastereoselectivity observed with unsymmetrical gem-disubstituted 
cyclopropenes 33, affording a 2.5-3.5/1 mixture of trans/cis adducts 34, constitutes a major 
drawback of this coupling12 (Scheme 12). 
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Scheme 12. 
 
 
 
Tenaglia reported a marked improvement to this methodology by the employ ent of the 
Herrmann-Beller (H-B) phosphapalladacycle 37 which catalyzed the addition of terminal alkynes 
to unsymmetrical gem-disubstituted cyclopropanes 35 to give alkynylcyclopropanes 36 as single 
diastereomers in good to excellent yields (Scheme 13.).13 The stereofacial discrimination at the 
approach of the bulky alkynylpalladium species is believed responsible for the 
diastereoselectivity control of the addition reaction. This was supported by the addition of 
deuterated alkynes in which the alkyne and the deuterium were found t be exclusively cis in 
relation (Scheme 14). 
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Scheme 13. 
 
 
 
The authors propose plausible mechanism for the coupling of cyclopropanes with 
terminal alkynes which starts with the mononuclear palladacycle 37b via the dissociation of the 
Herrmann-Beller phosphapalladacycle 37. The alkynylpalladium species 38 could be formed in 
the presence of alkyne with the loss of acetic acid. Coordination of the cyclopropene double 
bond followed by the syn carbopalladation afforded cyclopropylpalladium species 39, which 
upon protolytic cleavage with acetic acid releases the alkynylcclopropane 36 and regenerates  
the catalytic species 37b (Scheme 14.). 
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Scheme 14. 
 
 
The pioneering studies performed by Chisholm and Teneglia13 were essentially the sole 
examples of the transition metal-catalyzed pronucleophilic additions to cyclopropenes with 
retention of the strained cycle (Schemes 12 and 13). In contrast to these studies, in 2006, 
Yamamoto reported the palladium-catalyzed addition of carbon- and nitrogen-based 
pronucleophiles to 3,3-dihexylcyclopropene 40.14 The reaction occurred at elevated temperatures 
and was accompanied by ring opening, yielding olefins 45 similar to those obtained through 
Tsuji-Trost reactions. The proposed mechanistic rationale involved oxidative addition of a Pd(0) 
species into the C-C bond of cyclopropene 40 to give palladacyclobutene intermediate 42. The 
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latter, after reaction with a pronucleophile, afforded -allylpalladium species 43. An alternative 
suggested pathway involved oxidative addition to give Pd(II) species 44 followed by 
hydropalladation of the strained cyclopropene double bond to give species 44 which undergoes a  
thermally induced isomerization into the π-allylpalladium complex 43. Reductive elimination 
from the latter produced allylic products 45 in moderate to good yields. 
 
Scheme 15. 
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1.1.6. Cyclopropyl-Phosphorus Compounds 
 
For many years clopropylphosphonates and cyclopropylphosphonic acids have been the 
subject of interest for a variety of reasons. They have been prepared as mimics of 1-
aminocyclopropane carboxylic acid (α-ACC) with a high inhibitory activity for the ACC-
deaminase and alanine racemase,15 as analogues of (–)-allonorcoronamic acid33, as structural 
moieties of nucleotides, as potential herbicides or plant growth regulators, as potential 
insecticides16, as phosphonic analogues of the antidepressant Milnacipran17 and as constrained 
analogue of the GABA antagonist phaclophen.31  Derivatives of cyclopropylphosphonic acid also 
make attractive targets for drug discovery, as they are many examples of such structures among 
biologically active compounds (Figure 2) including antiproliferative,18 antiviral,19,20 and anti-
malarial agents.21  
 
Figure 2. 
 
 
 
17 
 
 
Cyclopropylphosphines have received attention as ligands for asymmetric catalysis since 
this class of ligands offer an advantageous combination of structural rigidity, low molecular 
weight on a well-defined and highly variable platform with unusual bond angles. Moreover, 
recent improvements in the stereoselective synthesis of this ring make exploring the use of 
cyclopropanes even more attractive. Minami and co-workers evaluated cyclopropyl based 
diphosphine ligands in an asymmetric allylic alkylation achieving up to 61% ee (Scheme 16).22 
Later, in 2004, Molander and co-workers also evaluated cyclopropyl phosphine liga ds in the 
same reaction, reaching very high yields of the products 47 in 93 % ee (Scheme 16).23 
 
Scheme 16. 
 
 
 
Rubin recently employed a novel class of chiral phosphanyl-oxazoline (PHOX) ligands 
with a conformationally rigid cyclopropyl backbone which were tested in the intermolecular 
asymmetric Heck reaction (Scheme 17). Dramatic stereo- and enantiodivergent effects resulting 
from subtle modifications to the ligand structure were observed providing ee’s up to 98 %.24  
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Scheme 17. 
 
 
 
1.1.7 Synthesis of cyclopropylphosphines and phosphonates 
 
 Derivatization of an existing cyclopropane scaffold including reactions of P-nucleophiles 
with cyclopropanone equivalents25 (Scheme 20) or P-electrophiles with cyclopropylmetals ( 
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Scheme 18)26 offer routes to cyclopropyl phosphorus moieties, however, the efficiency of these 
methods is dramatically decreased with increasing steric demand around the cyclopropyl core. 
 
Scheme 18. 
 
 
 
Easily accessible bromo and iodo-cyclopropane59,60 such as 48 readily undergo 
halo/lithium exchange without rearrangement upon treatment with tert-butyllithium in diethyl 
ether/pentane at –78 °C, and the resulting 1-lithio-cyclopropane can be trapped with various 
electrophiles. Molander23 (Scheme 19) and others24,27 have utilized electrophillic trapping 
chlorophosphines in the synthesis of various cyclopropyl- based phosphine ligands. 
 
Scheme 19. 
 
 
Fadel and co-workers reported an interesting approach for the synthe is of a wide variety 
of chiral aminocyclopropanephosphonic acids from readily available cyclopropyl acetals 50.28 
The acetals serving as cyclopropanone equivalents are converted into im nium salts 51 in the 
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presence of a chiral amine and acid which then undergo an Arbuzov reaction wi h trialkyl 
phosphite 52 to give the corresponding phosphonates 53 in moderate yields (Scheme 20). 
 
Scheme 20. 
 
 
 
 The stereoselectivity was controlled through the kinetic differentiation of diastereotopic 
faces, bulky substituents provided poor yields and good facial selectivity. Decreasing the steric 
demand increased yield but unfortunately dramatically dereased the facial selectivity (Scheme 
20). 
Michael-initiated ring closure (MIRC) as well as related 1,3-cyclizations have been 
utilized in the synthesis of a wide variety of cyclopropyl phosphonates.29 For example, the 
reaction initiated by a Michael addition of a phosphite species onto a α-halo Micheal acceptor 54 
afforded carbanion 55, which undergoes an intramolecular 1,3-cyclization to furnish 
phosphonates 56 in a modified Arbuzov reaction (Scheme 21).  
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Scheme 21. 
 
 
 
  
 α-Halomethyl phosphonates in the presence of base also undergo Michael addition to α,β-
unsaturated carbonyls followed by intamolecular cyclization to furnish cyclopropyl 
phosphonates This methodology was utilized by Swamy via a stereoselective synthesis of 
cyclopropylphosphonates from the reaction of readily accesible α-chlorophosphonates with alkyl 
acrylates and fumarates in the presence of sodium hydride.30 Similarly, in 1997 a report by 
Hanessian demonstrated the stereocontrolled conjugate addition of anions der ved from chiral α-
chlorophosphonamides 57 to α,β-unsaturated esters 58  leading to the corresponding 3-chloro 
ester adducts which undergo intramolecular expulsion of the chlorine atom to give constrained 
analogs of the GABA antagonist Phaclophen59 (Scheme 22).31 
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Scheme 22. 
 
 
 Cyclopropyl phosphine oxides/phosphonates may also be prepared via related 1,3 
cyclizations32 which  often involve nucleophillic attack on dibromoethane by a phospha-
methylene carbanion followed by intramolecular nucleophilic displacement (Scheme 23).   
 
Scheme 23. 
 
 
 
An interesting variation of this reaction was developed, for the synthesis of (1R,2R)-1-
amino-2-methylcyclopropanephosphonic acid 62 which was  achieved via the intramolecular 
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cycilzation of α-methylene phosphonate 61.33 The use of a non-racemic sulfonate ester 60 
allowed for the efficient construction of the allo-norcoronamic acid derivative 62 in 99% ee.      
 
Scheme 24. 
 
 
Various other 1,3-cyclizations have been reported.34 For example, 2-vinyl cyclopropyl 
phosphonates 64 have been prepared via the reaction of trans-1,4-dibromo-2-butene with 
phosphonates 63 via an intramolecular cyclization of in situ generated alkylphosphonate anions 
(Scheme 25).35  
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Scheme 25. 
 
 
 The synthesis of cyclopropyl phosphorus moieties 67 spans various modes of 2+1 
cycloadditions.36 One very common method for the synthesis of cyclopropanes, the metal-
catalyzed decomposition of diazocompounds in the presence of alkenes, has not been extensively 
applied to the synthesis of cyclopropylphosphonates. A few copper,37 rhuthenium,38 and 
rhodium39 catalyzed cycloaddions with diazomethylphosphonate 66 (DAMP) derivitives have 
been reported (Scheme 26). 
 
Scheme 26. 
 
 
 
Reactions of diazocompounds with vinyl phosphonates 68 are less prevalent,40 however, 
studies have shown [2 + 3] cycloadditions with diazomethane to afford phosphonylated 
dihydropyrazoles 6941 which upon heating provide cyclopropyl phosphonates 70. Beletskaya and 
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co-workers demonstrated this as a facile method accessing a rare class of cyclopropyl 
phosphonates.42 This reaction is of interest since very few methods enable the synthesis of 
cyclopropyl phosphonates in the absence of electron withdrawing groups (Scheme 27). 
 
Scheme 27. 
 
 
 
In 2004 Davies and coworkers demonstrated the enantioselective synthesis of 
cyclopropylphosphonates 73 with good yields and high enantioselectivity via metal-catalyzed 
decomposition of diazo compounds 72 in the presence of alkenes 7143 (Scheme 28). It is the 
most general method for enantioselective preparation of cyclopropyl hosphonates. Prior to this 
study only one example of enantioselective intermolecular cyclopropanation was known; the 
reaction of diisopropyl diazomethylphosphonate with styrene in the presenc  of a Ruthenium 
porphyrin complex affording marginal enantioselectivity.44 
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Scheme 28. 
 
 
 
Intramolecular versions of this transformation have also been reported, yielding bicyclic 
fused cyclopropylphosphonates 76.45  For example, Mann and co-workers developed a simple 
and expeditive route toward the synthesis of constrained cycloalkyl analogues of glutamic acid 
77 utilizing a rhodium catalyzed intramolecular cyclopropanation of vinyl phosphonate 75. 
(Scheme 29).46 
 
Scheme 29. 
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 Hanson and co-workers have explored diastereoselective intramolecular 
cyclopropanations47 with enantiopure allylic diazophosphonates 78, in which a double 
diastereotopic differentiation strategy on a phosphonoacetate templat was described. The 
approach utilizes Rh2(OAc)4 catalyzed intramolecular cyclopropanation (ICP) employing the 
(R)-pantolactone auxiliary 80 in the ester functionality of the phosphonoacetate. The olefinic 
diastereofacial selectivity of the bicyclic phosphonate 79 is governed by electronic and steric 
interactions in the reacting carbene intermediate, while the group selectivity is dictated by the 
chiral auxiliary (Scheme 30).  
 
Scheme 30.  
 
 
 
Other modes of [2+1] cycloaddions have been employed in the synthesis of 
cyclopropylphosphonates, including those involving Lewis acid activation (Scheme 31b)48 as 
well as Fischer carbenes (Scheme 31a).49 
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Scheme 31. 
 
 
Cycloadditions involving sulfur ylides have also been reported. In 2003, Mikolajczyk 
described asymmetric cyclopropanation of chiral phosphorylvinyl p-to ylsulfoxide 81 with ethyl 
(dimethylsulfuranylidene) acetate 82 (EDSA).50  
 
Scheme 32. 
 
 
 
Corey-Chaykovsky reactions with sulfoxonium ylides have reported with 
phosphonoacrylates.51 The cyclopropanation of aryl-phosphonoacrylates 84 with 
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dimethyloxosulfonium methylide 85 afforded trans cyclopropane derivatives 86 with high 
diastereoselectivity (Scheme 33). 
 
Scheme 33. 
 
 
Stable, enantiopure (phosphanyl)(silyl)carbenes 88, generated from the decomposition of 
diazo compound 87 react efficiently with acrylates  giving the corresponding cyclopropanes 89 
in good yields.  All monosubstituted alkenes provided exclusively the syn isomer with respect to 
the phosphanyl group, and the addition to disubstituted alkenes was totally stereospecific 
(Scheme 34).52  
 
Scheme 34. 
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Some exceptional methods have been developed including electrochemical53 and 
selective rearrangements.54 Recently Rubin55 and Marek56 independently reported on a novel 2,3-
rearrangement of cyclopropenylmethyl phosphinites  to methylenecyclopropylphosphine oxides 
(Scheme 35). Marek reported the reaction was thermally activated however, Rubin found that in 
striking contrast to the analogous rearrangement known for nonstrained llylic systems, the 
reaction does not proceed at all upon thermal activation; however, it can be efficiently mediated 
by Lewis bases. Unique stereoelectronic effects control the diastereoselectivity of this 
transformation, leading to predominant formation of the more sterically hindered products of 
densely substituted methylenecyclopropylphosphine derivatives. This methodology represents a 
valuable alternative to the existing approaches. 
 
Scheme 35. 
 
 
 
While a number of methods have been developed for the preparation of cycl propyl 
phosphonates, few methods have demonstrated broad scope, stereoselectivity and efficiency 
simultaneously. The high demand as well as the lack of general synthetic methods prompted the 
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exploration of a new synthetic tool which would allow access to a wide variety of 
cyclopropylphosphonates and phosphine oxides.  
1.2. Results and Discussion 
 
1.2.1. Initial studies 
 
Investigations into possible reaction conditions towards cyclopropylphosphonates began 
with different modes of possible addition of phosphonate species to cyclopropene. Thus, thermal
radical and base initiated reactions between 3-methyl-3-phenylcyclopropene 91a and 4,4,5,5-
tetramethyl-2-oxo-1,3,2-dioxaphospholane 92 were attempted and did not yield addition to the 
strained double bond (Scheme 36). Intrigued by the palladium catalyzed pronuclephillic 
additions to cyclopropanes reported by Yamamoto (Scheme 15), we began our investigations of 
the ring retentive palladium catalyzed hydrophosphorylation of cyclopropenes. 
 
Scheme 36. 
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 Our optimizations began with cyclopropene 91a and phosphonate 92 in the presence of 
various palladium sources and phosphine ligands (Table 1). Our intitial reaction conditions with 
Pd(OAc)2/PPh3 in dioxane at 100 
oC  (Table 1, entry 4) provided allylphosphonate 93a as the 
sole product. Most catalytic systems tested provided sluggish reactions with mixtures of ring 
retention to ring opening. Gratifyingly, employment of Pd(0) sources allowed for reactions at 
lower temperatures and provided ring retentive hydrophosphorylation of cycl propenes.   In the 
case of relatively electron rich cyclopropenes 91, we were able to drive the exclusive formation 
of allylphosphonates 93 a-c at high reaction temperatures even in the presence of a Pd(0) source
(Scheme 37). 
 
Scheme 37. 
 
 
 Varying the structural and electronic properties of the ligand had a marked affect on the 
outcome of the reaction. For example, TTMPP with Pd2dba3·CHCl3 only yielded a 13% GC 
conversion to desired phosphonate 94.  Employment of the electron-rich bidentate ligand dppf 
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provided 98% GC conversion to phosphonate 94 (Table 1 entry 8). However only a moderate 
facial selectivity of 4:1 (trans:cis) was observed. Employment of this catalytic system in the 
reaction of phosphonate 92 in the presence of  cyclopropene 91b bearing an electron 
withdrawing carboxylate functionality provided nearly quantative conversion with excellent 
facial selectivity of 19:1 (Table 1, entry 11), while Pd(PPh3)4 provided only 3:1 facial selectivity 
(Table 1, entry 10).  
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Table 1. Optimizing conditions for ring retentive hydrophosphorylation. 
 
 
no. R catalyst 94, % 
(trans/cis)b 
93, 
%b 
1 Ph (-allylPdCl)2/TTMPP
c 60 (2.5:1) 10 
2 Ph (π-allylPdCl)2/ PPh3 7 (N/D) - 
3 Ph Pd(OAc)2/TTMPP 45 (15:1) 40 
4 Ph Pd(OAc)2/PPh3
d 0 90 
5 Ph Pd(OAc)2/ PPh3 30 (4.5:1) 34 
6 Ph Pd2dba3·CHCl3/TTMPP 13 (N/D) - 
7 Ph Pd2dba3·CHCl3/dppe NR - 
8 Ph Pd2dba3·CHCl3/dppf 98 (4:1) - 
9 Ph Pd(PPh3)4 89 (19:1) 6 
10 CO2Me Pd(PPh3)4 100 (3:1) - 
11 CO2Me Pd2dba3·CHCl3/dppf 97 (9:1) - 
 
   (a) Reactions performed on a 0.1 mmol scale. (b) GC conversion.   
   (c) TTMPP - tris(2,4,6-trimethoxyphenyl)phosphine. 
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1.2.2. Hydrophosphorylation of cyclopropenes 
 
 We then set out to investigate the scope and limitations of the reaction with the optimized 
reaction conditions in hand. The installation of electron withdrawing groups at C-3 had a 
significant effect on the outcome of the reaction. For example, carboxylate and carboxamide 
substituted cyclopropanes did not provide allylphosphonate products even at elev ed 
temperatures in the presence of Pd(II) sources. In contrast to the phenyl-substituted analog, these 
more stable carboxylate substituted cyclopropenes reacted smoothly at rt within 1-2 hrs 
providing densely substituted cyclopropyl phosphonates in excellent yields an  good facial 
selectivities. 3-Carboxamide substituted cyclopropenes required slightly elevated temperatures 
(Scheme 38). 
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Scheme 38. 
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 The diastereoselectivity of hydrophosphorylation was controlled by sterics, as evident 
from the comparison of the results obtained using 1-methyl-substituted 
cyclopropenylcarboxylates 91b-d with those of the 1-phenyl- (91e) and 1-TMS-substituted 
analogs (91f).  Indeed, while the reactions of cyclopropenes 91b-d predominantly provided 
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products 94a-d in a trans-configuration, introduction of the bulky phenyl substituent in the 
structure (91e) led to a significant deterioration of the diastereoselectivity (94e).  Finally, 
installation of an even larger TMS-group (91f) resulted in reversal of diastereoselectivity, 
affording cyclopropyl phosphonate 94f with the phosphorus moiety oriented cis with respect to 
the ester function. 
 
1.2.3. Hydrophosphinylation 
 
The recent advances in the development of cyclopropyl based phosphine liga ds23, 24 
prompted us to explore the possibility of hydrophosphinylation. To our delight the conditions 
optimized for hydrophosphorylation also proved efficient for the hydrophosphinylation reaction 
(Scheme 39).  The reactivity pattern was similar to that observed in the hydrophosphorylation 
reaction. Thus, ester 91b underwent the transformation quickly at room temperature, while 
reaction of amides 91i and 91l required extended heating at 50-55 oC for complete conversion.  
Importantly, in all three cases the corresponding cyclopropylphosphine oxides 96a-c were 
obtained in excellent yield as single diastereomers (Scheme 39). 
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Scheme 39. 
 
 
Reaction conditions.61a: 1 h at 25 oC; 61b: 48 h at 55 oC; 61c: 78 h at 50 oC. 
 
 
1.2.4. Investigation of the reaction mechanism 
 
 Subjection of deuterated cyclopropene 91a-d2 to the optimized reaction conditions 
provided a mixture of two diastereomers 94a-d2 and 94a-d2 (Scheme 40). In both cases the 
deuterium labels were found to have a relative c s relationship to each other. This is experimental 
evidence that the reaction mechanism involves a syn-specific concerted hydropalladation step. 
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Scheme 40. Hydrophosphorylation of dueterated cyclopropene 
 
 
 
Based on these observations a  plausible mechanistic rationale for this transformation is 
proposed (Scheme 41).  First, oxidative addition of palladium into the P-H bond produces 
palladium hydride species 98.   Subsequent migratory insertion of cyclopropene 91 affords 
cyclopropylpalladium complex 99.  The latter, upon reductive elimination (path A), produces 
cyclopropylphosphonate 94.  Alternatively, at higher temperatures, species 99 would undergo 
ring cleavage via β-carbon elimination (path B).  The resulting π-allylpalladium species 100, 
after reductive elimination, would affordallylphosphonate 93. 
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Scheme 41. Mechanistic rationale for the Pd-catalyzed hydrophosphorylation of cyclopropenes. 
 
 
 
This mechanism is supported by several observations. The steric control of the 
diastereoselectivity is evidence of the hydropalladation step, since coordination of cyclopropene 
91 to species 98 would favor the less hindered face providing the observed trans-selectivity. 
Also, the observation that cyclopropenes bearing electron withdrawing funtionalites did not 
provide ring opening products 93 could be explained by the destabilization of the π-
allylpalladium species 100.  It should also be noted that the installation of bulky ligands around 
the metal center facilitates reductive elimination thereby avoiding β-carbon elimination which 
would furnish allyl phosphonate 93.  
According to the mechanistic rationale proposed in Scheme 2, the diastreoselectivity of 
the reaction is controlled by steric factors at the hydropallad tion step 9899.  Since this step 
proceeds with release of strain energy, it should be irreversibl and, therefore, kinetically-
41 
 
 
controlled.  Thus, our experiments demonstrated that the diastereoselectivity in the 
hydrophosphorylation of cyclopropene 91e deteriorates at higher temperatures (Table 2), which 
is consistent with the proposed reaction mechanism. 
 
Table 2. Temperature Effect Observed in the Palladium-Catalyzed Hydrophosphorylation of 
91e. 
 
 
no. temperature, oC trans/cis ratio 
1 20 1.63:1 
2 40 1.60:1 
3 60 1.51:1 
4 100 1.10:1 
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1.3. Conclusion 
 
In conclusion, a novel, efficient transition metal-catalyzed method for iastereoselective 
addition of cyclic phosphites and phosphine oxides across the strained double b nd of cyclopro-
pene was developed. The formation of allylic phosphonates was avoided by mploying a 
Pd(0)/bulky ligand catalyst system which facilitates reductive elimination. The mechanism is 
supported by experimental evidence which insists on a hydropalladation step, thus providing 
insight as to the diastereoselectivity.   This transformation is applicable to a wide range of 3,3-
disubstituted cyclopropenes and is general with respect to the electronic nature of the P-H entity. 
The discovered method has great potential for providing expeditious acces to a series of novel 
functionalized cyclopropylphosphonic acids and cyclopropylphosphines.  
 
1.4. Experimental Procedures 
 
1.4.1. Materials and Methods. 
 
NMR spectra were recorded on a Bruker Avance DPX-400 instrument, equipped with a 
quadruple-band gradient probe (H/C/P/F QNP) or Bruker Avance DRX-500 with a dual 
carbon/proton cryoprobe (CPDUL). 13C NMR spectra were registered with broad-band 
decoupling. Signs (+) and (-) represent positive and negative intensities of signals in the 13C 
DEPT-135 or in phase-edited HSQC experiments. Column chromatography was carried out 
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employing silica gel (Selecto Scientific, 63-200 µm).  Pre-coated silica gel plates (Merck 
Kieselgel 60 F-254) were used for thin-layer chromatography. GC/MS analyses were performed 
on a Shimadzu GC-2010 gas chromatograph interfaced to a Shimadzu GCMS 2010 mass 
selective detector, and equipped with an AOC-20i auto-injector and an AOC-20S auto-sampler 
tray (150 vials).  30 m x 0.25 mm x 0.25 µm capillary column, SHR5XLB, 
polydimethylsiloxane, 5% Ph was employed.  Helium (99.96%), additionally purified by passing 
consecutively through a CRS oxygen/moisture/hydrocarbon trap (#202839) and VICI 
oxygen/moisture trap (P100-1), was used as a carrier gas.   
Anhydrous methanol was obtained from commercially available HPLC-grade solvent by 
double distillation from sodium metal chunks under inert atmosphere.  Anhydrous dioxane was 
prepared by refluxing commercially available ACS-grade product with sodium-ketyl complex, 
followed by distillation in slow stream of nitrogen.  Anhydrous dimethylsulfoxide was purchased 
form Sigma-Aldrich and used as received.  Palladium complexes and phosphine ligands were 
obtained from Strem Chemicals.  
 
1.4.2. Synthesis of cyclopropene carboxylates 
 
3-methyl-3-phenylcyclopropene 91a,57 methyl 1-phenyl-2-cyclopropenecarboxylate58 
91e, ethyl 3-(trimethylsilyl)-3-cyclopropenecarboxylate 91f ,57  dimethyl cycloprop-2-ene-1,1-
dicarboxylate 91g,10 and cyclopropenylcarboxamides113 were prepared according to published 
procedures. Syntheses of all other cyclopropenes are described in the following section. 4,4,5,5-
Tetramethyl-1,3-dioxaphospholane-2-oxide 92 was obtained from pinacol and PCl3 according to 
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the published procedure.58  All other chemicals were purchased from commercial sources and 
used as received.  
Esters of 1-methylcycloprop-2-ene-1-carboxylic acid were prepared according to the 
modified Baird-Bolesov protocol59, involving dehydrohalogenation of potassium 2-bromo-1-
methylcyclopropyl carboxylate.  This approach helps to circumvent problems associated with 
low stability of the ester function towards nucleophilic attack by tert-butoxide under the 
relatively harsh reaction conditions required for installation of the cyclopropene double bond.  
To a suspension of K2CO3 (50 g, 0.36 mol) in anhydrous MeOH (250 mL) was added 2-bromo-
1-methylcyclopropanecarboxylic acid 10160 (32.6 g, 0.18 mol) in 100 mL of MeOH.  The 
mixture was stirred overnight, filtered under pressure of dry nitrogen, and evaporated dry to 
obtain solid potassium 2-bromo-1-methylcyclopropyl carboxylate 102.  To completely remove 
the remaining methanol, the solid was powdered and dried in vacuum (< 1 torr) at 90-100 oC for 
15 hrs.   
 
Scheme 42: Synthesis of Cyclopropene Carboxylates 
 
 
 
45 
 
 
Methyl 1-methylcycloprop-2-ene-1-carboxylate (91b): Typical procedure. 
 Potassium 2-bromo-1-methylcyclopropyl carboxylate 101 (32.46 g, 149 mmol) was 
dissolved in 150 mL of anhydrous DMSO and added rapidly via a cannula to a solution of 
potassium tert-butoxide (20 g, 180 mmol) in 30 mL of DMSO (the solution was prepared by 
heating the mixture to 60 oC until the solid was dissolved, then cooling to 30 oC).  The mixture 
was stirred at 50 oC for 2 hrs.  Over this time, the reaction mixture turned very viscous and 
further stirring became impossible.  Then methyl iodide (37 mL, 0.6 mol) was added with 
cooling and the liquefied mixture was stirred for 30 min, quenched with wa er, and extracted 
with ether.  Combined organic solutions were washed with water, brine, dried over MgSO4, 
filtered, and evaporated.  The residue was distilled in vacuum (bp. 68-70 oC/ 5 torr) to provide 
8.64 g (77.1 mmol, 52%) of titled cyclopropene 91b. 1H NMR (400.13 MHz, CDCl3) δ 6.98 (s, 
2H), 3.63 (s, 3H), 1.37 (s, 3H); 13C NMR (100.67 MHz, CDCl3) δ 177.5, 109.9 (+, 2C), 51.9 (+), 
27.7, 21.7 (+). 
 
Allyl 1-methylcycloprop-2-ene-1-carboxylate (73c). 
The reaction was carried out according to the typical procedure, starting from 20 g (91.4 
mmol) of carboxylate 101 followed by quenching with allyl bromide (17.3 mL, 200 mol) instead 
of methyl iodide, to afford the titled cyclopropene as a colorless oil, b.p. 60-64 oC/10 torr.  Yield 
7.83 g, (56.7 mmol, 62%). 
1H NMR (400.13 MHz, CDCl3) δ 7.01 (s, 2H), 5.90 (ddt, J = 17.2 Hz, 10.6 Hz, 5.6 Hz 1H), 5.28 
(dq, J = 17.2 Hz, 1.5 Hz, 1H), 5.20 (dq, J = 10.6 Hz, 1.5 Hz, 1H), 4.55 (dt, J = 5.6 Hz, 1.5 Hz, 
2H), 1.41 (s, 3H); 13C NMR (100.67 MHz, CDCl3) δ 176.6, 132.4 (+), 117.4 (-), 109.8 (+, 2C), 
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65.2 (-), 27.7, 21.6 (+). GC/MS: m/z 138 (M+) <1%, 123 (M-Me) <1%, 97 (M-All) 15%, 53 
(M-CO2All) 100%. 
 
Benzyl 1-methylcycloprop-2-ene-1-carboxylate (91d).  
The reaction was carried out according to the typical procedure, sta ting from 2.0 g (9.14 
mmol) of carboxylate 101 followed by quenching with benzyl bromide (1.2 mL, 10 mmol) 
instead of methyl iodide, to afford the titled cyclopropene. Purification by preparative column 
chromatography on Silica gel (eluent hexane/EtOAc 20:1, Rf 0.31) afforded a colorless oil, yield 
687 mg (3.66 mmol, 40%). 
1H NMR (400.13 MHz, CDCl3) δ 7.43-7.31 (m, 5H), 7.04 (s, 2H), 5.13 (s, 2H), 1.46 (s, 3H);  
13C 
NMR (100.67 MHz, CDCl3) δ 176.8, 136.4, 128.4 (+, 2C), 128.9 (+), 127.7 (+, 2C), 109.8 (+, 
2C), 66.2 (-), 27.7, 21.7 (+);  GC/MS: m/z 188 (M+) <1%, 91 (PhCH2
+) <60%, 53 (M-CO2Bn) 
100%. 
 
1.4.3 Preparation of deuterium-labeled cyclopropene 
 
Scheme 43 
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94a-d2:  To a stirred solution of cyclopropene 91a (2.00 g, 15.4 mmol) in anhydrous 
hexanes (20 mL) at -30 oC was added a solution of n-butyllithium (2.5 M in hexane, 15.4 mL, 
38.5 mmol, 2.5 equiv).  The mixture was stirred for 30 min at 0 oC and quenched with deuterium 
oxide (3 mL, 150 mmol, 9.7 equiv).  The organic phase was separated, dried over MgSO4, 
filtered, and concentrated.  The residue was distilled in vacuum (bp 60-62 oC at 10 torr) to afford 
62-d2 as a colorless oil.  Yield 1.80 g (13.6 mmol, 89%).  
1H NMR and EI MS analyses indicated 
a deuterium incorporation of 80-85% at both the C1 and C2 positions. 
 
1.4.4 Synthesis of Cyclopropylphosphonates 
 
Typical procedure A. 94a: In a nitrogen filled glove box, a dry 4 ml Wheaton vial 
was charged with palladium tetrakis (5.8 mg, 0.05 mmol, 10 mol%) and 2.0 ml of 
dioxane. 4,4,5,5-Tetramethyl-2-oxo-1,3,2-dioxaphospholane (82.0 mg, 0.5 mmol) 
was added and the resulting mixture was stirred for 1 min. Cyclopropene 91a (98 mg, 0.75 
mmol, 1.5 eq) was added and the reaction mixture was stirred for 1 hr at r.t. The solvent was 
removed in vacuum and purified by preparative column chromatography on silica gel, eluting 
with hexane: EtOAc 3:2 to afford 125 mg (0.43 mmol, 86%) of trans-94a. 
Typical procedure B. All loading operations were performed in a nitrogen-filled glovebox.  An 
oven-dried 2 mL Wheaton vial was charged with 1,1’-bis (diphenylphosphino)ferrocene (dppf) 
(27.7 mg, 0.05 mmol, 10 mol%), tris(dibenzylideneacetone) dipalladium chloroform adduct 
(12.9 mg, 0.025 mmol, 5 mol%), and dry dioxane (1 mL).  The mixture was stirred at r.t. for 5 
min, then 4,4,5,5-tetramethyl-2-oxo-1,3,2-dioxaphospholane (2) (82.0 mg, 0.5 mmol) and 
Me
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cyclopropene 91a (98 mg, 0.75 mmol, 1.5 equiv) were added.  The reaction mixture was stirred 
for 18 hrs at 55 oC.  When GC/MS analysis showed the reaction was complete, the mixture was 
filtered through a short bed of silica gel and concentrated in vacuum.  The residue was purified 
by preparative column chromatography on silica gel, eluting with hexane/EtOAc, 3:2 to afford 
131 mg (0.45 mmol, 71%) of major (Rf 0.20) and 19 mg (0.06 mmol, 11%) of minor (Rf 0.15) 
diastereomer. 
 Major  (trans-94a): 1H NMR (400.13 MHz, CDCl3) δ 7.33-7.30 (m, 4H), 7.25-7.21 (m, 
1H), 1.72 (s, 3H), 1.54 (s, 6H), 1.52-1.44 (m, 2H), 1.46 (s, 3H), 1.40 (s, 3H), 1.07 (ddd, J = 9.4 
Hz, 6.3 Hz, 4.8 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 146.1 (d, 
3JPC = 3.7 Hz), 128.5 (+, 
2C), 127.3 (+, 2C), 126.5 (+), 87.73, 87.66, 28.4 (d, 2JCP = 4.4 Hz), 24.7 (d, 
3JCP = 3.7 Hz, +), 
24.5 (d, 3JCP = 3.7 Hz, +, 2C), 23.9 (d, 
3JCP = 5.9 Hz, +), 22.2 (d, 
3JCP = 5.1 Hz, +), 20.7 (d, 
1JCP 
= 183.7 Hz, +), 19.6 (d, 2JCP = 5.1 Hz, -);  
31P NMR (161.98 MHz, CDCl3) δ 42.1; GC/MS (Rf = 
14.25 min) m/z 294 (1%, M+), 279 (1% M-Me), 211 (40%), 130 (100%); HRMS (TOF ES) 
Found 317.1286, Calculated for C16H23O3PNa (M+Na) 317.1283 (0.9 ppm). Minor  (cis-
94a): 1H NMR (400.13 MHz, CDCl3) δ 7.43 (d, J = 7.3 Hz, 2H), 7.32 (t, J = 7.3 Hz, 2H), 7.23 (t, 
J = 7.3 Hz, 1H), 1.79 (ddd, 3JHP = 19.7 Hz, JHH = 5.8 Hz, 4.6 Hz, 1H), 1.49 (d, 
4JHP = 2.3 Hz, 
3H), 1.46 (s, 3H), 1.42 (s, 6H), 1.37 (s, 3H), 1.26 (ddd, 3JHP = 10.1 Hz, JHH = 9.1 Hz, 4.6 Hz, 
1H), 1.01 (ddd, 2JHP = 5.1 Hz, JHH = 9.1 Hz, 5.8 Hz, 1H);  
13C NMR (100.67 MHz, CDCl3) δ 
141.4 (d, 3JPC = 5.1 Hz), 128.9 (+, 2C), 128.1 (+, 2C), 126.9 (+), 87.6, 86.9, 29.5 (d, 
3JCP = 4.4 
Hz, +), 29.3 (d, 2JCP = 4.4 Hz), 24.7 (d, 
3JCP = 2.9 Hz, +), 24.5 (d, 
3JCP = 4.4 Hz, +), 24.4 (d, 
3JCP 
= 5.1 Hz, +), 23.8 (d, 3JCP = 6.6 Hz, +), 21.9 (d, 
1JCP = 185.9 Hz, +), 18.5 (d, 
2JCP = 5.1 Hz, -);  
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31P NMR (161.98 MHz, CDCl3) δ 40.6; GC/MS (Rf = 13.91 min) m/z 294 (1%, M+), 279 (1% 
M-Me), 211 (30%), 130 (100%). 
 
94a-d2:  The reaction was performed according to the typical procedure B starting 
with 79 mg (0.6 mmol, 1.5 equiv) of cyclopropene 62-d2.  The residue was purified 
by preparative column chromatography on silica gel, eluting with hexane:EtOAc, 
3:2 to afford 77 mg (0.25 mmol, 63%) of major (Rf 0.20) and 40 mg (0.13 mmol, 
34%) of minor (Rf 0.15) diastereomer. 
 
94b:  The reaction was performed according to the typical procedure B, 
employing 91b (65mg, 0.5mmol). The crude residue was purified by 
preparative column chromatography eluting with EtOAc/hexanes (3:1) (Rf 
0.26). Yield: 110 mg, (0.40 mmol, 80%). 
1H NMR (400.13 MHz, CDCl3) δ3.72 (s, 3H), 1.62 (s, 3H), 1.60 (m, 1H), 1.51 (s, 3H), 1.50 (s, 
3H), 1.40 (s, 3H), 1.39 (s, 3H), 1.36 (m, 1H) 1.31 (m, 1H); 13C NMR (100.67 MHz, CDCl3) 
δ174.2(d, 3JCP = 4.4 Hz), 88.4, 88.1, 53.0 (+), 24.7 (d, 
2JCP = 2.9 Hz), 24.6 (d, 
3JCP = 3.7 Hz, +), 
24.5 (d, 3JCP = 4.4 Hz, +), 24.1 (d, 
3JCP = 5.9 Hz, +), 23.9 (d, 
3JCP = 5.9 Hz, +), 21.5 (d, 
1JCP = 
185.1 Hz, +), 21.1 (d, 2JCP = 5.1 Hz, -), 14.8 (d, 
3JCP = 4.4 Hz, +);  
31P NMR (161.98 MHz, 
CDCl3) δ 38.8; GC/MS (Rt = 12.48 min) m/z  276 (1%, M
+), 261 (3%, M – Me), 245 (10%, M - 
OMe), 162 (100%); HRMS (TOF ES) Found 277.1205, 299.1017, Calculated for C12H22O5P 
(M+H) 277.1205 (0.0 ppm), C12H21O5PNa (M+Na) 299.1024 (2.3 ppm). 
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94c:  The reaction was performed according to the typical procedure B, 
employing cyclopropene 91c (70mg, 0.5mmol). The crude reaction 
mixture was purified by preparative column chromatography eluting wth 
EtOAc/hexane (1:1) (Rf 0.35) to give 113 mg (0.38 mmol, 75%).  
  1H NMR (400.13 MHz, CDCl3) δ 5.9 (ddt, J = 17.2 Hz, 10.9 Hz, 5.6 Hz, 1H), 5.3 (ddt, J 
= 17.2 Hz, 2H), 4.6 (d, J = 5.6 Hz, 2H), 1.64 (s, 3H), 1.62 (m, 2H), 1.51 (s, 3H), 1.50 (s, 3H), 
1.40 (s, 3H), 1.39 (s, 3H), 1.60 (s, 3H), 1.35 (m, 1H); 13C NMR (100.67 MHz, CDCl3) δ 173.3 
(d, 3JCP = 5.1 Hz), 131.8 (+), 118.0 (-), 88.3, 88.1, 65.8 (-), 53.4 (+), 24.76, 24.72 (+), 24.6 (d, 
3JCP = 3.7 Hz, +), 24.4 (d, 
3JCP = 4.4 Hz, +), 24.1 (d, 
3JCP = 5.1 Hz, +), 23.9 (d, 
3JCP = 5.1 Hz, +), 
21.6 (d, 1JCP = 185.9 Hz, +), 21.1 (d, 
2JCP = 3.7 Hz, -), 14.8 (+);  
31P NMR (161.98 MHz, CDCl3) 
δ 38.7;  GC/MS (Rt = 13.22 min) m/z  302 (1%, M
+), 287 (3%, M - Me), 245 (10%, M- OC3H5), 
83 (100%);  HRMS (TOF ES) Found 315.1133, Calculated for C18H20O3P (M+H) 315.1150 (8.3 
ppm). 
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 94d: The reaction was performed according to the typical procedure B, 
employing cyclopropene 91d (94 mg, 0.5 mmol). The crude residue was purified by preparative 
column chromatography eluting with EtOAc/Hexanes (2:1) (Rf 0.30). Yield: 169 mg, (0.47 
mmol, 94%). 
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1H NMR (400.13 MHz, CDCl3) δ (m, 5H), 5.16 (d, J = 12.6 Hz), 5.14 (d, J = 12.6 Hz), 1.71-
1.57 (m, 2H), 1.51 (s, 3H), 1.49 (s, 3H), 1.39 (s, 3H), 1.36 (s, 3H), 1.60 (s, 3H), 1.37-1.32 (m, 
1H); 13C NMR (100.67 MHz, CDCl3) δ (d, 
3JCP = 4.4 Hz), 135.7, 128.6 (+, 2C), 128.3 (+), 127.9, 
(+, 2C), 88.3, 88.2, 67.0 (-), 24.9 (d, 2JCP = 2.2 Hz), 24.8 (d, 
3JCP = 3.7 Hz, +), 24.5 (d, 
3JCP = 4.4 
Hz, +), 24.2 (d, 3JCP = 5.1 Hz, +), 23.9 (d, 
3JCP = 5.9 Hz, +), 21.7 (d, 
1JCP = 185.2 Hz, +), 21.2 (d, 
2JCP = 5.1 Hz, -), 15.0 (d, 
3JCP = 4.4 Hz, +);  
31P NMR (161.98 MHz, CDCl3) δ 38.6;  GC/MS (Rt 
= 17.01 min) m/z  352 (7%, M+), 91 (100%, PhCH2
+); HRMS (TOF ES) Found 375.1339, 
Calculated for C18H25O5PNa (M+Na) 375.1137 (0.5 ppm). 
 
94e: The reaction was performed according to the typical procedure B, 
employing cyclopropene 91e (174 mg, 1.0 mmol). The crude residue was 
separated by preparative column chromatography (eluent: 
EtOAc/CH2Cl2/hexanes 3:1:1) to afford two fractions (Rf 0.32) and (Rf 0.22).  
Yields 119.4 mg (35 mmol, 71%) and 47.8 mg (14 mmol, 28%), respectively.  
Major  (trans-94e):  1H NMR (400.13 MHz, CDCl3) δ 7.63-7.61 (m, 2H), 7.57-7.49 (m, 3H), 
3.68 (s, 3H), 2.23-2.09 (m, 3H), 1.67 (s, 3H), 1.632 (s, 3H), 1.626 (s, 3H), 1.60 (s, 3H); 13C 
NMR (100.67 MHz, CDCl3) δ 173.3, 134.2 (d, 
3JCP = 5.1 Hz), 130.8 (+, 2C), 127.90 (+), 127.85 
(+, 2C), 88.2, 87.6, 53.0 (+), 34.6 (d, 2JCP = 2.9 Hz), 24.6 (d, 
3JCP = 3.7 Hz, +), 24.4 (d, 
3JCP = 4.4 
Hz, +), 24.3 (d, 3JCP = 4.4 Hz, +), 23.8 (d, 
3JCP = 2.9 Hz, +), 22.9 (d, 
1JCP = 195.4 Hz, +), 19.4 (d, 
2JCP = 5.1 Hz, -);  
31P NMR (161.98 MHz, CDCl3) δ 36.5; HRMS (TOF ES): Found 361.1176 
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(100%), 339.1349 (30%); Calculated for C17H24O5PNa (M+Na) 361.1181 (0.5 ppm), C17H24O5P 
(M+H) 339.1361 (1.2 ppm). 
 
Minor (cis-94e):  1H NMR (400.13 MHz, CDCl3) δ7.44-7.42 (m, 2H), 7.35-
7.29 (m, 3H), 3.71 (s, 3H), 2.19 (ddd, JPH = 20.0 Hz, J = 7.1 Hz, 4.3 Hz, 1H), 
1.68-1.55 (m, 2H), 1.533 (s, 3H), 1.528 (s, 3H), 1.45 (s, 3H), 1.42 (s, 3H);  13C 
NMR (100.67 MHz, CDCl3) δ 170.6 (d, 
3JCP = 7.3 Hz), 138.1 (d, 
3JCP = 3.7 
Hz), 129.3 (+, 2C), 128.3 (+, 2C), 127.8 (+), 87.92, 87.87, 52.7 (+), 36.7 (d, 2JCP = 4.4 Hz), 24.6 
(d, 3JCP = 3.7 Hz, +), 24.3 (d, 
3JCP = 4.4 Hz, +), 24.2 (d, 
3JCP = 4.4 Hz, +), 23.8 (d, 
3JCP = 5.9 Hz, 
+), 22.7 (d, 1JCP = 185.2 Hz, +), 18.4 (d, 
2JCP = 4.4 Hz, -);  
31P NMR (161.98 MHz, CDCl3) δ 
37.8;  HRMS (TOF ES): Found 361.1166 (100%), 339.1354 (80%); Calculated for C17H24O5PNa 
(M+Na) 361.1181 (1.5 ppm), C17H24O5P (M+H) 339.1361 (0.7 ppm). 
 
94f: The reaction was performed according to the typical procedure B, 
employing cyclopropene 91f (92 mg, 0.5 mmol) using THF as a solvent. The 
crude residue was purified by preparative column chromatography eluting with 
EtOAc/hexanes (3:1) to give light-brown oil (Rf 0.31). Yield: 172 mg (0.49 mmol, 99%). 
1H 
NMR (400.13 MHz, CDCl3) δ 4.20-4.14 (m, 2H), 1.80 (ddd, 
3JPH = 17.7 Hz,  J = 6.1 Hz, 4.0 Hz, 
1H), 1.51 (s, 3H), 1.48 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.15 (ddd, 3JPH 
= 9.9 Hz,  J = 8.3 Hz, 4.0 Hz, 1H), 0.93 (ddd, 2JPH = 6.3 Hz,  J = 8.3 Hz, 6.1 Hz, 1H), 0.10 (s, 
9H); 13C NMR (100.67 MHz, CDCl3) δ 87.8, 87.4, 61.0 (-), 24.8 (d, 
3JCP = 2.9 Hz, +), 24.4 (d, 
3JCP = 3.7 Hz, +), 24.3 (d, 
3JCP = 4.4 Hz, +), 23.8 (d, 
3JCP = 6.6 Hz, +), 21.6 (d, 
2JCP = 5.9 Hz), 
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16.5 (d, 1JCP = 184.4 Hz, +), 14.5 (d, 
2JCP = 3.7 Hz, -), 14.1 (+), -3.1 (-, 3C); 
31P NMR (161.98 
MHz, CDCl3) δ 40.4;  GC/MS (Rt = 13.47 min) m/z  349 (1%, M + H
+), 333 (45%, M – Me), 303 
(20%, M – Et), 73 (100%, Me3Si
+); HRMS (TOF ES) Found 371.1432, Calculated for 
C15H29O5SiPNa (M+Na) 371.1440 (3.2 ppm). 
 
 91g: The reaction was performed according to the typical procedure B, 
employing cyclopropene 91g (75 mg, 0.5 mmol). The crude reaction mixture 
was purified by preparative column chromatography eluting with 
EtOAc/hexane (3:1) (Rf 0.25) to give an orange oil. Yield: 160 mg (0.5 mmol, 100%). 
1H NMR 
(400.13 MHz, CDCl3) δ 3.81 (s, 3H), 3.77 (s, 3H), 1.98 (ddd, 
2JPH = 19.2 Hz, J = 7.6 Hz, 4.4 Hz, 
1H), 1.78 (ddd, 3JPH = 7.8 Hz, J = 9.9 Hz, 4.4 Hz, 1H); 1.67 (ddd, 
3JPH = 4.2 Hz, J = 9.9 Hz, 7.6 
Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 169.5 (d, 
3JCP = 4.4 Hz), 166.5 (d, 
3JCP = 6.6 Hz), 
89.0, 88.3, 53.3 (+), 53.2 (+), 34.5 (d, 2JCP = 6.6 Hz), 24.6 (d, 
3JCP = 3.7 Hz, +), 24.4 (d, 
3JCP = 
4.4 Hz, +), 24.1 (d, 3JCP = 5.1 Hz, +), 23.9 (d, 
3JCP = 5.9 Hz, +), 21.3 (d, 
1JCP = 185.2 Hz, +), 18.6 
(d, 2JCP = 4.4 Hz, -);  
31P NMR (161.98 MHz, CDCl3) δ 36.2; GC/MS (Rf = 13.63 min) m/z 321 
(1%, M + H+), 262 (30%, M  - CO2CH2), 204 (100%, M
 - (CO2Me)2); HRMS (TOF ES) Found 
321.1104, Calculated for C13H22O7P (M+H) 321.1103 (0.3 ppm). 
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94h: The reaction was performed according to the typical procedure B, 
employing cyclopropene 91h (77 mg, 0.5 mmol). The crude residue was filtered through a short 
bed of silica gel eluting with EtOAc. The obtained residue after removal of solvent was purified 
by preparative column chromatography eluting with EtOAc/MeOH (1:1) (Rf 0.5) Yield: 154 mg 
(0.485 mmol, 97%).  
1H NMR (400.13 MHz, CDCl3) δ 3.67-3.51 (br, 4H), 3.37-3.27 (br, 4H), 1.59 (s, 3H), 151-1.47 
(m, 1H), H), 1.50 (s, 3H), 1.49 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.29-1.18 (m, 2H), 1.29-1.18 
(m, 3H), 1.12-1.04 (br, 3H); 13C NMR (100.67 MHz, CDCl3) δ 171.8 (d, 
3JCP = 5.1 Hz), 88.3, 
87.9, 41.1 (br, -), 39.0 (br. -), 27.3 (d, 2JCP = 5.12 Hz), 24.6 (d, 
3JCP = 4.4 Hz, +), 24.5 (d, 
3JCP = 
4.4 Hz, +), 24.2 (d, 3JCP = 5.1 Hz, +), 24.0 (d, 
3JCP = 5.1 Hz, +), 18.3 (d, 
2JCP = 5.9 Hz, -), 18.2 
(d, 1JCP = 183.0 Hz, +), 17.5 (d, 
3JCP = 5.1 Hz, +), 13.8 (br, +), 12.4 (br, +); 
31P NMR (161.98 
MHz, CDCl3) δ 40.1;  GC/MS (Rt = 12.46 min) m/z  317 (1%, M
+), 245 (3%, M+ – NEt2), 154 
(30%, Et2NCO(Me)C=CH-CH2
+), 72 (100%, Et2N
+); HRMS (TOF ES) Found 340.1649, 
Calculated for C15H28NO4PNa (M+Na) 340.1654 (1.5 ppm). 
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94i: The reaction was performed according to the typical procedure B, 
employing cyclopropene 91i (54 mg, 0.3 mmol) The crude residue was purified by preparative 
column chromatography on Silica gel eluting with EtOAc (Rf = 0.23).  Yield 85 mg (0.24 mmol, 
82%).  
1H NMR (400.13 MHz, CDCl3) δ 4.59 (m, 1H), 3.33 (m, 1H), 1.60 (s, 3H), 1.52 (s, 3H), 1.51 (m, 
1H) 1.50 (s, 3H), 1.43 (s, 3H), 1.42 (s, 3H), 1.37 (m, 6H), 1.30 (m 2H), 1.22 (m, 6H); 13C NMR 
(100.67 MHz, CDCl3) δ 170.1 (d, 
3JCP = 5.1 Hz), 88.3, 87.8, 48.4 (+), 45.7 (+), 29.0 (d, 
2JCP = 
5.1 Hz), 24.7 (d, 3JCP = 3.7 Hz, +), 24.5 (d, 
3JCP = 4.4Hz, +), 24.2 (d, 
3JCP = 4.4Hz , +), 24.1 (m, 
+, 2C), 20.7 (+),20.5 (+), 20.3 (+), 20.1 (+), 17.9 (d, 1JCP = 182.2 Hz, +), 18.1 (d, 
2JCP = 5.9 Hz, -
), 17.5 (d, 2JCP = 5.1 Hz); 
31P NMR (161.98 MHz, CDCl3) δ 40.3; GC/MS (Rf = 14.83 min) m/z 
345 (1%, M+), 330 (5%, M - Me), 245 (35%, M - N(i-Pr)2), 135 (100%); HRMS (TOF ES) Found 
346.2122, Calculated for C17H33NO4P (M+H) 346.2147 (7.2 ppm). 
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 94j: The reaction was performed according to the typical procedure B 
employing cyclopropene 91j (83 mg, 0.5 mmol).  The crude residue was purified by preparative 
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column chromatography on Silica gel (eluent: EtOAc) (Rf: 0.1). Yield: 142 mg (0.43 mmol, 
86%). 
1H NMR (400.13 MHz, CDCl3) δ 3.61(br. s, 8H), 1.52 (s, 3 H), 1.46-1.42 (m, 1H), 1.44 (s, 3H), 
1.43 (m, 1H) 1.34 (s, 6H), 1.20-1.14 (m, 2H);  13C NMR (100.67 MHz, CDCl3) δ 170.9 (d, 
3JCP = 
5.1 Hz), 88.3, 87.9, 66.5 (-, 2C), 46.1 (br. -), 42.3 (br. -), 26.6 (d, 2JCP = 4.4 Hz), 24.4 (d, 
3JCP = 
3.7 Hz, +, 2C), 24.0 (d, 2JCP = 5.1Hz, +), 23.8 (d, 
2JCP = 5.1Hz, +), 18.1 (d, 
1JCP = 183.0 Hz, +), 
17.6 (d, 2JCP = 5.9 Hz -), 17.2 (d, 
3JCP = 5.1 Hz, +);  
31P NMR (161.98 MHz, CDCl3) δ 39.2; 
GC/MS (Rf = 16.847 min) m/z 331 (1% , M
+), 330 (5%, M - Me), 245 (50% M - N(CH2CH2)2O, 
163 (98%), 136 (100%); HRMS (TOF ES) Found 354.1434, Calculated for C15H26NO5PNa 
(M+Na) 354.1446 (3.4 ppm). 
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 94k: The reaction was performed according to the typical procedure B. 
employing cyclopropene 91k (80 mg, 0.5 mmol).  The crude residue was purified by preparative 
column chromatography on Silica gel doped with triethylamine (eluent: EtOAc/MeOH 3:1) (Rf: 
0.1). Yield: 172 mg (0.5 mmol, >99%). 
 
1H NMR (400.13 MHz, CDCl3) δ 3.89-3.52 (m, 4H), 2.46-2.38 (m, 4 H), 2.32 (s, 3H), 1.61 (s, 
3H), 1.52 (m, 1H) 1.52 (s, 3H), 1.51 (s, 3H), 1.43 (s, 3H), 1.42 (s, 3H), 1.25 (m, 2H);  13C NMR 
(100.67 MHz, CDCl3) δ 170.9 (d, 
3JCP = 5.1 Hz), 88.3, 88.0, 46.5 (br. -, 2C), 46.0 (+), 27.1 (d, 
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2JCP = 4.4 Hz), 24.6 (d, 
2JCP = 2.9 Hz), 24.2 (d, 
2JCP = 5.9Hz), 24.0 (d, 
2JCP = 5.1Hz +), 18.2 (d, 
1JCP = 185.1 Hz, +), 18.0 (d, 
2JCP = 5.6 Hz -), 17.5 (d, 
3JCP = 5.1 Hz, +);  
31P NMR (161.98 MHz, 
CDCl3) δ 39.6. 
 
1.4.5. Synthesis of cyclopropylphosphine oxides 
 
 
96a: Typical procedure. An oven dried 2 mL Wheaton vial was charged with 
1,1’-bis (diphenylphosphino)ferrocene (dppf)  (27.7 mg, 0.05 mmol, 10 
mol%), tris(dibenzylideneacetone) dipalladium chloroform adduct (12.9 mg, 
0.025 mmol, 5 mol%), and diphenylphosphine oxide (101.0 mg, 0.5 mmol) under a nitrogen 
atmosphere. The mixture was then dissolved in dry dioxane (1 ml) and stirred for 5 min. Then, 
methyl 1-methylcycloprop-2-ene-1-carboxylate (95.8 mg, 0.55 mmol) was added via syringe and 
the reaction was stirred for 1 hr at 25 oC.  When TLC analysis showed no starting material 
remained, the reaction mixture was concentrated and the residue was purified by preparative 
column chromatography (eluent: EtOAc/hexanes 3:1) to afford white a solid (Rf 0.4).  Yield: 
145.0 mg (47 mmol, 92%).  
1H NMR (400.13 MHz, CDCl3) δ 7.82-7.77 (m, 2H), 7.72-7.67 (m, 2H), 7.59-7.55 (m, 1H), 
7.53-7.43 (m, 5H), 3.73 (s, 3H), 2.07 (ddd, 2JPH = 17.4 Hz, J = 10.1 Hz, 7.3 Hz, 1H), 1.71 (ddd, 
3JPH = 9.3 Hz, J = 9.4 Hz, 4.0 Hz, 1H), 1.65 (ddd, 
3JPH = 15.4 Hz, J = 7.3 Hz, 4.0 Hz, 1H), 1.50 
(s, 3H); 13C NMR (100.67 MHz, CDCl3) δ 174.5, 134.5 (d, 
1JCP = 104.7 Hz), 133.2 (d, 
1JCP = 
104.7 Hz), 131.9 (d, 4JCP = 2.9 Hz, +), 131.7 (d, 
4JCP = 2.2 Hz, +), 130.9 (d, 
2JCP = 10.2 Hz, +, 
Me
CO2Me
P
PhPh
O
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2C), 130.7 (d, 2JCP = 9.5 Hz, +, 2C), 128.7 (d, 
3JCP = 11.7 Hz, +, 2C), 128.5 (d, 
3JCP = 11.7 Hz, +, 
2C), 52.5 (+), 25.6 (d, 2JCP = 2.9 Hz), 22.7 (d, 
1JCP = 98.8 Hz, +), 18.7 (d, 
2JCP = 4.4 Hz, -), 14.1 
(d, 3JCP = 4.4 Hz, +); 
31P NMR (161.98 MHz, CDCl3) δ 28.4;  GC/MS (Rt = 16.48 min) m/z  314 
(12%, M+), 202 (100%, Ph2POH
+); HRMS (TOF ES) Found 315.1133, Calculated for C18H20O3P 
(M+H) 315.1150 (5.4 ppm). 
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O
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96b: The reaction was carried out according to the typical procedure, 
employing cyclopropene 91h (46 mg, 0.3 mmol).. The crude residue was purified by preparative 
column chromatography eluting with EtOAc (Rf 0.15). Yield: 95 mg (0.27 mmol, 89%). 
1H NMR (400.13 MHz, CDCl3) δ 8.15-8.04 (m, 2H), 7.68-7.59 (m, 2H), 7.53-7.45 (m, 3H), 
7.44-7.32 (m, 3H), 3.61-3.28 (m, 4H) 1.86 (ddd, 1JPH = 12.1 Hz, 
2J = 9.9 Hz, 6.8 Hz, 1H), 1.63 
(ddd, 3JPH = 14.9 Hz, J = 6.8 Hz, 4.3 Hz, 1H), 1.53 (s, 3H) 1.43 (ddd, 
3JPH = 9.9 Hz, J = 8.3 Hz, 
4.3 Hz, 1H), 1.14 (m, 6H); 13C NMR (100.67 MHz, CDCl3) δ 172.0 (d, 
3JCP = 2.9 Hz), 134.9 (d, 
1JCP = 103.9 Hz), 133.5 (d, 
1JCP = 103.9 Hz), 131.6 (d, 
4JCP = 2.2 Hz, +), 131.2 (d, 
4JCP = 10.2 
Hz, +, 2C), 131.2 (+), 130.4 (d, 2JCP = 9.5 Hz, +, 2C), 128.5 (d, 
2JCP = 12.4  Hz, +, 2C), 128.2 (d, 
3JCP = 12.4 Hz, +, 2C), 60.16, 40.9 (-), 38.88 (-), 28.9 (d, 
2JCP = 4.4 Hz), 18.8 (d, 
1JCP = 100.3 
Hz, +), 16.5 (d, 3JCP = 4.4 Hz, +), 15.6 (d, 
2JCP = 4.4 Hz, -), 13.6 (+) 12.3 (+);  
31P NMR (161.98 
MHz, CDCl3) δ 30.0;  GC/MS (Rt = 15.68 min) m/z  355 (2%, M
+), 340 (7%, M – Me), 382 
(15%, M – HNEt2), 255 (42%, M – CONEt2), 201 (23%, Ph2PO
+), 154 (100%, M – Ph2PO); 
HRMS (TOF ES) Found 378.1585, Calculated for C21H26NO2PNa (M+Na) 378.1599 (3.7 ppm). 
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96c: The reaction was carried out according to the typical procedure, 
employing 91i (77 mg, 0.3 mmol).. The crude residue was purified by 
preparative column chromatography. Eluent: EtOAc (Rf = 0.2). Yield 106 
mg (0.28 mmol, 60%). 
1H NMR (400.13 MHz, CDCl3) δ  8.11(m, 2H), 7.69 (m, 2H), 7.58-7.39 (m, 6H), 4.39 (m, 1H), 
3.30 (m, 1H) 1.84 (ddd, 2JPH = 12.4 Hz,  J = 9.9 Hz, 7.1 Hz, 1H), 1.61 (ddd, 
3JPH = 15.2 Hz, J = 
6.8 Hz, 4.3 Hz, 1H), 1.51 (s, 3H), 1.45 (m, 1H), 1.40 (d,  J = 6.6 Hz, 3H), 1.36 (d,  J = 6.6 Hz, 
3H), 1.13 (m, 6H); 13C NMR (100.67 MHz, CDCl3) δ 171.5 (d, 
3JCP = 2.9 Hz), 135.3, (d, 
1JCP = 
103.2 Hz), 133.7 (d, 1JCP = 103.2 Hz), 131.7 (d, 
4JCP = 2.2 Hz, +), 131.5 (+), 131.4 (+), 131.3 (+), 
130.6 (d, 2JCP = 9.5 Hz, 2C), 128.6 (d, 
3JCP = 11.7  Hz, +, 2C), 128.4 (d, 
3JCP = 12.4 Hz, +, 2C), 
48.6 (+), 45.7 (+), 30.4 (2JCP = 4.4  Hz), 20.6 (+), 20.4 (+, 2C), 20.1 (+), 19.0 (d, 
1JCP = 100.3 Hz, 
+), 16.6 (d, 3JCP = 5.1 Hz), 15.6 (d, 
2JCP = 4.4 Hz); 
31P NMR (161.98 MHz, CDCl3) δ 30.2; 
HRMS (TOF ES) Found 368.1743, Calculated for C20H28NO2PNa (M-Me+Na) 368.1755 (3.3 
ppm).  
 
1.4.6. Assignment of relative configuration 
 
 The obtained sample of cyclopropylphosphonate 94a contained two separable 
diastereomeric compounds, a less polar major fraction A and a more polar minor fraction B.  
Elucidation of the relative configuration was performed based on analysis of NMR spectra, as 
follows.   In the minor product, the carbon next to phosphorus atom (20.7 ppm) was identified 
Me
O
N
P
PhPh
O
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owing to a very characteristic splitting into a doublet with a large coupling constant value (1JCP = 
185.9 Hz).  The adjacent proton (1.01 ppm) was assigned based on the 1H-13C HSQC experiment 
(1313C NMR (CDCl3, 100.67 MHz) δ172.0 see Apendix A.2.).  The same experiment allowed 
for the assignment of protons at 1.79 and 1.26 ppm to the methylene group in the cyclopropane 
ring.  The well resolved signals of all three protons of the cyclopropyl ring in the 1H NMR 
spectrum of the minor product allowed for the measurement of the corr sp nding spin-spin 
coupling constants.  Thus, a typical AMX system in 1,1,2-trisubstituted cyclopropane rings 
usually gives 3JHH(cis) > 
3JHH(trans) > 
2JHH, which is consistent with positioning of the protons 
as depicted in Figure 3.  In addition, the same relationship was observed for proton-phosphorus 
coupling constants (shown in green): 3JPH(cis) > 
3JPH(trans) > 
2JPH.  Protons in the spectrum of 
the major diastereomer were assigned in a similar manner (Figure 3), even though complete 
analysis of the J-coupling was impossible due to partial overlapping of the signals in 1H 
spectrum of the methylene group (1.45 ppm and 1.50 ppm).  The configuration of quaternary 
carbons of the small rings can be assigned based on comparison of chemical shifts of the protons 
in CH2 group.  Indeed, in cyclopropyl systems the methyl substituent typically demonstrates a 
minor shielding effect on cis-vicinal protons.  At the same time, both phenyl and phosphoryl 
groups have profound deshielding effect.  These considerations allowed fr the unambiguous 
assignment of the cis-configuration (relative 1R,2R) for the minor, and the trans-configuration 
(relative 1S,2R) for the major diastereomer (Figure 3). 
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Figure 3. Assignment of relative configurations of diastereomeric products 94a. 
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Figure 4. Assignment of relative configuration of deuterium labeled compounds. 
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 Relative configuration of the deuterium-labeled compounds 94a-d2, obtained in the 
hydrophosphorylation of cyclopropene 191a-d2 was assigned based upon the comparison of the 
1H, 2H NMR and 1H-13C HSQC NMR data measured for labeled and non-labeled products (see 
section A.3.).   These data showed that for both diastereomeric products all deuterium labels are 
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located in geminal and trans-vicinal positions and no deuterium incorporation was observed into 
the cis-vicinal position.  Also, the only spin-spin coupling remained after deuterium 
incorporation was the cis-proton-phosphorus interaction with 3JPH ~ 19-20 Hz.The obtained data 
unambiguously confirmed that the described palladium-catalyzed hydrophosphorylation 
proceeds exclusively in syn-fashion. 
 
Figure 5. . Overlays of 1H and 2H spectra of the products isolated from hydrophosphorylation of 
94a and 94a-d2:  A) 
1H spectrum of trans-91-d2; B) 
1H spectrum of trans-94a; C) 2H spectrum of 
trans-94a-d2;  D) 
1H spectrum of cis-94a-d2; E) 
1H spectrum of cis-94a; F) 2H spectrum of cis-
94a-d2. 
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Relative configuration of diastereomeric compounds 94e was assigned analogously.  
Analysis of coupling constants for the major (less polar) diastereomer was impossible due to 
severe overlapping of proton signals of the cyclopropane ring.  However, the corresponding 
signals were mostly resolved in the spectrum of the minor (more polar) diastereomer.  
Simulation of the 1H NMR spectrum for the cyclopropane ring AMXP-system (Figure 6) 
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allowed for the assignments depicted in Figure 7. Assignment of relative configurations of 
diastereomeric products 94e (E =CO2Me). Configuration of the quaternary center was assigned 
based on a NOESY experiment.  A NOE effect between the cyclopropyl CH group (1.58 ppm) 
and the ortho-protons of the phenyl ring (7.43 ppm) was observed; accordingly, a cis-
relationship between these groups was established.  Therefore, cis-configuration (relative 1S,2R) 
was assigned to the minor (more polar) product, while a trans-configuration (relative 1R,2R) was 
assigned to the major (less polar) diastereomer. 
 
Figure 6. Experimental (blue) and simulated (red) spectra of the minor (more polar) 
diastereomer 94e. 
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Figure 7. Assignment of relative configurations of diastereomeric products 94e (E =CO2Me). 
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 In the same way, the trans-configuration (relative 1S,2R) of compound 94f was assigned.  
Simulation of the four-spin system of phosphorylcyclopropane ring and the corr sponding values 
of chemical shifts and spin-spin coupling constants are presented in (Figure 8) and (Figure 9A), 
respectively.  Relative configuration of the quaternary center in the three-membered ring was 
assigned based on a NOESY experiment (Figure 9B). NOE effects w re detected between the 
TMS-group (0.10 ppm) and the two protons in the cyclopropyl ring (0.93 ppm and 1.15 ppm). 
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Figure 8. Experimental (blue) and simulated (red) spectra of 94f. 
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Figure 9.  Assignment of relative configurations of diastereomeric products 94f (E = CO2Et). 
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Chapter 2. Formal Nucleophilic Substitution of Bromocyclopropanes 
 
2.1 Introduction 
 
Cyclopropanols and cyclopropyl ethers are an important class of molecules for both organic 
synthesis61 and medicinal chemistry. They are a plethora of examples among bi lo ically active 
natural products62 and synthetic medicinal agents,63 such as phorbol,64 brenazocine,65 and 
LY37926866 (Figure 10). 
 
Figure 10. 
 
 
 
Although a plethora of methods have been developed for construction of cyclopropyl 
ethers, efficient protocols that allow for direct functionalization of a pre-existing cyclopropane 
moiety are scarce. Obviously the most efficient method to accomplish such functionalizations 
would involve a direct nucleophilic substitution onto cyclopropane; however, it is well 
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recognized that classical nucleophilic substitution in strained carbo ycles is highly disfavored.67 
Both the SN1and SN2 pathways are much higher in energy as compared to non-strained syst ms 
due to the distortion of the bond angles from 120o to 60o   (Figure 11). Also, the cyclopropyl 
cation 101 generated in the SN1 mechanism would likely isomerize into the allyl cation 102 as 
studies have shown that such isomerization proceeds virtually without a measurable activation 
barrier (Scheme 44).68 In fact, only a handful of examples claiming direct nucleophilic 
substitutions of cyclopropanes have been reported. 
 
Figure 11. 
 
 
 
Scheme 44. 
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2.1.2. Pathways to formal nucleophilic substitution 
 
 In 1979, a direct intramolecular SN2 substitution of bicyclic fused bromocyclopropanes was 
demonstrated (Scheme 45). Reaction of 103 with t-BuOK proceeded to give intramolecular 
substitution with inversion of configuration with respect to the bromine providing the 
corresponding spiro-oxirane 104. Interestingly, the endo-diastereomer 105 underwent 
intramolecular substitution with nucleophilic attack from the more hindered face also proceeding 
through inversion of configuration to provide spiro-oxirane 106.67 
 
Scheme 45 
 
 
 The stereochemistry of the deamination of (-)-spiropentylamine in acetic cid was studied 
by Wiberg et al. Reaction of the chiral amine hydrochloride 107 with nitrous acid in acetic acid 
led to a mixture of 3-methylenecyclobutyl acetate 111, 2-methylenecyclobutyl acetate 112, and 
spiropentyl acetate 109 in a 1:2:3 ratio. It was found that the major product, (-)-spiropentyl 
acetate, was formed with essentially complete inversion of configuration. This suggests that it is 
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formed via an SN2 displacement on the spiropentyldiazonium ion. However formation of 2-
methylenecyclobutyl acetate and 3-methylenecyclobutyl acetate advocates for concurrent 
formation of a cyclopropyl cation, which quickly undergoes ring expansion and cleavage 
(Scheme 46). 
 
Scheme 46 
 
 
 
 While direct displacements are scarce, SN1-like nucleophilic substitiutions are possible 
with halocyclopropanes possessing strongly electron-donating geminal substituents (Scheme 47, 
eq. 1). Formal nucleophilic substitutions may also proceed via a 1,2-elimination to generate a 
cyclopropene intermediate, followed by addition of a nucleophile across the trained double 
bond (Scheme 47, eq. 2). 
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Scheme 47 
 
 
 
 
2.1.2. Nucleophilic substitution via stabilization of cyclopropyl cations. 
 
The presence of an electron donating substituent geminal to a leaving group stabilizes the 
resulting carbocation intermediate, which could be trapped with various nucleophiles. In a study 
concerning the stabilities of cyclopropyl cations, de Meijere demonstrated that these reactive 
cationic intermediates may be stabilized with a phenyl thienyl group and hinder the ring opening 
pathway.69 For example, methanolysis of chlorocyclopropyl sulfide 112 led to 43% of methoxide  
substitution 115 along with 57% of the ring opening product 116 (Scheme 48). The necessity of 
a geminal stabilizing substituent was demonstrated by the methanolysis of 117 which underwent 
exclusive ring opening to provide the corresponding diene 118 in 85% yield (Scheme 49). 
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Scheme 48. 
 
Scheme 49. 
 
 
 
An α-cyclopropyl group is known to have the largest stabilizing effect of any α-alkyl 
substituent on a carbocation68 indeed methanolysis of chloro cyclopropyldispiro derivative 120
accordingly proceeded without ring opening to yield only the methyl ether 119. Exclusive 
substitution also occurred in the presence of the relatively weak nucleophi e NaOAc giving the 
corresponding cyclopropyl acetate 121 in quantitive yield (Scheme 50).69  
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Scheme 50. 
 
 
 
The addition of anilines to O-stabilized cationic intermediates was demonstrated by Loeppky 
in 2000. Reaction of 1-bromo-1-ethoxy cyclopropane 123 with various aniline nucleophiles 123 
in the presence of triethylamine provided aminal derivatives 124 in yields up to 78%. The 
ethoxide moiety was efficiently removed by reaction with NaBH4 to afford the corresponding 
cyclopropyl anilines 125 (Scheme 51).70 
 
Scheme 51. 
 
 
 
It has also been demonstrated that both electron deficient and electron ri h phenols 126 serve 
as nucleophilic partners in additions to stabilized cyclopropyl cations 127. The reactions were 
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relatively sluggish and required high temperatures, nonetheless various thi cyclopropyl phenols 
128 were synthesized in moderate to good yields. Subsequent reduction of 128 with NaBH4 
provided the corresponding cyclopropyl phenols 129 in modest overall yields (Scheme 52).71  
 
Scheme 52. 
 
 
 Stabilization of cyclopropyl cations is not limited to oxygen and sulfur. Vilsmaier 
demonstrated that an amino moiety in silyl-protected hemiaminal 130 promotes the nucleophilic 
substitution of the geminal OSiM3 group by stabilizing the intermediate cyclopropyl cation 131
(Scheme 53).72 The addition of Meldrums acid in the presence of NaOH to iminium 
cyclopropane 131 affords compound 132 via a nucleophilic addition of the enolate to 
intermediate imine 131. A twofold substitution occurs in the presence of other carbon73 a d 
oxygen-based nucleophiles to provide cyclopropyl products 134.   
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Scheme 53. 
 
 
Ishihara demonstrated that stabilized cyclopropyl cations may also be generated in the 
presence of vicinal silanes and undergo ring retentive nucleophilic atta k.74 Treatment of bicycle 
135 with silver trifluorocetate afforded cyclopropyl cation 136 and after nucleophilic attack 
provided intermediate 137. Loss of the halide and formation of stabilized carbocation 138 
followed by nucleophilic addition gave dialkyl cyclopropyl acetals 139 in medium to high 
overall yields (Scheme 54). It was also demonstrated that the pres nce of the β-TMS substituent 
is essential to ring retentive substitution as subjection of the corr sponding methyl substituted 
derivative 139 underwent exclusive ring expansion to give cycloheptane 140 (Scheme 55).72  
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Scheme 54. 
 
 
 
Scheme 55. 
 
 
 
 SN1-type nucleophilic substitution involving stabilized cyclopropyl cation intermediates 
in certain cases allows for efficient ring retentive derivatization of cyclopropanes. At the same 
time, cation-stabilizing functionalities introduced as requisite elem nts in the structure of starting 
materials makes this methodology very substrate dependent and give little flexibility for process 
diversification. 
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An alternative route to nucleophilic substitution involves the base assisted in situ generation 
of cyclopropene intermediates from the corresponding cyclopropyl halides followed by trapping 
with an appropriate nucleophile.  
 
2.1.3. Formal nucleophilic substitution via trapping of cyclopropene intermediates 
  
 Cyclopropenes are commonly synthesized via dehydrohalogenation of cyclopropyl 
halides108 in the presence of base. In the event that a pronucleophile is present the base employed 
for dehydrohalogenation may also form the corresponding nucleophilic specie  wh ch undergoes 
nucleophilic attack across the strained double bond of cyclopropene. Unsubstituted cyclopropyl 
bromides are the simplest substrates utilized in such a process and have been employed in the 
synthesis of a number of useful cyclopropane derivatives. For example, alkylation with 
bromocyclopropane has been performed successfully with alcohols.75,76 (Scheme 56, eq 1, 2) 
phenols77 (Scheme 56, eq. 3) and amides78 (Scheme 56, eq 4, 5) in the synthesis of various 
medicinally relevant structures.   
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Scheme 56. 
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 Reactions of this type have been investigated with substituted halocyclopropanes as well 
as dihalocyclopropanes. However, slight modifications to steric bulk or electronics on the 
cyclopropane moiety severely complicate the efficiency of nucleophilic substitution as the 
formation and stability of the generated cyclopropene intermediate are highly dependent on these 
factors. For example, the reactivity of 1-bromo-2-(chloromethyl)cyc opropane 141 in the 
presence of NaOH and various nucleophiles was investigated by Jonczyk and co-workers79. It  
was found that simple stirring of 141 with an excess of alcohols, in the presence of powdered 
sodium hydroxide and triethylbenzylammonium chloride (TEBAC1) as a cat lyst, in DMSO, at 
ambient temperature gives rise to 1-(alkoxymethy1ene)cyclopropanes 143 in high yields 
(Scheme 57). Alcohols of different structure, including aliphatic, ali yclic, as well as those 
substituted by an aryl or heterocyclic group reacted efficiently. It was found that the reaction 
indeed proceeds through cyclopropene 142a as indicated by crude NMR analysis. The authors do 
not comment on the possibility of addition to aromatic resonance structure 142b, as no products 
of nucleophilic addition corresponding to this species were observed. Intrestingly, the addition 
of more acidic pronucleophiles such as thiols, phenols, and nitriles gave exclusive side chain 
substitution products 144. In these cases formation of cyclopropene intermediate 142awas never 
observed. This is due to the higher acidities of the pronucleophiles which do not allow for the 
appropriate pH necessary for formation of 142.  
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Scheme 57. 
 
 
 
  
 Dihalocyclopropanes also undergo elimination-addition type transformati ns to provide 
disubstituted cyclopropanes. It was shown that dichlorocyclopropane 145 in the presence of 
potassium isopropoxide gave a mixture of mono- and disubstituted products 148 and 149 in 0.7 
and 72 % yield respectively (Scheme 58).80  
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Scheme 58. 
 
  
 The double bond of cyclopropene 146, generated from dihalocyclopropane 145 by 
reaction with potassium isopropoxide, migrates to a position of greater stability to give 
methylene cyclopropane 147 but when excess potassium isopropoxide is present a facile addition 
occurs to afford di-substituted cyclopropane 149. Similarly, it was found that addition of iPrOK 
to dichlorocyclopropane 150 afforded substituted methylene cyclopropanes 154 and 155 
approximately in a 1:1 ratio. The author proposed that this reaction proceeded via an initial 1,2-
dehydrohalogenation to provide cyclopropene intermediate 151, which further isomerized into 
methylene cyclopropane 152. The latter then experienced a second dehydrohalogenation to yield 
1-methyl-3-methylenecyclopropene intermediate 153. Sequential addition afforded 28 and 154 in 
31% and 155 in 35% yield. (Scheme 59). 
 
81 
 
 
Scheme 59 
 
 
 The relative amounts of 154 and 155 formed reflect two opposing factors operating in the 
transition state. The relative stabilities of developing charge will favor 154, but steric factors 
should favor 155. Thus, the two factors appear to be of nearly equal importance when the 
nucleophile is isopropoxide ion. Interestingly the use of methoxide ion, a smaller nucleophile, 
afforded analogous products 158 and 157 in the ratio 2:1 respectively. It is important to note that 
conversion of intermediate 152 into -allyl species 156, since it would provide exclusive 
formation of 157 (Scheme 60).80  
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Scheme 60. 
 
  
 Substitution may also occur through activated methylene cyclopropane intermediates. For 
example, deMeijere demonstrated the in situ generation of conjugated methylene cyclopropanes 
160 generated from bromocyclopropane 159 in the presence of base. These reactive 
intermediates may be trapped by an various nucleophiles to afford substituted cyclopropanes 
161. Nitrogen and oxygen-based nucleophiles underwent clean nucleophilic add tion to give 
compound 161 in excellent yields. However lower yields were observed in the cas of carbon 
nucleophiles. (Scheme 61).81 
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Scheme 61. 
 
 
 
2.1.4. Formal nucleophilic substitution via conjugated cyclopropene intermediates and 
stereoselective additions. 
 
Conjugated cyclopropenes are inherently extremely reactive and are ifficult to isolate.89 
This extraordinary reactivity has proven valuable in the development of formal nucleophilic 
substitutions with a wider variety of pronucleophiles as compared to the non-conjugated 
counterparts. To date, only a handful of investigators have utilized these int rmediates in formal 
substitution reactions. 
In an attempt to synthesize dimethyl 1-aminocyclopropane-1,2-dicarboxylate 165 via the 
in situ generation of Michael acceptor 163, it was found that MeOH adduct 164 was the only 
isolable product. MeOH was unavoidably introduced into the system by partial hydrolysis of 
162. Indeed, intermediate 163 is formed and trapped by NH2, however, it quickly decomposes to 
give a mixture of ring opening products.82 The possibility of formation of a cyclopropyl cation in 
this case is highly unlikely, as the carboxylate functionality would greatly destabilize the 
intermediate. Thus, the reaction is assumed to occur via intermediate 163 (Scheme 62). 
84 
 
 
Scheme 62. 
 
 
  
 Conjugated intermediates such as 163 have found limited utility in formal nucleophilic 
substitutions involving dihalides. For example, it was shown that 2,2-dichlorocyclopropyl phenyl 
sulfides of type 166 are unstable to alcoholysis, and in the presence of the strong base potsium 
tert-butoxide gives enynes 167 as illustrated in (Scheme 63). The accelerating effect of the sulfur 
atom is considered to be a driving force for this exocyclic ring opening reaction, since sulfur can 
stabilize the positive charge developed in intermediate 166a.83  
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Scheme 63. 
 
 
 
Expectedly, replacement of the phenylmercapto group in 166 by the phenylsulfonyl group (as 
in 168) destabilized the intermediate ion corresponding to 166a and provided ring retention. 
Thus, subjection of 168 to base in the presence of competing nucleophiles afforded disubstitution 
products 169 and 170  in excellent yields. Interestingly, 168 in the presence of thiophenol and 2 
equivalents of NaOEt gave exclusively the sulfide addition  product 170 in quantitative yield and 
no formation of the cyclopropyl ethyl ether corresponding by attack by ethoxide ion was 
detected.84 (Scheme 64). 
 
Scheme 64. 
 
 
86 
 
 
In the presence of base compounds such as 168 form highly unstable reactive conjugated 
cyclopropene 171 which are immediately trapped by a nucleophilic species to give, upon 
protonantion, intermediate 173. Sequential deprotonation affords conjugated intermediate 174 
which undergoes nucleophilic attack to afford disubstituted cyclopropanes 175 (Scheme 65). 
 
Scheme 65. 
 
 
 
Jonczyk has demonstrated analogous substitutions with 2,2-dichlorocyclopropanecarbonitrile 
176 with various nucleophiles in aqueous NaOH and tetrabutylammonium bromide (TBAB) as a 
phase transfer catalyst.85 Cyclopropane 176 undergoes dehydrochlorination to give intermediate 
177, which is trapped by the nucleophile. Sequential dehydrochlorination followed by 
conjugated nucleophilic addition affords disubstituted cyclopropanes 180 in modest to good 
yields. Phenols, thiophenols, and alcohols reacted well under these conditions. To prove the 
formation of cyclopropene 177 as a transient product leading to 178, cyclopropene 177 was 
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generated in situ and trapped with 2,3-dimethylbuta-1,3-diene to afford the Diels-Alder adduct 
181 in 35% yield (Scheme 67). 
 
Scheme 66. 
 
 
 
Scheme 67. 
 
  
Although addition of nucleophiles to in situ generated conjugated cyclopropenes is well 
documented, until recently only a single example demonstrated stereo elective addition. Wiberg 
showed that bromocyclopropane 182 upon dehydrobromination with t-BuOK in t-BuOH 
produced a highly unstable intermediate 183. The latter once formed, immediately reacted with 
the t-BuO- nucleophile to afford trans-adduct 185. Since intermediate 183 is planar, addition of 
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tert-butoxide can occur to either face, however, a thermodynamically-driven epimerization 
occurs upon heating favoring the more stable trans product 185 (Scheme 68).86  
 
Scheme 68. 
 
 
 In a remarkable expansion to this methodology Rubin recently showcased 
diastereoselctive formal nucleophilic substitution of bromocyclopropane crboxamides (Scheme 
69). Various primary, secondary and tertiary alcohols reacted smoothly with secondary and 
tertiary cyclopropyl carboxamides 186. The use of non-competitive KOH in the presence of 18-
crown-6 (10 mol%) allowed for efficient generation of intermediate 187, which is promptly 
intercepted by in situ generated alkoxide or aryloxide. Remarkably the reaction conditions also 
enabled base assisted thermodynamically-driven epimerization to afford trans-products 188 in 
very high yields and excellent diastreoselectivities.87 
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Scheme 69. 
 
 
The methodology was also expanded towards the addition of thiols and thiophenols which 
under similar reaction conditions initially afforded a mixture of trans-189 and cis-189 in a 1:1 
ratio. However upon subjection to t-BuOK and 10 mole % 18-crown-6 base assisted 
epimerization allowed to upgrade the selectivity and afforded trans-189 in excellent yields and 
diastereoselectivities up to 30:1 (Scheme 70).88 
 
Scheme 70. 
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 Rubin and co-workers also developed an efficient and highly diastereoselective formal 
substitution of 2-bromocyclopropane carboxamides 186 with secondary amides. The reaction 
conditions allowed for the facile construction of a number of conformation lly constrained trans-
cyclopropyl-diamides derivatives 190 as sole products in excellent yields.89  
 
Scheme 71. 
 
 
Few scattered reports exist demonstrating diastereoselective other examples of formal 
nucleophilic substitution. Diastereoselctivity in all these cases, however, was imparted by 
excessive rigidity and bulk. For example, addition of t-BuOK to chlorocyclopropane 191 
afforded cyclopropyl ether 193 in poor yield as a single diastereomer (Scheme 72, eq 1).90 
Analogously treatment of 194 with t-BuOK provided addition to the convex face and furnished 
196 as a single diastereomer (Scheme 72 eq 2).91 
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Scheme 72. 
 
 
 
2.1.5. Conventional Methods for the preparation of Cyclopropanol derivatives. 
 
Except for the recent examples of formal nucleophilic substitution demonstrated by Rubin, 
this methodology has not yet presented itself as a mainsteam method for the preparation of 
cyclopropanol derivitives. There are, however, a few powerful methods for the preparation of 
such compounds. Discussed below are selected recent examples showing different approaches to 
cyclopropanol derivitives. The most important of these methods is the cyclopropanation of enol 
ethers and esters, which may be performed with several different types of carbene equivalents. 
For example Connell and coworkers recently demonstrated that the classical Simmons-Smith132 
protocol represents a facile method for the cyclopropanation of enol acetates. Treatment of 
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homoallylic alcohol 197 with diethyl zinc and diiodomethane gave cyclopropyl acetates 198 in 
high yields and decent diastereoselectivity (Scheme 73). 92 
 
Scheme 73. 
 
 
 
 The base-assisted generation of dihalocarbenes in the presence of olefins is one of the 
widely employed methods for the construction of cyclopropanes. This methodology was recently 
used in the assembly of polysachride-derived cyclopropyl scaffolds. Treatment of benzyl 
protected enolate 199 with aq. NaOH in the presence of a chloroform and a phase transfe  
catalyst afforded the corresponding cyclopropyl ether 200 in 75% yield (Scheme 74).93 
 
Scheme 74. 
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By far the most widely utilized method for the construction of cyclopropyl ethers is the metal 
assisted cycloaddition of protected enolates and metalo-carbenes generated from the 
decomposition of diazomethane derivitives. Wertz and coworkers demonstrated the synthesis of 
spiroacetals which were prepared from the corresponding cyclopropyl ether67 (Scheme 75).94 
Treatment of enol ether 201 with diazo acetate and copper powder afforded the corresponding 
donor acceptor cyclopropane 202 in good yields. This type of cycloaddition is also the most 
commonly employed in the preparation of Donor-acceptor cyclopropanes (DACs). 
 
Scheme 75. 
 
 
  
 Intramolecular cycloadditions offer routes to useful bicyclic cyclopropyl ethers, which 
are normally accessed through cycloadditions with cyclic enol thers.95 Gharpure developed a 
highly regio- and diastereoselective synthesis of DACs 205 employing intramolecular 
cyclopropanation of vinylogous carbonates 204 with carbenes in the presence of Cu(acac)2 s a 
catalyst (Scheme 76).96 These substituted DACs display high reactivity allowing for the 
regioselective cleavage of the cyclopropane leading to THF derivatives 206.  
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Scheme 76. 
 
 
 
 Cyclopropanations of olefins with alkoxycarbene equivalents provides a route to 
cyclopropyl ethers and DACs, however, most of these protocols are limit d by the availability of 
the corresponding Fisher carbenes. Nonetheless, metalo-carbenes hav  been extensively 
employed in the construction of cyclopropanol scaffolds. For example, wh n arylcarbene 
chromium complexes 208 were treated in THF at low temperatures, with one equivalent of 1-
aminodienes 207, cyclopropane derivatives 209 were obtained, after hydrolysis with silica gel, in 
moderate yield and as single diastereoisomers.  
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Scheme 77.  
 
    
The Kulinkovich reaction allows for a direct and efficient route to cyclopropanols97 in one 
step from readily accessible esters. Its applicability to the synthesis of cyclopropyl ethers is 
limited, since it requires alkylation of the corresponding alcohol. N netheless it is a powerful 
tool and has been extensively employed in the synthesis of unprotected cyclopropanols. For 
example, classical Kulinkovich conditions were used in the total synthesis of Cyathins A3 and B2 
from cyclopropanol 211 dervived from ester 210 (Scheme 78.).98 
 
Scheme 78. 
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2.1.6. Synthetic utility of DACs  
 
Cyclopropane derivatives vicinally substituted by donor and acceptor groups are particularly 
suitable for synthetic applications, since electronic effects of these substituents force activation 
of the cyclopropanes towards ring opening and uncover avenues for a wide variety of interesting 
transformations. A number of useful protocols employing DACs have been d veloped. For 
example DACs serve as efficient electrophiles in nucleophilic addition reactions to provide open 
chain substitutions.99 This reactivity has been exploited by Charette in the addition of amine  and 
phenol nucleophiles. The Lewis acid-catalyzed ring-opening of methyl 1-
nitrocyclopropanecarboxylates 212 with amine nucleophiles 213 is very efficient and  proceeds 
at room temperature and with complete preservation of the enantiomeric purity from the 
electrophilic center of the cyclopropane to the acyclic product 214 in good to excellent yields 
(Scheme 79).100  
 
Scheme 79 
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Addition of a wide variety of  phenol nucleophiles to 215 in the presence of Cs2CO3 also 
proceeded efficiently to give the corresponding ring opening products 216 in medium to high 
yields with complete preservation of the enantiomeric purity from the electrophilic center of 212 
(Scheme 80).101 
 
Scheme 80 
 
 
DACs also serve as all carbon 1,3 dipoles in various [3 + 2]102, [3 + 3]103, and [3 + 
4.]107cycloaddition reactions. Johnson and co-workers recently reported an efficient preparation 
of enantioenriched tetrahydrofuran (THF) derivatives 218 through a dynamic kinetic asymmetric 
transformation of racemic malonate-derived donor-acceptor cyclopropanes 217 via asymmetric 
[3 + 2] cycloaddition with aldehydes.104  
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Scheme 81. 
 
 
  
 Pagenkopf demonstrated annulations between DA-cyclopropanes 221 with pyridines and 
quinolines for the synthesis of indolizines and benzoindolizines. Despite som limitations in 
substrate scope, this methodology provides convenient new pathways to access  variety of 
indolizine scaffolds 222 (Scheme 82).105 
 
Scheme 82. 
 
 
  
 A [3+3] cycloaddition of aromatic azomethine imines 223 with 1,1-cyclopropane diesters 
224 was achieved by Charette using Ni(ClO4)2 as a catalyst. The methodology provided access to 
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unique tricyclic dihydroquinoline 225 derivatives with dr up to 6.6:1. Notably complete retention 
of stereogenic information of the cyclopropane was observed (Scheme 83).106 
 
Scheme 83. 
 
 
  
 Ivanova and co-workers recently developed an analogue of the Diels–Alder reaction with 
donor–acceptor cyclopropanes as dienophiles. This formal [4+3] cycloaddition between 2-aryl 
cyclopropane diesters 227 and 1,3-diphenylisobenzofuran 226 proceeds under mild reaction 
conditions to yield two isomeric cycloadducts 228 in a combined yield of 84–92 % (Scheme 
84).107 
Scheme 84. 
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 DACs synthetic utility has stretched to its incorporation in the total syntheses of several 
natural products. For example, the total synthesis of (±)-goniomitine 230 was accomplished in 17 
linear steps with 5.2% overall yield. A synthetic highlight included the first application of a 
formal [3 + 2] cycloaddition between a highly functionalized nitrile and a donor-acceptor 
cyclopropane to prepare an indole scaffold (Scheme 85) 
 
Scheme 85. 
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2.2. Results and Discussion 
 
2.2.1. Introduction 
  
 While investigating the base-assisted 1,2-dehydrohalogenation of 3,3-disubstituted 
bromocyclopropanes 231a into 3,3-disubstituted cyclopropenes 91 possessing a non-conjugate 
strained double bond,108 we noticed trace amounts of t-BuOH adduct 232c as a single 
diastereomer (Scheme 86). This was exciting since additions of oxygen-based nucleophiles to 
3,3-disubstituted cyclopropenes are scarce. All reported examples of this transformation were 
performed on C2V-symmetric substrates and thus did not have a stereoselectivity issue.
109  We 
envisioned that the facial selectivity of the nucleophilic addition to these substrates could be 
efficiently controlled by steric factors. This effect was observed in the previously reported 
additions of metallic entities to cyclopropenes bearing significantly different by size substituents 
at C3 (Scheme 7).  Also, generation of the strained intermediate 91 in situ would eliminate the 
olefin isolation step and thus expand the range of applicable substrates to the most sensitive 
cyclopropenes. 
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Scheme 86. 
 
 
  
2.2.2. Steric control of diastereoselectivity in the formal nucleophilic substitution of 
bromocyclopropane 
 
 To obtain complete conversion in t-BuOK addition, we carried out the reaction of 2-
bromo-1-methyl-1-phenylcyclopropane 91a with excess t-BuOK (2.0 equiv) in the presence of 
catalytic 18-crown-6 ether (10 mol%) at various temperatures.  It was found that at 80 oC 
bromocyclopropane 231a was transformed into 232c as the sole product in excellent yield.  
Remarkably, the addition proceeded with very high facial selectivity, producing a single trans-
diastereomer.  Similarly, the reaction of bromocyclopropane bearing n ethyl substituent at C3, 
provided tert-butyl ether 231g in high yield and excellent diastereoselectivity, thus confirming 
the efficient steric control (Scheme 87.). Inspired by this result, we tested a series of more 
nucleophilic primary and secondary alkoxides in the addition reaction with 91a in the presence 
of 1.5 equiv of t-BuOK.  We were pleased to find that both n-propoxide and isopropoxide 
underwent efficient addition, providing the corresponding cyclopropyl ethers 232a and 232b as 
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sole products in high yields and excellent diastereoselectivities (Scheme 87).   Benzyl-
protected110 cyclopropanol 231e was also obtained in good yield in the reaction carried out in the 
presence of benzylic alcohol. O-Nucleophiles bearing additional functional groups were also 
successfully employed in this transformation. Thus, 2-(dimethylamino)ethanol reacted 
uneventfully affording 232f in high yield. 
 
Scheme 87. 
 
 
  
  
 The addition of allyl alcohols to 231a was also investigated and it was found that rather 
than providing the corresponding allyl ether 97, cyclopropyl enol undergoes a a base-assisted 
1,3-prototropic rearrangement to provide 96h  as the sole product in very high yield and 
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excellent diastereoselectivity. Notably, the thermodynamically driven rearrangement provided 
only E-isomer (Scheme 88.) 
 
Scheme 88. 
 
 
 
 Intrigued by this rearrangement, we investigated the addition of propargylic alcohol to 
231a. This reaction also was accompanied by a formal 1,3-prototropic rearrangement via 
propargyl ether 235 to provide the corresponding allenyl ether 232i in 82% yield (Scheme 89) 
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Scheme 89. 
 
 
 
 When amino alcohols were employed as competing nucleophiles, only addition by the 
oxygen terminus was observed. Thus, alkoxides possessing a secondary amine functionality 
reacted chemoselectively producing cyclopropyl ethers 236a, 236b, 236c, and 236e with no 
corresponding cyclopropylamine derivatives 237 detected (Scheme 90).  Likewise, the reaction 
of 95a with amino alcohol bearing a primary amine function afforded cyclopropyl ether 236d as 
a sole product. The free amine is not nucleophilic enough to participate in this process and 
generation of the more nucleophilic amide is inefficient as t-BuOK is not a strong enough base. 
Therefore the amine is easily outcompeted by the in situ generated alkoxide to afford the 
corresponding ethers exclusively. 
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Scheme 90. 
 
  
 Considering the relatively high reactivity of phenoxides in previously reported formal 
nucleophilic substitutions, and attempting to expand the range of possible nucleophiles for this 
transformation we explored the possibility of phenoxide addition in the reaction between phenol 
and 231a.  Surprisingly, only traces of phenylcyclopropyl ether 232j were detected in the crude 
reaction mixture; instead tert-butyl ether 232c was obtained as the major product (Scheme 91), 
while use of KOH instead of t-BuOK resulted in no reaction. The addition of p-methoxyphenol 
and p-nitrophenol also failed to give the corresponding aryl ethers. To account for this 
phenomenon, two alternative mechanistic hypotheses can be considered. According to the first 
rationale, addition of both phenoxide and tert-butoxide species to cyclopropene 91a is 
irreversible, but the kinetic rate of the phenoxide addition is significantly lower than that of tert-
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butoxide (k2>>k1). The second hypothesis presumes that the addition of the more nucleophilic 
phenoxide is reversible; and the relatively high nucleofugality of phenoxide111 results in the 
formation of the thermodynamically favored product (Scheme 91) 232c. 
 
Scheme 91. 
 
 
  
 To obtain additional mechanistic evidences that could support or rule out the second 
pathway, we attempted synthesis of the aryl ether 232k. However, employment of our standard 
reaction conditions failed to provide necessary amounts of 232k. Attempts to prepare 232k by 
nucleophilic addition of p-methoxyphenol across the C=C bond of the isolated cyclopropene 91 
using different base and solvent combinations, were also unsuccessful (Scheme 92).  
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Scheme 92. 
 
 
  
 In contrast, a reaction between 4-methoxyphenol and more electron deficient 
cyclopropene 91l, generated in situ from the corresponding mono bromocyclopropane  i  the 
presence of catalytic 18-crown-6 and t-BuOK, in DMSO at 100 oC  afforded a 1:1 mixture of 
phenoxide adduct 242m and tert-butyl ether 242e. Product 242m was isolated in 20% yield and 
re-subjected to the reaction with t-BuOK. However no formation of the t rt-butyl ether 242e was 
observed which ruled out the hypothesis about the reversibility of the phenoxide addition, and 
suggested that addition is controlled by kinetic factors. The inferior reactivity of aryloxides 
compared to tert-butoxide is opposite to that observed in the conjugate addition.  Although this 
phenomenon is not yet completely understood, the non-conjugate strained double bond of 
cyclopropene 91i apparently behaves as a relatively hard electrophile as opposed to the s ft 
conjugate double bond in 1-cyclopropene carboxamides described above (Scheme 69). 
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Scheme 93. 
 
 
 
2.2.3. Direction control of diastereoselectivity through carboxamides 
 
 An attempt to facilitate the addition of an aryloxide species wa made by carrying out the 
reaction in an intramolecular fashion.  Bromocyclopropane 237 possessing a tethered phenol was 
treated with a base under the standard reaction conditions (Scheme 94). Nonetheless, no 
benzoxazacine product 240 was formed; the intermolecular addition of tert-butoxide took place 
instead, providing 239 as a sole product.  Remarkably, cis-diastereomer of 239 was obtained 
exclusively, controlled by a strong chelating effect of the 2-(aminomethyl)phenolate moiety in 
intermediate 238  (Scheme 94). 
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Scheme 94. 
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 Accordingly, we probed the ability of other functional groups to co rdinate to potassium 
cation which serves as a delivery vehicle in the directed addition of alkoxides from the more 
sterically hindered face.  Gratifyingly, it was found that c rboxamide moiety can serve as an 
excellent directing group, governing the addition of nucleophiles from the mor  hindered face. 
Thus, reactions of secondary and tertiary amides 242 with excess t-BuOK afforded the 
corresponding tert-butyl ethers 242d and 242e in high yield and excellent cis-selectivity (Scheme 
95).  Analogously, high facial selectivity was observed in the reaction of sterically hindered 
secondary amides.  Additions carried out in the presence of competing alkoxides, including 
primary 242a, 242f, 242h, and secondary 242b, species revealed both very high diastereo- and 
chemoselectivity. Finally, cis-adducts of 2-methoxyethanol (242j), 2-(dimethylamino)ethanol 
(242k), and 4-pentenol (242h, 242l) were obtained in high yields, once again highlighting the 
excellent functional group compatibility of this transformation.  
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Scheme 95 
 
 
  Cyclopropenylcarboxamides are slightly more reactive as compared to the more electron 
rich 3-alkyl-3-aryl derivitives. With this in mind the addition of allyl alcohols was investigated 
and it was hypothesized that at lower temperatures the 1,3-prototropic rearrangement could be 
avoided to access cyclopropyl allyl ethers. Initially reaction of 241f and allylic alcohol carried 
out at 80 oC afforded allyl ether 243f contaminated with the corresponding E-prop-1-enyl ether 
244f. However when the reaction temperature was lowered to 50 oC the rearrangement was 
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avoided and the corresponding allyl ether 243f was obtained exclusively in 91% yield. Similarly, 
other 2-bromocyclopropancarboxamides underwent efficient formal substitution to produce the 
corresponding allylic ethers 243c-f.  Interestingly reaction of 241 with prenyl and geranyl 
alcohols proceeded uneventfully to give ethers 243b and 243a, respectively (Scheme 96). It 
should be noted that resubjection of bulkier allyl ethers 243c-d to the action of tert-butoxide at 
elevated temperatures did not cause rearrangements to enol ethers 244; this is hypothesized to be 
due to a steric effect caused by the bulky amide functions. 
 
Scheme 96. 
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 Allyl alcohols also reacted smoothly with enolizable carboxamides 245. Addition of 
cinnamyl and allyl alcohols proceeded without rearrangement and the allyl thers 246a,b were 
obtained in 81% and 95% yield, respectively. However the facial selectivity was not controlled 
through directing effects providing cis-cyclopropyl allyl ethers, rather the more 
thermodydnamically favored trans adducts were obtained exclusively (Scheme 97). As 
demonstrated in recent publications by Rubin, the in situ generated conjugated cyclopropene 247
undergoes nucleophilic attack and a thermodynamically favored epimerization of 248a to 248b 
affords the corresponding trans adducts 112(Scheme 98).88  
 
Scheme 97. 
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Scheme 98 
 
 
The addition of propargylic alcohol 234 to enolizable carboxamide 245b was also 
investigated. It was hypothesized that in the presence of a weaker b se and at lower temperatures 
the prototropic rearrangement could be avoided. Indeed, the rearrangement into the allenyl ether 
did not proceed under these conditions, and the reaction afforded propargylic ether 246c in 65% 
yield and as a single isomer (Scheme 99). 
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2.2.4. Direction control of diastereoselectivity through carboxylates 
 
 Having had success in the formal nucleophilic substitution of carboxamides, attention 
was turned to the possibility of formal substitutions on non-conjugated cyclopropyl carboxylates. 
Our attempts to add various nucleophiles to carboxylate 102a provided no substitution and led to 
quick decomposition of the starting material and formation of dark resins. It is presumed that 
tert-butoxide attacked the more electrophilic carbonyl function of the est r rather than the C=C 
bond of cyclopropene, which ultimately led to ring opening. A putative structu e of the 
decomposition product 249 is provided below. (Scheme 100). 
 
Scheme 100. 
 
 
 
It was found, however, that the corresponding diastereomeric mixtures of potassium 1-methyl-2-
bromocyclopropylcarboxylates 102 could be efficiently used instead of cyclopropyl esters.  
Thus, it was previously demonstrated that treatment of 102 with t-BuOK in dry DMSO at 50 oC 
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effects 1,2-dehydroboromination to produce cyclopropene-3-carboxylic salt 103.  The latter upon 
trapping in situ with an SN2-active alkyl halide affords the corresponding ester.
112  We observed 
very similar reactivity when carboxylate 102 was treated with the base and catalytic 18-crown-6 
in a THF solution at 50 oC (Scheme 101).   The corresponding cyclopropenylesters 91b (R = 
Me), 91c (R = Allyl), and 91d (R = Bn) were produced cleanly, as judged by GC/MS and 1H 
NMR analysis of the crude reaction mixtures.  In contrast, dehydrobromination of 102 carried 
out at 80 oC with excess t-BuOK resulted in exclusive formation of salt 103a, which after 
subsequent treatment with methyl iodide or allyl bromide afforded th  corresponding cis-esters 
250b or 250e as sole products in high yield (Scheme 101). Remarkably, similarly to the 
carboxamide function, the carboxylate moiety in intermediate 103 served as an effective 
directing group for the diastereoselective nucleophilic attack. 
 
Scheme 101. 
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 Directed additions of  competing n-propoxide and isopropoxide nucleophiles gave rise to 
cis-esters 250e and 250f in good overall yields and excellent cis-selectivities (Scheme 102).  
Benzyl-protected cis-cyclopropanol 250b was readily produced in the presence of benzyl 
alcohol.  Employment of pent-4-enyl alcohol as a pronucleophile allowed for efficient 
preparation of cyclopropyl ethers 250c and 250d possessing a terminal olefin moiety in the side 
chain.  
 
Scheme 102. 
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  In contrast to the described above nucleophilic attack of allylic a koxides on 
carboxamides (Scheme 102.), the analogous addition to carboxylates 102 was accompanied by a 
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facile base-assisted 1,2-migration of the double bond of 252 to afford, after electrophilic quench, 
E-propenyl ether 250i (Scheme 103.).  Such difference in reactivity can be attributed to a higher 
kinetic C-H acidity of the cis-allyloxide moiety, as a result of lower sterical hindrance exrt d by 
the carboxylic moiety compared to a more bulky carboxamide functionality. 
 
Scheme 103. 
 
 
 
2.3. Conclusion 
 
 An efficient formal nucleophilic substitution of bromocyclopropanes with oxygen-based 
nucleophiles has been developed. This transformation proceeds via a stereoconvergent 
dehydrobromination, followed by diastereoselective addition of a nucleophiic species across the 
strained C=C bond of a cyclopropene intermediate. This methodology is the first to show stereo 
selective formal nucleophilic substitutions of 3,3-disubstituted cyclopropanes. The 
diastereoselective addition can be efficiently controlled by either sterics or a directing effect of 
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appropriate functional groups, such as carboxamides or carboxylic salts. This methodology also 
allows access to densly substituted DACs and potentially medicinally valuable cyclopropanol 
derivitives. 
 2.4. Experimental Procedures 
2.4.1. General Information 
 
 See Chapter 1.4.1. for general remarks and list of  instrumentation. Anhydrous 
dimethylsulfoxide was purchased form Acros Organics and used as received. Anhydrous diethyl 
ether and tetrahydrofuran were obtained by passing degassed HPLC-grade commercially 
available solvents consecutively through two columns with activated alumina (Innovative 
Technology). All other chemicals were purchased from Sigma-Aldrich or Acros Organics, and 
used as received. 
 2-bromocyclopropane carboxamides 242 were all prepared according to published 
procedures.113 For the preparation of 1-methyl-2-bromocyclopropane carboxalates see ection 
1.4.2. Procedures for all other monobromides are provided below. 
 
2.4.2. Preparation of 2-Bromocyclopropanes  
 
 (2-Bromo-1-methylcyclopropyl)methylamine (252): 300 mL of 30% aqueous 
ammonia solution was stirred at 0 oC in 1000 mL Erlenmeyer flask, closed with a rubber stopper 
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with one 6 mm hole.  Acyl chloride 5 (25.0 g, 127 mmol) was added by small portions using 
Pasteur pipette.  Caution: the addition causes a violent exothermic reaction, which may be 
accompanied with producing a white fog of ammonium chloride, and even splashing of the 
ammonia solution.  It is essential to carry out the reaction in a well-ventilated fume-hood.  The 
addition of acyl chloride must be slow.  The use of an addition funnel is ot practical, since it’s 
dropping tube and valve bore can be blocked by ammonium chloride.  After the addition was 
complete the mixture was stirred in the open flask overnight to remv  the excess of ammonia.  
By this time a white solid precipitate was formed, which wasfiltered on a Büchner funnel.  The 
filter cake was washed with ice-cold distilled water, and then dried: first on air, then in vacuum 
desiccator over P2O5 to obtain 2-bromo-1-methylcyclopropanecarboxamide as white powder.  
Yield 13.8 g (77.5 mmol, 61%).  This material (12.7 g, 71.2 mmol) without further purification 
was stirred in anhydrous THF (100 mL) and BH3-SMe2 complex (11.4 g, 14.2 mL, 150 mmol) 
was added.  The resulting mixture was stirred at reflux for 10 hrs, t en the solvent was removed 
in vacuum, and the glassy residue was digested by 10% aqueous HCl (250 mL).  Caution: this 
process is accompanied with violent gas evolution and stench.  All the operations must be 
performed under well-ventilated fume-hood.  The obtained aqueous solution was washed with 
dichloromethane (75 mL), and basified with solid NaOH at 0 oC. Formed oily precipitate was 
extracted with dichloromethane (3 x 75 mL), washed with brine, dried with anhydrous K2CO3, 
filtered and concentrated.  Fractionation in vacuum (bp 72-75 oC at 16 mm Hg) gave amine 20 as 
a colorless oil.  Yield 8.14 g (49.6 mmol, 70%).  GC Rt 5.09 min (minor), 5.45 min (major) 
1H 
NMR (CDCl3, 400.13 MHz) δ [2.90 (dd, J = 7.8 Hz, 4.3 Hz) & 2.82 (dd, J = 7.6 Hz, 4.3 Hz), 
∑1H], [2.90 (d, J = 13.4 Hz) & 2.55 (d, J = 13.4 Hz), ∑1H], [2.74 (d, J = 13.4 Hz) & 2.54 (d, J = 
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13.4 Hz), ∑1H], [1.28 (s) & 1.16 (s), ∑3H], 1.18 (br.s, 2H), [1.06 (dd, J = 7.8 Hz, 6.4 Hz) & 0.98 
(dd, J = 7.6 Hz, 6.1 Hz), ∑1H], [0.76 (dd, J = 6.1 Hz, 4.3 Hz) & 0.65 (dd, J = 6.4 Hz, 4.3 Hz), 
∑1H];  13C NMR (CDCl3, 100.67 MHz) δ 49.7 (-), 49.1 (-), 28.4 (+), 27.7 (+), 23.9 (-), 23.3, 
21.7, 20.5 (-), 20.2 (+), 18.7 (+);  HRMS (TOF ES) found 164.0080, calcd for C15H11BrN (M+H) 
164.0075 (3.0 ppm). 
 
Scheme 104 . Preparation of 2-{[(2-Bromo-1methylcyclopropyl) methylamino]methyl}phenol 
(237) 
 
 
 
 
2-{[(2-Bromo-1-methylcyclopropyl)methylamino]methyl}phenol (237): amine 252 (500 mg, 
3.05 mmol) and salicylic aldehyde (253) (372 mg, 3.05 mmol) were stirred in methanol (5 mL) 
for 24 hrs at room temperature.  Then the solvent was removed in vacuum and the residue was 
purified by preparative column chromatography on Silica gel (eluent h xane-EtOAc 10:1) to 
obtain 2-(((2-bromo-1-methylcyclopropyl)methylimino)methyl)phenol (254) as a yellow oil (Rf 
0.4).  Yield 595 mg (2.22 mmol, 73%).  This material was dissolved in methanol (10 mL) and 
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NaBH4 (420 mg, 11 mmol) was added in one portion.  The mixture was stirred at room 
temperature for 48 hrs, then methanol was removed in vacuum, the residue was dissolved in 10% 
aqueous HCl (25 mL) and washed with dichloromethane (20 mL).  Then the aqueous phase was 
basified with solid NaOH and the amine was extracted with EtOAc (3 x 20 mL).  The combined 
organic phases were washed with brine, dried with anhydrous K2CO3, filtered and concentrated 
to obtain the amine 237 as a colorless oil, yield 522 mg (1.93 mmol, 87%).  This material was 
pure enough to carry out the next step without any additional purification.   
1H NMR (CDCl3, 400.13 MHz) δ 7.22-7.18 (m, 1H), [7.03 (d, J = 8.1 Hz) & 7.01 (d, J = 8.1 
Hz), ∑1H], [6.88 (dd, J = 8.1 Hz, 1.0 Hz) & 6.86 (dd, J = 8.3 Hz, 0.8 Hz), ∑1H], 6.83-6.79 (m, 
1H), [4.14 (d, J = 13.6 Hz) & 4.04 (d, J = 13.6 Hz), ∑1H], [3.97 (d, J = 13.9 Hz) & 3.94 (d, J = 
13.6 Hz), ∑1H], [2.97 (d, J = 12.4 Hz) & 2.67 (d, J = 12.4 Hz), ∑1H], 2.88 (dd, J = 8.1 Hz, 4.6 
Hz, 1H), [2.73 (d, J = 12.4 Hz) & 2.46 (d, J = 12.4 Hz), ∑1H], [1.37 (s) & 1.26 (s), ∑3H], [1.29 
(ps.-t, J = 6.8 Hz, 6.3 Hz), 1.07 (ps.t, J = 7.6 Hz, 6.8 Hz), ∑1H], [0.85 (dd, J = 6.3 Hz, 4.3 Hz) & 
0.74 (dd, J = 6.3 Hz, 4.5 Hz), ∑1H];  13C NMR (CDCl3, 100.67 MHz) δ 158.1, 158.0, 128.8 (+), 
128.7 (+), 128.4 (+), 128.3 (+), 122.5, 122.0, 119.1 (+), 119.0 (+), 116.4 (+), 116.3 (+), 55.9 (-), 
55.5 (-), 52.9 (-), 52.1 (-), 27.8 (+), 27.7 (+), 22.0 (-), 21.0 (+), 20.8 (-), 19.0 (+);  HRMS (TOF 
ES) found 270.0496, calcd for C12H17NOBr (M + H) 270.0493 (1.1 ppm). 
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Scheme 105. 2,2-Dibromo-1-ethyl-1-phenylcyclopropane (256g) 
 
 
 
 2,2-Dibromo-1-ethyl-1-phenylcyclopropane (256g): To a vigorously stirred (1500 rpm) 
mixture of α-ethylstyrene (255)114 (1.73 g, 13.1 mmol), cetrimide (100 mg), bromoform (9.93 g, 
39.3 mmol, 3.0 equiv.), and dichloromethane (5 mL) was added dropwise a 50% aqueous 
solution of NaOH (10 mL).  The mixture was stirred for 20 hrs at room temperature, when GC 
analysis showed full conversion of the starting styrene.  The mixture was quenched with water 
(50 mL) and extracted with CH2Cl2 (3 x 50 mL). Combined organic phases were washed 
consecutively with saturated aqueous NH4Cl (50 mL), brine (50 mL), then dried with MgSO4, 
filtered and concentrated in vacuum.  The residue was distilled in Kugelröhr (0.4 torr, oven temp. 
120-130 oC).  Yield 3.94 g (13.0 mmol, 99%).  1H NMR (400.13 MHz, CDCl3) δ 7.39 (t, J = 7.3 
Hz, 2H), 7.34-7.29 (m, 3H), 2.19 (dq, J = 14.4 Hz, 7.3 Hz, 1H), 2.08 (d, J = 7.6 Hz, 1H), 1.83 
(dq, J = 14.4 Hz, 7.3 Hz, 1H), 1.76 (d, J = 7.6 Hz, 1H), 0.89 (t, J = 7.3 Hz, 3H);  13C NMR 
(125.76 MHz, CDCl3) δ 140.2, 129.5 (+, 2C), 128.1 (+, 2C), 127.2 (+), 41.0, 36.8, 33.7 (-), 32.8 
(-), 11.3 (+); GC: Rt = 9.79 min. 
 
2-Bromo-1-ethyl-1-phenylcyclopropane (231g): To a stirred solution of dibromocyclopropane 
256 (3.94 g, 13.0 mmol) and Ti(OPr-i)4 (37 mg, 0.13 mmol, 10 mol%) in anhydrous ether was 
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added dropwise 3N solution of EtMgBr (5.2 mL, 15.6 mmol, 1.2 equiv.).  The mixture was 
stirred at room temperature for 1 hr, when GC analysis showed complete conversion.  The 
mixture was quenched with saturated aqueous NH4Cl (10 mL), then 10% aqueous sulfuric acid 
(10 mL) and diethyl ether (30 mL) were added.  The organic layer was separated; the aqueous 
phase was extracted with ether (3 x 15 mL).  Combined organic phases were washed with brine, 
dried with MgSO4, filtered and concentrated in vacuum.  The residue was purified by flash
column chromatography on Silica gel eluting with hexane to afford the title compound as 
mixture of diastereomers (1.48:1, colorless oil, Rf 0.43, 0.33).  Yield 2.226 g (9.89 mmol, 76%).  
1H NMR (400.13 MHz, CDCl3) δ 7.43-7.26 (m, 5H), [3.32 (dd, J = 8.1 Hz, 4.6 Hz) & 3.16 (dd, J 
= 7.6 Hz, 4.3 Hz), ∑1H], [2.08-1.85 (m) & 1.42-1.25 (m), ∑3H], [1.60 (ps.-t, J = 7.6 Hz, 6.6 Hz) 
& 1.07 (dd, J = 6.1 Hz, 4.5 Hz), ∑1H], [0.95 (t, J = 7.3 Hz) & 0.88 (t, J = 7.3 Hz), ∑3H];  13C 
NMR (100.67 MHz, CDCl3) major: δ 142.6, 128.8 (+, 2C), 128.3 (+, 2C), 126.6 (+), 31.9, 30.9 (-
), 30.1 (+), 21.7 (-), 10.94 (+);  minor: 140.3, 130.4 (+, 2C), 127.9 (+, 2C), 126.8 (+), 33.5, 33.4 
(-), 27.3 (+), 20.8 (-), 10.87 (+);  GC: Rt = 8.47 min (two diastereomers are not resolved); HRMS 
(TOF ES): found 145.1025, calculated for C11H13 (M-Br) 145.1023 (1.4 ppm). 
 
2.4.3. Additions to Alkyl Aryl bromocyclopropanes 
 
 (1R*,2S*)-tert-Butyl 2-methyl-2-phenylcyclopropyl ether (232c): An oven-
dried 10 mL Weaton vial was charged with t-BuOK (2.38 mmol, 266 mg), 18-
crown-6 ether (0.12 mmol, 21 mg), 1-methyl-1-phenyl-2-bromocyclopropane 
(231a) (1.19 mmol, 250 mg), and anhydrous THF (5 mL).  The mixture was stirred for 18 hr at 
OBu-t
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80 oC, then quenched with water, and extracted with CH2Cl2 (3 x 20 mL).  The combined organic 
phases were washed with brine, dried with CaCl2, filtered and concentrated in vacuum.  The 
residue was purified by flash column chromatography on Silica gel to obtain (1-methyl-2-tert-
butoxycyclopropyl)benzene as a clear oil (Rf 0.20, eluent – hexane).  Yield 226 mg (1.11 mmol, 
93%).  1H NMR (CDCl3, 400.13 MHz) δ 7.35-7.31 (m, 2H), 7.25-7.18 (m, 3H), 3.32 (dd, J = 7.3 
Hz, 4.0 Hz, 1H), 1.50 (s, 3H), 1.31 (s, 9H), 1.26 (dd, J = 7.3 Hz, 6.1 Hz, 1H), 0.79 (dd, J = 6.1 
Hz, 4.0 Hz, 1H);  13C NMR (CDCl3, 100.67 MHz) δ 146.2, 128.3 (+, 2C), 126.1 (+, 2C), 125.4 
(+), 74.3, 58.8 (+), 28.1 (+, 3C), 24.6, 20.8 (-), 18.8 (+);  1H NOE NMR (CDCl3, 500.13 MHz) δ 
0.79 (4%) upon irradiation at 1.50 ppm; GC: Rt 9.50 min; HRMS (TOF ES) found 227.1412, 
calcd for C14H20ONa (M + Na) 227.1407 (2.2 ppm).  
 
(1R*,2S*)-(1-Methyl-2-propoxycyclopropyl)benzene (232a): An oven-dried 
10 mL Weaton vial was charged with t-BuOK (2.38 mmol, 266 mg), 18-crown-
6 ether (0.12 mmol, 32 mg), 1-methyl-1-phenyl-2-bromocyclopropane (231a) 
(1.19 mmol, 250 mg), and anhydrous THF (5 mL).  The mixture was stirred for 2 min, and then 
n-propanol (1.78 mmol, 107 mg) was added.  The resulting mixture was stirred for 18 hr at 80 
oC, then quenched with water, and extracted with CH2Cl2 (3 x 20 mL).  Combined organic 
phases were washed with brine, dried with CaCl2, filtered and concentrated in vacuum.  The 
residue was purified by flash column chromatography on Silica gel to obtain (1-methyl-2-
propoxycyclopropyl)benzene as a clear oil (Rf 0.15, eluent – hexane).  Yield 224 mg (1.18 mmol, 
99%).  1H NMR (CDCl3, 400.13 MHz) δ 7.34-7.30 (m, 2H), 7.26-7.18 (m, 3H), 3.61-3.52 (m, 
2H), 3.37 (dd, J = 7.1 Hz, 3.8 Hz, 1H), 1.69 (sextet, J = 7.1 Hz, 2H), 1.53 (s, 3H), 1.17 (dd, J = 
O
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7.1 Hz, 6.1 Hz, 1H), 1.00 (t, J = 7.6 Hz, 3H), 0.87 (dd, J = 6.1 Hz, 3.8 Hz, 1H);  13C NMR 
(CDCl3, 100.67 MHz) δ 146.0, 128.3 (+, 2C), 126.9 (+, 2C), 125.7 (+), 73.0 (-), 64.5 (+), 26.1, 
23.0 (-), 20.4 (-), 18.8 (+), 10.7 (+);  1H NOE NMR (CDCl3, 500.13 MHz) δ 0.87 (5%) upon 
irradiation at 1.53 ppm;  GC: Rt 9.54 min; HRMS (TOF ES) found 209.1769, calcd for 
C13H23ON (M + NH4) 209.1780 (5.3 ppm).  
 
(1R*,2S*)-(2-Isopropoxy-1-methylcyclopropyl)benzene (232b): was obtained 
according to the procedure described for preparation of compound 232a, employing 
isopropanol (1.78 mmol, 107 mg) instead of n-propanol.  Yield 217 mg (1.14 
mmol, 96%), colorless oil (Rf 0.35, hexane).  
1H NMR (CDCl3, 400.13 MHz) δ 7.34-7.31 (m, 
2H), 7.26-7.19 (m, 3H), 3.70 (septet, J = 6.1 Hz, 1H), 3.43 (dd, J = 7.3 Hz, 3.8 Hz, 1H), 1.52 (s, 
3H), 1.27 (d, J = 6.1 Hz, 3H), 1.26 (d, J = 6.1 Hz, 3H), 1.19 (dd, J = 7.3 Hz, 5.8 Hz, 1H), 0.85 
(dd, J = 5.8 Hz, 3.8 Hz, 1H);  13C NMR (CDCl3, 100.67 MHz) δ 146.1, 128.3 (+, 2C), 126.7 (+, 
2C), 125.6, 72.3 (+), 62.5 (+), 26.1, 22.5 (+), 21.9 (+), 20.4 (-), 19.1 (+);  1H NOE NMR (CDCl3, 
500.13 MHz) δ 0.85 (3%) upon irradiation at 1.52 ppm;  GC: Rt 9.17 min; HRMS (TOF ES) 
found 197.1527, calcd for C13H18OLi (M + Li) 197.1518 (4.6 ppm).  
 
(1R*,2S*)-N,N-Dimethyl-2-(2-methyl-2-phenylcyclopropoxy)ethylamine 
(232f): was obtained according to the procedure described for preparation of 
compound 232a employing 2-(dimethylamino)ethanol (158 mg, 1.78 mmol) 
instead of n-propanol.  Yield 215 mg (0.98 mmol, 83%), colorless oil (Rf  0.1, 
EtOAc).  1H NMR (CDCl3, 400.13 MHz) δ 7.31 (t, J = 7.8 Hz, 2H), 7.24 (d, J = 7.1 Hz, 2H), 
O
NMe2
O
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7.20 (t, J = 7.3 Hz, 1H), 3.75-3.65 (m, 2H), 3.39 (dd, J = 7.1 Hz, 3.5 Hz, 1H), 2.62-2.57 (m, 2H), 
2.32 (s, 6H), 1.53 (s, 3H), 1.16 (ps.-t, J = 7.1 Hz, 6.1 Hz, 1H), 0.90 (dd, J = 6.1 Hz, 3.5 Hz, 1H);  
13C NMR (CDCl3, 100.67 MHz) δ 145.9, 128.3 (+, 2C), 126.8 (+, 2C), 125.7 (+), 69.1 (-), 64.8 
(+), 58.8 (-), 45.8 (+), 26.1, 20.3 (-), 18.8 (+);  HRMS (TOF ES) found 242.1530, calcd for 
C14H21NONa (M + Na) 242.1521 (3.7 ppm). 
 
(1R*,2S*)-2-Methyl-2-phenylcyclopropyl (1E)-prop-1-enyl ether (232h): was 
obtained according to the procedure described for preparation of compound 232a, 
employing allyl alcohol (1.78 mmol, 103 mg) instead of n-propanol.  Yield 222 mg 
(1.18 mmol, 98%), colorless oil (Rf 0.25, hexane).  
1H NMR (CDCl3, 400.13 MHz) 
δ 7.35-7.20 (m, 5H), 6.18 (dq, J = 6.3 Hz, 1.8 Hz, 1H), 4.52 (ps.-quintet, J = 6.6 Hz, 1H), 3.69 
(dd, J = 7.1 Hz, 3.5 Hz, 1H), 1.65 (dd, J = 6.8 Hz, 1.8 Hz, 3H), 1.52 (s, 3H), 1.24 (ps.-t, J = 7.1 
Hz, 6.3 Hz, 1H), 0.99 (dd, J = 6.3 Hz, 3.5 Hz, 1H);  13C NMR (CDCl3, 100.67 MHz) δ 145.3, 
145.1 (+), 128.4 (+, 2C), 127.0 (+, 2C), 126.0 (+); 102.1 (+), 64.8 (+), 26.1, 20.1 (-), 19.2 (+), 9.2 
(+);  1H NOE NMR (CDCl3, 500.13 MHz) δ 0.99 (5%) upon irradiation at 1.52 ppm;  GC: Rt 
9.56 min; HRMS (TOF ES) found 211.1095, calcd for C13H16ONa (M + Na) 211.1099 (1.9 
ppm). 
 
 [(1R*,2S*)-2-(Benzyloxy)-1-methylcyclopropyl]benzene (232e): An 
oven-dried 10 ml Wheaton vial was charged with potassium tert-
butoxide (113 mg, 1.05 mmol, 1.5 equiv) and of 18-crown-6 (19 mg, 
11 mmol, 10 mol%), and anhydrous THF (8 mL).  2-Bromo-1-methyl-1-phenylcyclopropane 
Me
O
O
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(147 mg, 0.7 mmol, 1.0 equiv) was added, followed by benzyl alcohol (113 mg, 1.05 mmol, 1.5 
equiv). The mixture was stirred for 13 hr at 80 oC, when GC showed the reaction was complete.  
The mixture was quenched with water (5 ml), and extracted with EtOAc (4 x 10 ml).  Combined 
organic phases were washed with brine (10 mL), dried with MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel (Rf = 
0.9, Hexane/EtOAc 1:1) to afford the title compound as colorless oil.  Yield 125 mg (0.53 mmol, 
75%).  1H NMR (400.13 MHz, CDCl3) δ 7.47-7.23 (m, 10H), 4.71 (d, J = 11.4 Hz, 1H), 4.70 (d, 
J = 11.4 Hz, 1H), 3.53 (dd, J = 7.1 Hz, 3.8 Hz, 1H), 1.62 (s, 3H), 1.24 (ps.-t, J = 7.1 Hz, 5.8 Hz, 
1H), 0.98 (dd, J = 5.8 Hz, 3.8 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ145.8, 137.9, 128.4 (+, 
2C), 128.3 (+, 2C), 127.9 (+, 2C), 127.7 (+), 126.9 (+, 2C), 125.8 (+), 73.4 (-), 64.4 (+), 26.3, 
20.4 (-), 19.0 (+);  GC: Rt 11.43 min; HRMS (TOF ES): found 256.1705, calculated for 
C17H22NO (M+NH4) 256.1701 (1.6 ppm). 
 
[(1R*,2S*)-2-tert-Butoxy-1-ethylcyclopropyl]benzene (232g):  An oven-
dried 10 ml Wheaton vial was charged with tert-butoxide (235 mg, 2.10 mmol, 
3.00 equiv), 18-crown-6 (18 mg, 0.07 mmol, 10 mol%), and anhydrous THF (8 
mL).  2-Bromo-1-ethyl-1-phenylcyclopropane (147 mg, 0.70 mmol, 1.0 equiv) was added via 
syringe.  The reaction mixture was stirred at 80 deg for 13 hr, when GC showed the reaction was 
complete.  The mixture was quenched with water (5 mL) and extracted wi h EtOAc (4 x 10 mL).  
Combined organic phases were washed with brine (10 mL), dried with MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash column chromatography 
(Rf = 0.6, Hexane/EtOAc 5:1) to afford a colorless oil.  Yield 130 mg (0.56 mmol, 85%).  
1H 
O
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NMR (400.13 MHz, CDCl3) δ 7.33 (ps.-t, J = 7.8 Hz, 7.1 Hz, 2H), 7.27 (d, J = 7.8 Hz, 2H), 7.21 
(t, J = 7.1 Hz, 1H), 3.28 (dd, J = 7.1 Hz, 4.0 Hz, 1H), 1.96 (dqd, J =  14.2 Hz, 7.3 Hz, 1.8 Hz, 
1H), 1.67 (dq, J = 14.2 Hz, 7.3 Hz, 1H), 1.32 (s, 3H), 1.26 (ddd, J = 7.1 Hz, 5.8 Hz, 1.8 Hz, 1H), 
0.93 (t, J = 7.3 Hz, 3H), 0.69 (dd, J = 5.8 Hz, 4.0 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 
144.4, 128.2 (+, 2C), 127.9 (+, 2C), 125.6 (+), 74.3, 59.0 (+), 31.4, 28.2 (+, 3C), 25.3 (-), 17.8 
(-), 11.3 (+);  GC: Rt 8.76 min; HRMS (TOF ES): found 219.1748, calculated for C16H23O 
(M+H) 219.1749 (0.5 ppm). 
O  ((1R*,2S*)-1-Methyl-2-(propa-1,2-dien-1-yloxy)cyclopropyl)benzene 
(232i):  Was prepared according to Typical Procedure, employing (2-bromo-1-
methylcyclopropyl)benzene (105 mg, 0.50 mmol, 1.00 equiv) and propargyl alcohol (34 mg, 
0.60 mmol, 1.2 equiv). The reaction was carried out at 80oC for 3 hrs.  Preparative column 
chromatography of the residual oil on silica gel afforded the title compound as a colorless oil, Rf 
0.20 (hexane).  Yield 76 mg (0.41 mmol, 82%).  1H NMR (400.13 MHz, CDCl3) δ 7.24-7.16 (m, 
4H), 7.11 (tdd, J = 6.6 Hz, 2.5 Hz, 1.8 Hz, 1H), 6.69 (t, J = 5.9 Hz, 1H), 5.38 (dd, J = 8.3 Hz, 6.1 
Hz, 1H), 5.34 (dd, J = 8.6 Hz, 6.1 Hz, 1H), 3.48 (dd, J = 7.1 Hz, 3.8 Hz, 1H), 1.40 (s, 3H), 1.16 
(t, J = 6.6 Hz, 1H), 0.87 (dd, J = 6.2 Hz, 3.7 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 201.6, 
145.2, 128.3 (+, 2C), 126.9 (+, 2C), 125.9 (+), 121.5 (+), 90.6 (-), 63.0 (+), 25.8, 20.4 (-), 18.9 
(+);  FT IR (NaCl, cm-1): 3059, 2932, 2378, 2291, 2253, 1798, 1730, 1686, 1628, 1603, 1578, 
1541, 1528, 1508, 1497, 1483, 1464, 1448, 1375, 1364, 1267, 1171, 1121, 1109, 1094, 1070, 
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1041, 1030, 1011, 918, 808, 764, 700, 588;  HRMS (TOF ES): found 187.1119, calculated for 
C13H15O (M+H) 187.1123 (2.1 ppm). 
 
2.4.4. Amino Alcohol Additions 
 
 
N-Benzyl-3-((1R*,2S*)-2-methyl-2-phenylcyclopropoxy)propan-1-
amine (236b) (Typical Procedure):  To a stirred suspension of t-BuOK (141 mg, 
1.26 mmol, 2.50 equiv), 18-crown-6 (13 mg, 50 µmol, 10 mol%) in anhydrous 
THF (1 mL) was added (2-bromo-1-methylcyclopropyl)benzene (18a) (106 mg, 
0.503 mmol, 1.00 equiv), followed by 3-(benzylamino)propan-1-ol (125 mg, 0.76 mmol, 1.51 
equiv).  The mixture was stirred at 80 oC for 18 hrs.  Then, the KBr precipitate was filtered off 
on a fritted funnel and the filtrate was concentrated in vacuum. Preparative column 
chromatography of a residue on silica gel doped with triethylamine afforded the title compound 
as a light orange oil, Rf 0.30 (EtOAc).  Yield 134 mg (0.45 mmol, 90%).  
1H NMR (400.13 
MHz, CDCl3) δ 7.48-7.21 (m, 10H), 3.88 (s, 2H), 3.78-3.69 (m, 2H), 3.41 (dd, J = 7.1 Hz, 3.5 
Hz, 1H), 2.85 (t, J = 6.9 Hz, 2H), 1.93 (quin, J = 6.6 Hz, 2H), 1.57 (s, 3H), 1.21 (t, J = 6.4 Hz, 
1H), 0.90 (dd, J = 5.8 Hz, 3.8 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 145.7, 140.2, 128.2 
(+, 2C), 128.2 (+, 2C), 128.0 (+, 2C), 126.72 (+), 126.68 (+, 2C), 125.6 (+), 69.5 (-), 64.4 (+), 
53.9 (-), 46.6 (-), 30.0 (-), 25.9, 20.3 (-), 18.7 (+);  FT IR (cm-1, film): 3338, 3061, 3026, 2951, 
2828, 2870, 1589, 1495, 1454, 1447, 1360, 1169, 1119, 1092, 1028, 827, 760, 743, 698;  HRMS 
(TOF ES): found 318.1838, calculated for C20H25NONa (M+Na) 318.1834 (1.3 ppm).  
PhMe
O
N
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N-(3-((1R*,2S*)-2-Methyl-2-phenylcyclopropoxy)propyl)hexan-1-amine 
(236a):  Was prepared according to Typical Procedure, employing (2-bromo-1-
methylcyclopropyl) benzene (111 mg, 0.52 mmol, 1.0 equiv) and 3-
(hexylamino)propanol (110 mg, 0.69 mmol, 1.3 equiv).  Preparative column chromatography on 
silica gel doped with triethylamine afforded the title compound as a yellowish oil, Rf 0.50 
(Hexane/EtOAc 8:1). Yield 139 mg (0.48 mmol, 92%).  1H NMR (400.13 MHz, CDCl3) δ 7.34-
7.27 (m, 2H), 7.26-7.16 (m, 3H), 3.71-3.61 (m, 2H), 3.35 (dd, J = 6.9 Hz, 3.7 Hz, 1H), 2.74 (t, J 
= 6.9 Hz, 2H), 2.62 (t, J = 7.2 Hz, 2H), 1.89-1.80 (m, 2H), 1.50 (s, 3H), 1.53-1.45 (m, 2H), 1.38-
1.25 (m, 7H), 1.15 (t, J = 6.6 Hz, 1H), 0.93-0.87 (m, 3H), 0.84 (dd, J = 5.9 Hz, 3.7 Hz, 1H);  13C 
NMR (100.67 MHz, CDCl3) δ 145.9, 128.3 (+, 2C), 126.8 (+, 2C), 125.7 (+), 69.8 (-), 64.5 (+), 
50.1 (-), 47.4 (-), 31.8 (-), 30.2 (-), 30.1 (-), 27.1, 26.1 (-), 22.6 (-), 20.4 (-), 18.8 (+), 14.0 (+);  
FT IR (cm-1, film): 3319, 2955, 2928, 2870, 2856, 2816, 1497, 1458, 1447, 1364, 1292, 1240, 
1171, 1132, 1090, 1070, 1028, 1013, 997, 933, 891, 827, 762, 744, 727, 698, 534; HRMS (TOF 
ES):  found 312.2305, calculated for C19H31NONa (M+Na) 312.2303 (0.6 ppm).   
 
N-(Furan-2-ylmethyl)-3-((1R*,2S*)-2-methyl-2-phenylcyclopropoxy)propan-
1-amine (236c):  Was prepared according to Typical Procedure, employing (2-
bromo-1-methylcyclopropyl)benzene (110 mg, 0.52 mmol, 1.0 equiv) followed 
by 3-((furan-2-ylmethyl)amino)propan-1-ol (124 mg, 0.80 mmol, 1.5 equiv).  Preparative 
column chromatography of the residue on silica gel doped with triet ylamine afforded the title 
compound as a light orange oil, Rf 0.50 (Hex/EtOAc 5:1).  Yield 119 mg (0.42 mmol, 80%).  
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NMR (400.13 MHz, CDCl3) δ 7.38 (dd, J = 1.8 Hz, 0.8 Hz, 1H), 7.35-7.27 (m, 2H), 7.26-7.17 
(m, 3H), 6.33 (dd, J = 3.2 Hz, 1.9 Hz, 1H), 6.20 (d, J = 2.8 Hz, 1H), 3.82 (s, 2H), 3.66 (td, J = 
6.2 Hz, 2.5 Hz, 2H), 3.35 (dd, J = 7.1 Hz, 3.8 Hz, 1H), 2.77 (t, J = 6.9 Hz, 2H), 1.86 (quin, J = 
6.6 Hz, 2H), 1.57 (quin, J = 6.4 Hz, 1H), 1.50 (s, 3H), 1.16 (t, J = 6.4 Hz, 1H), 0.84 (dd, J = 5.8 
Hz, 3.8 Hz, 1H); 13C NMR (100.67 MHz, CDCl3) δ 154.0, 145.9, 141.8 (+), 128.4 (+, 2C), 126.9 
(+, 2C), 125.8 (+), 110.1 (+), 106.8 (+), 69.7 (-), 64.6 (+), 46.6 (-), 46.3 (-), 30.1 (-), 26.1, 20.4 (-
), 18.8 (+);  FT IR (KBr, cm-1): 3105, 3086, 3072, 2951, 2928, 2868, 1161, 1148, 1117, 1092, 
1072, 1028, 762, 733, 700; HRMS (TOF ES): found 286.1802, calculated for C18H24NO2 (M+H) 
286.1807 (1.7 ppm). 
 
N-(2-(2-((1R*,2S*)-2-Methyl-2-phenylcyclopropoxy)ethoxy)-
ethyl)butan-1-amine (236e):  Was prepared according to Typical 
Procedure employing (2-bromo-1-methylcyclopropyl)benzene (231a) (106 mg, 0.50 mmol, 1.0 
equiv) and 2-(2-(butylamino)ethoxy)ethanol (99 mg, 0.62 mmol, 1.3 equiv).  Preparative column 
chromatography of the residue on silica gel doped with triethylamine afforded the title comp-
ound as an yiellow oil, Rf 0.50 (EtOAc/MeOH 20:1). Yield 120 mg (0.41 mmol, 82%).  
1H NMR 
(400.13 MHz, CDCl3) δ 7.34-7.26 (m, 2H), 7.25-7.16 (m, 3H), 3.79-3.74 (m, 2H), 3.71-3.66 (m, 
2H), 3.63 (t, J = 5.3 Hz, 2H), 3.43 (dd, J = 7.1 Hz, 3.5 Hz, 1H), 3.41-3.33 (m, 1H), 2.84-2.79 (m, 
2H), 2.66-2.60 (m, 2H), 1.89 (br. s., 1H), 1.52 (s, 3H), 1.54-1.43 (m, 1H), 1.41-1.30 (m, 2H), 
1.16 (t, J = 6.6 Hz, 1H), 0.93 (t, J = 7.3 Hz, 3H), 0.88 (dd, J = 5.8 Hz, 3.8 Hz, 1H);  13C NMR 
(100.67 MHz, CDCl3) δ 145.8, 128.3 (+, 2C), 126.8 (+, 2C), 125.7 (+), 70.6 (-), 70.4 (-), 70.1 (-), 
64.8 (+), 49.6 (-), 49.3 (-), 32.2 (-), 26.2, 20.43 (-), 20.41 (-), 18.7 (+), 14.0 (+);  FT IR (cm-1,
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film): 3321, 3059, 3024, 2957, 2928, 2872, 1670, 1603, 1578, 1541, 1497, 1458, 1447, 1377, 
1348, 1323, 1292, 1246, 1173, 1121, 1095, 1055, 1028, 1013, 995, 951, 920, 872, 827, 762, 748, 
698, 669, 650, 596, 534, 473, 409;  HRMS (TOF ES):  found 292.2271, calculated for 
C18H30NO2 (M+H) 292.2277 (2.1 ppm).   
 
3-((1R*,2S*)-2-Methyl-2-phenylcyclopropoxy)propan-1-amine (236d): Was 
prepared according to Typical Procedure, employing (2-bromo-1-
methylcyclopropyl)benzene (231a) (102 mg, 0.49 mmol, 1.0 equiv) and 3-
aminopropan-1-ol (66 mg, 0.88 mmol, 1.7 equiv).  Preparative column chromatography on silica 
gel doped with triethylamine afforded the title compound as an pale orange oil, Rf 0.50 
(EtOAc/MeOH 1:1).  Yield 80 mg (0.39 mmol, 81%).  1H NMR (400.13 MHz, CDCl3) δ ppm 
7.33-7.28 (m, 2H), 7.24-7.18 (m, 3H), 3.71-3.66 (m, 2H), 3.70 (br. s, 2H), 3.36 (dd, J = 6.9 Hz, 
3.7 Hz, 1H), 2.94 (t, J = 6.6 Hz, 1H), 2.03-1.96 (m, 2H), 1.88 (quin, J = 6.5 Hz, 1H), 1.50 (s, 
3H), 1.16 (app. t, J = 6.9 Hz, 6.1 Hz, 1H), 0.84 (dd, J = 6.1 Hz, 3.8 Hz, 1H);  13C NMR (100.67 
MHz, CDCl3) δ ppm 145.6, 128.3 (+, 2C), 126.8 (+, 2C), 125.8 (+), 68.7 (-), 64.5 (+), 38.2 (-), 
30.2 (-), 26.0, 20.3 (-), 18.8 (+);  FT IR (cm-1, film): 3354, 3292, 3057, 3024, 2955, 2928, 2872, 
1558, 1539, 1497, 1404, 1362, 1339, 1294, 1250, 1169, 1092, 1028, 1013, 955, 922, 829, 698, 
650, 536; HRMS (TOF ES):  found 206.1547, calculated for C13H20NO (M+H) 206.1545 (1.0 
ppm). 
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2.4.5. Addition to Amides 
 
Me
ButO
N
H
HO  (1R*,2R*)-2-{[(2-tert-Butoxy-1-methylcyclopropyl)methylamino]-
methyl}phenol (239): was prepared from bromocyclopropane 237 (135 mg, 0.50 mmol) and t-
BuOK (170 mg, 1.50 mmol) in the presence of 18-crown-6 (13 mg, 0.05 mmol, 10 mol%).  The 
mixture was stirred in anhydrous THF (5 mL) at 80 oC for 20 hrs.  The mixture was partitioned 
between water and EtOAc and extracted with EtOAc (3 x 20 mL).  The combined organic phases 
were washed with brine, dried over MgSO4, filtered and concentrated.  The residue was purified 
by preparative column chromatography on Silica gel, eluent EtOAc to afford yellowish oil.  
Yield 91 mg (0.35 mmol, 69%).  1H NMR (C6D6, 500.13 MHz) δ 7.28 (dd, J = 7.3 Hz, 1.5 Hz, 
1H), 7.25 (ps.-td, J = 8.2 Hz, 6.9 Hz, 1.6 Hz, 1H), 6.97 (dd, J = 6.9 Hz, 1.3 Hz, 1H), 6.88 (td, J = 
7.3 Hz, 1.3 Hz, 1H), 3.77 (d, J = 13.9 Hz, 1H), 3.67 (d, J = 13.9 Hz, 1H), 2.83 (dd, J = 6.0 Hz, 
3.5 Hz, 1H), 2.67 (d, J = 11.7 Hz, 1H), 2.55 (d, J = 11.7 Hz, 1H), 1.14 (s, 9H), 0.96 (s, 3H), 0.39 
(dd, J = 5.4 Hz, 3.5 Hz, 1H), 0.30 (ps.-t, J = 6.0 Hz, 5.4 Hz, 1H);  13C NMR (CDCl3, 100.67 
MHz) δ 158.5, 128.5 (+), 128.1 (+), 122.9, 118.7 (+), 116.3 (+), 74.5, 56.4 (+), 53.1 (-), 53.0 (-), 
28.1 (+, 3C), 21.2 (+), 19.9 (-), 19.3;  1H NOE NMR (CDCl3, 500.13 MHz) δ 1.14 (5%) upon 
irradiation at 2.83 ppm;  HRMS (TOF ES) found 264.1957, calcd for C16H26NO2 (M + H) 
264.1963 (2.3 ppm). 
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 (1R*,2S*)-2-tert-Butoxy-N,N-diethyl-1-methylcyclopropanecarboxamide 
(242e): An oven-dried 10 mL Wheaton vial was charged with cyclopropylbromide 
241e (233 mg, 1.00 mmol), t-BuOK (343 mg, 3.50 mmol), 18-crown-6 (26.4 mg, 
0.100 mmol, 10 mol%), and anhydrous THF (5 mL).  The mixture was stirred at 80 oC overnight 
when GC showed the reaction was complete.  The mixture was quenched wit  water (5 mL) and 
extracted with EtOAc (4 x 10 mL).  Combined organic phases were ashed with brine (10 mL), 
dried with MgSO4, filtered and concentrated under reduced pressure. The residue was purified by 
flash column chromatography (Rf = 0.15, Hexane/EtOAc 3:1) to afford a colorless oil, yield 197 
mg (0.87 mmol, 87%).  1H NMR (500.19 MHz, CDCl3) δ 3.59 (dq, J = 14.2 Hz, 6.9 Hz, 1H), 
3.53 (dq, J = 14.2 Hz, 6.9 Hz, 1H), 3.41 (dq, J = 14.2 Hz, 6.9 Hz, 1H), 3.24 (dq, J = 14.2 Hz, 6.9 
Hz, 1H), 3.13 (dd, J = 3.20 (dd, J = 5.6 Hz, 3.5 Hz, 1H), 1.22 (s, 3H), 1.23-1.20 (m, 4H), 1.19 (s, 
9H), 1.08 (t, J = 6.9 Hz, 3H), 0.64 (ps.-t, J = 5.8 Hz, 5.6 Hz, 1H);  13C NMR (125.76 MHz, 
CDCl3) δ 171.2, 74.7, 56.6 (+), 40.7 (-), 38.2 (-), 28.0 (+, 3C), 24.6, 21.0 (-), 20.8 (+), 14.1 (+), 
12.2 (+);  HRMS (TOF ES) found 228.1968, calcd for C13H26NO2 (M + H) 228.1964 (0.9 ppm). 
 
(1R*,2S*)-N,N-Diethyl-1-methyl-2-propoxycyclopropanecarboxamide (242f): 
An oven-dried 10 mL Weaton vial was charged with t-BuOK (168 mg, 1.50 
mmol), 18-crown-6 ether (26 mg, 0.10 mmol), 2-bromo-N,N diethyl-1-methyl-
cycloprop-2-enecarboxamide 241e (248 mg, 1.00 mmol), n-propanol (112 µL, 90 
mg, 1.50 mmol) and anhydrous THF (5 mL).  The mixture was stirred for 18 hrs at 80 oC, and 
then partitioned between water and ethylacetate.  The organic phase was separated; the aqueous 
layer was extracted with EtOAc (3 x 20 mL).  The combined organic phases were washed with 
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brine, dried with MgSO4, filtered and concentrated.  Purification of the residue by preparative 
column chromatography afforded the title compound as a colorless oil, yield 213 mg (0.94 
mmol, 94%).  1H NMR (CDCl3, 400.13 MHz) δ 3.62 (dq, J = 14.2 Hz, 7.1 Hz, 1H), 3.51-3.23 
(m, 5H), 3.19 (dd, J = 5.6 Hz, 3.5 Hz, 1H), 1.47 (sextet, J = 6.8 Hz, 2H), 1.19 (t, J = 7.2 Hz, 3H), 
1.19 (s, 3H), 1.16 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 1.06 (t, J = 7.1 Hz, 3H), 0.82 (t, J = 7.3 Hz, 3H), 
0.56 (ps.-t, J = 5.8 Hz, 5.6 Hz, 1H); 13C NMR (CDCl3, 100.67 MHz) δ 170.8, 71.8 (-), 62.9 (+), 
40.9 (-), 38.5 (-), 27.4, 22.7 (-), 20.5 (+), 18.3 (-), 13.9 (+), 12.2 (+), 10.5 (+);  1H NOE NMR 
(CDCl3, 500.13 MHz)   3.19 (5%) and 0.56 (4%) upon irradiation at 1.19 ppm;  HRMS (TOF 
ES) found 214.1813, calcd for C12H24NO2 (M + H) 214.1807 (2.8 ppm). 
 
 
(1R*,2S*)-2-Butoxy-N,N-diethyl-1-methylcyclopropanecarboxamide (242g): 
was obtained according to the procedure described for compound 242f, employing 
n-butanol (137 µL, 11 mg, 1.50 mmol) instead of n-propanol.  Yield 220 mg (0.91 
mmol, 91%), colorless oil.  1H NMR (CDCl3, 400.13 MHz) δ 3.63 (dq, J = 14.2 
Hz, 7.1 Hz, 1H), 3.49-3.34 (m, 4H), 3.24 (dq, J = 14.2 Hz, 7.1 Hz, 1H), 3.20 (dd, J = 5.6 Hz, 3.5 
Hz, 1H), 1.48-1.40 (m, 2H), 1.33-1.25 (m, 2H), 1.20 (t, J = 7.1 Hz, 3H), 1.19 (s, 3H), 1.17 (dd, J 
= 5.8 Hz, 3.5 Hz, 1H), 1.06 (t, J = 7.1 Hz, 3H), 0.85 (t, J = 7.3 Hz, 3H), 0.57 (ps.-t, J = 5.8 Hz, 
5.6 Hz, 1H);  13C NMR (CDCl3, 100.67 MHz) δ 170.8, 70.0 (-), 62.9 (+), 40.9 (-), 38.5 (-), 31.5 
(-), 27.4, 20.5 (+), 19.2 (-), 18.3 (-), 14.0 (+), 13.8 (+), 12.2 (+);  HRMS (TOF ES) found 
226.1817, calcd for C13H24NO2 (M - H) 226.1807 (4.4 ppm). 
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(1R*,2S*)-1-{[1-Methyl-2-(pent-4-enyloxy)cyclopropyl]carbonyl}pyrrolidine 
(242h): was obtained according to the procedure described for compound 242f, 
employing bromocyclopropane 241f (237 mg, 1.00 mmol) and 4-penten-1-ol 
(155 µL, 129 mg, 1.50 mmol).  Yield 218 mg (0.92 mmol, 92%).  Rf 0.30 
(hexane-EtOAc 2:3).  1H NMR (CDCl3, 400.13 MHz) δ 5.74 (ddt, J = 16.9 Hz, 10.1 Hz, 6.6 Hz, 
1H), 4.95 (dq, J = 16.9 Hz, 1.5 Hz, 1H), 4.91 (dq, J = 10.1 Hz, 1.5 Hz, 1H), 3.84-3.79 (m, 1H), 
3.47-3.35 (m, 5H), 3.15 (dd, J = 5.6 Hz, 3.5 Hz, 1H), 2.00 (ps.-q, J = 7.8 Hz, 6.8 Hz, 1H), 1.94-
1.83 (m, 2H), 1.81-1.74 (m, 2H), 1.55 (ps.-quintet, J = 7.6 Hz, 6.6 Hz, 2H), 1.21 (s, 3H), 1.18 
(dd, J = 5.8 Hz, 3.5 Hz, 1H), 0.55 (ps.-t, J = 5.8 Hz, 5.6 Hz, 1H); 13C NMR (CDCl3, 100.67 
MHz) δ 169.9, 138.1 (+), 114.6 (-), 69.4 (-), 62.2 (+), 46.3 (-), 45.9 (-), 30.1 (-), 28.5 (-), 28.1, 
26.2 (-), 24.1 (-), 19.3 (+), 17.7 (-);  HRMS (TOF ES) found 238.1805, calcd for C14H24NO2 (M 
+ H) 238.1807 (0.8 ppm). 
 
(1R*,2S*)-1-Methyl-N-octyl-2-propoxycyclopropanecarboxamide (242a):  
was prepared from bromocyclopropane 241b (250 mg, 0.861 mmol) according 
to the procedure described for compound 242f.  Yield 218 mg (0.810 mmol, 
94%), colorless oil.  1H NMR (CDCl3, 400.13 MHz) δ 6.48 (br.s, 1H), 3.50 (t, 
J = 6.8 Hz, 2H), 3.31 (dd, J = 6.6 Hz, 4.3 Hz, 1H), 3.26-3.17 (m, 2H), 1.62 (sextet, J = 7.3 Hz, 
2H), 1.49-1.42 (m, 2H), 1.30-1.25 (m, 10H), 1.20 (s, 3H), 1.11 (dd, J = 6.1 Hz, 4.3 Hz, 1H), 0.94 
(t, J = 7.3 Hz, 3H), 0.91 (ps.-t, J = 6.4 Hz, 1H), 0.88 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 
100.67 MHz) δ 173.5, 73.2 (-), 64.8 (+), 39.3 (-), 31.7 (-), 29.5 (-), 29.22 (-), 29.15 (-), 27.0 (-), 
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25.0, 22.64 (-), 22.58 (-), 22.1 (-), 20.0 (+), 14.0 (+), 10.5 (+);  HRMS (TOF ES) found 
270.2427, calcd for C16H32NO2 (M + H) 270.3433 (2.2 ppm). 
 
(1R*,2S*)-N-Hexyl-2-isopropoxy-1-methylcyclopropanecarboxamide 
(242b): was prepared from bromocyclopropane 241a (250 mg, 0.954 mmol) 
according to the procedure described for compound 242f, employing 
isopropanol (110 µL, 86 mg, 1.43 mmol) instead of n-propanol.  Yield 209 mg (0.868 mmol, 
91%), colorless oil.  1H NMR (CDCl3, 400.13 MHz) δ 6.54 (br.s, 1H), 3.76 (septet, J = 6.1 Hz, 
1H), 3.31 (dd, J = 6.6 Hz, 4.5 Hz, 1H), 3.27-3.12 (m, 2H), 1.48-1.41 (2H), 1.30-1.24 (m, 6H), 
1.21 (d, J = 6.1 Hz, 3H), 1.19 (s, 3H), 1.18 (d, J = 6.1 Hz, 3H), 1.07 (dd, J = 5.8 Hz, 4.5 Hz, 1H), 
0.90 (ps.-t, J = 6.6 Hz, 5.8 Hz, 1H), 0.86 (t, J = 7.1 Hz, 3H);  13C NMR (CDCl3, 100.67 MHz) δ 
173.5, 73.0 (+), 62.5 (+), 39.2 (-), 31.4 (-), 29.4 (-), 26.6 (-), 24.9, 22.5 (-), 22.1 (-), 22.0 (+), 21.6 
(+), 20.0 (+), 19.9 (+); HRMS (TOF ES) found 242.2122, calcd for C14H28NO2 (M + H) 
242.2120 (0.8 ppm). 
 
(1R*,2S*)-2-tert-Butoxy-N-(tert-butyl)-1-methylcyclopropanecarboxamide 
(242c): was prepared from bromocyclopropane 241c (100 mg, 0.43 mmol) and t-
BuOK (96 mg, 0.85 mmol) according to the procedure described for preparation 
of compound 242f.  Yield 89 mg (0.39 mmol, 92%), colorless oil.  1H NMR (CDCl3, 400.13 
MHz) δ 6.57 (br.s, 1H), 3.27 (dd, J = 6.8 Hz, 4.6 Hz, 1H), 1.34 (s, 9H), 1.31 (s, 9H), 1.18 (s, 
3H), 1.03 (dd, J = 6.1 Hz, 4.6 Hz, 1H), 0.94 (ps.-t, J = 6.8 Hz, 6.1 Hz, 1H); 13C NMR (CDCl3, 
100.67 MHz) δ 173.5, 76.2, 58.3 (+), 50.3, 28.8 (+, 3C), 27.6 (+, 3C), 24.4, 23.0 (-), 19.7 (+); 1H 
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NOE NMR (CDCl3, 500.13 MHz) δ1.18 (5%) upon irradiation at 3.27 ppm;  HRMS (TOF ES) 
found 228.1973, calcd for C13H26NO2 (M + H) 228.1963 (4.4 ppm). 
 
(1R*,2S*)-N-Benzhydryl-2-tert-butoxy-1-methylcyclopropanecarboxamide 
(242d): was prepared from bromocyclopropane 241d (206 mg, 0.50 mmol), t-
BuOK (201 mg, 1.50 mmol), and 18-crown-6 (16 mg, 0.06 mmol) according to the typical 
procedure.  The crude product was purified by Flash column chromatography on silica gel, 
eluent hexane-EtOAc 5:1.  Yield: 151 mg (0.45 mmol, 75%).   1H NMR (CDCl3, 400.13 MHz) δ 
7.42 (d, J = 7.3 Hz, 1H), 7.34-7.23 (m, 10H), 6.27 (d, J = 7.3 Hz, 1H), 3.35 (dd, J = 6.8 Hz, 4.5 
Hz, 1H), 1.25 (s, 3H), 1.23 (dd, J = 6.4 Hz, 4.5 Hz, 1H), 1.10 (s, 9H), 1.05 (ps.-t, J = 6.8 Hz, 6.4 
Hz, 1H);  13C NMR (CDCl3, 100.67 MHz) δ 173.5, 142.3, 142.2, 128.6 (+, 2C), 128.4 (+, 2C), 
127.8 (+, 2C), 127.3 (+), 126.94 (+), 126.89 (+, 2C), 76.4, 58.5 (+), 56.7 (+), 27.4 (+, 3C), 24.0, 
23.4 (-), 19.8 (+);  1H NOE NMR (CDCl3, 500.13 MHz) δ 1.25 (7%) upon irradiation at 3.35 
ppm;  HRMS (TOF ES) found 360.1935, calcd for C22H27NO2Na (M + Na) 360.1940 (1.4 ppm). 
28.1 (+, 3C), 24.1 (+), 14.3 (-);  HRMS (TOF ES): found 236.1627, calculated for C12H23NO2Na 
(M+Na) 236.1626 (0.4 ppm). 
 
 (1S*,2R*)-2-(benzyloxy)-N,N-diethyl-1-methylcyclopropane-
carboxamide (242i): Typical Procedure: Bromocyclopropane 241e 
(70.2 mg, 1.00 eq, 0.30 mmol) was added to a mixture of 66.6 mg of t-
BuOK (2.0 eq,  0.60 mmol) and 7.8 mg of 18-crown- 6 ether (10%, 30 µmol). Then 49 mg of 
Benzyl alcohol ( 1.5 eq, 0.45 mmol) was added and the reaction mixture was stirred in anhydrous 
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THF (1 mL) overnight at 80 deg. The reaction mixture was partitioned between water (10ml), 
brine and EtOAc (3 × 20ml). The combined organic phases were dried with Na2SO4, filtered and 
concentrated. The residue was filtered through a short bed of Silica gel (EtOAc) to afford the 
title compound as colorless oil.  Yield 74 mg (0.28 mmol, 95%).  1H NMR (400.13 MHz, 
CDCl3) δ 7.36-7.24 (m, 5H), 4.58 (d, J = 12.1 Hz, 1H), 4.49 (d, J = 11.9 Hz, 1H), 3.69 (dq, J = 
14.4 Hz, 7.3 Hz, 1H), 3.54-3.37 (m, 2H), 3.31 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 3.31 (dq, J = 14.2 
Hz, 7.1 Hz, 1H), 1.32 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 1.24 (s, 3H), 1.22 (t, J = 7.3 Hz, 3H), 1.10 (t, 
J = 7.1 Hz, 3H), 0.66 (t, J = 5.9 Hz, 1H);   13C NMR (100.67 MHz, CDCl3) δ 170.7, 138.1, 128.2 
(+, 2C), 127.5 (+, 2C), 127.4 (+), 72.3 (-), 62.7 (+), 41.1 (-), 38.6 (-), 27.8, 20.6 (+), 18.5 (-), 14.0 
(+), 12.4 (+);  FT IR (cm-1, film): 2990, 2980, 1713, 1623, 1433, 1364, 1259, 1223, 1159, 1132, 
1090, 1047, 1003, 910, 733, 698, 648, 530;  HRMS (TOF ES): found 262.1817, calculated for 
C16H24NO2 (M+H) 262.1807 (3.8 ppm).   
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 (1R*,2S*)-N,N-Diethyl-2-(2-methoxyethoxy)-1-methylcyclo-
propanecarboxamide (242k): Was prepared according to Typical Procedure, employing bromo-
cyclopropane 241e  (117 mg, 1.00 eq, 0.50 mmol) and ethylene glycol monomethyl ether (57 
mg, 1.0 eq, 0.5 mmol).  Preparative column chromatography on Silica gel fforded the title 
compound as a clear oil Rf 0.40 (hexane/EtOAc 3:1).   Yield 102 mg (0.44 mmol, 89%).  
1H 
NMR (400.13 MHz, CDCl3) δ 3.72-3.56 (m, 2H), 3.53 (ddd, J = 10.9 Hz, 4.9 Hz, 3.5 Hz, 1H), 
3.47-3.35 (m, 4H), 3.29 (s, 3H), 3.28-3.21 (m, 2H), 1.20-1.18 (m, 1H), 1.18 (s, 3H), 1.18 (t, J = 
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7.2 Hz, 3H), 1.04 (t, J = 7.1 Hz, 3H), 0.59 (ps.-t, J = 5.9 Hz, 1H);  13C NMR (100.67 MHz, 
CDCl3) δ 170.6, 71.6 (-), 69.6 (-), 63.2 (+), 58.9 (+), 41.0 (-), 38.5 (-), 27.6 (+), 20.5, 18.2 (-), 
13.9 (+), 12.2 (+);  FT IR (cm-1, film): 2968, 2934, 2874, 2824, 2737, 1722, 1634, 1518, 1427, 
1379, 1364, 1348, 1323, 1304, 1259, 1219, 1200, 1167, 1128, 1101, 1067, 1030, 957, 920, 903, 
860, 800, 760;  HRMS (TOF ES): found 229.1677, calculated for C12H23NO3 (M
+) 229.1678 (0.4 
ppm). 
 
 (1S*,2R*)-2-(2-(Dimethylamino)ethoxy)-N,N-diethyl-1-
methylcyclopropanecarboxamide (242k):  Was prepared according to 
Typical Procedure VI, employing bromocyclopropane 241e  (117 mg, 1.00 eq, 0.50 mmol) and 
2-N,N-dimethylaminoethanol (67 mg 1.5 eq, 0.75 mmol).  Preparative column chromatography 
on Silica gel to afford the titled compound as a clear oil, Rf 0.20 (EtOAc).  Yield 97 mg (0.40 
mmol, 80%).  1H NMR (400.13 MHz, CDCl3) δ 3.62-3.53 (m, 2H), 3.52-3.39 (m, 2H), 3.37-3.21 
(m, 2H), 3.15 (dd, J = 5.7 Hz, 3.7 Hz, 1H), 2.31 (t, J=5.8 Hz, 2H), 2.11 (s, 6H), 1.11 (t, J = 7.1 
Hz, 3H), 1.10 (s), 1.11-1.09 (m, 1H), 0.97 (t, J = 7.1 Hz, 3H), 0.49 (t, J = 5.9 Hz, 1H);  13C NMR 
(100.67 MHz, CDCl3) δ 170.6, 68.7 (-), 63.1 (+), 58.2 (-), 45.7 (+, 2C), 41.0 (-), 38.5 (-), 27.4, 
20.4 (+), 18.1 (-), 13.9 (+), 12.3 (+);  FT IR (cm-1, film): 2970, 2934, 2874, 1637, 1462, 1427, 
1381, 1364, 1348, 1323, 1304, 1219, 1200, 1167, 1128, 1101, 1067, 1030, 957, 903, 473; HRMS 
(TOF ES): found 243.2080, calculated for C13H27N2O2 (M+H) 243.2073 (2.9 ppm). 
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 (1S,2R)-N,N-Diethyl-1-methyl-2-(pent-4-enyloxy)cyclopro-
panecarboxamide (242i): Was prepared according to Typical Procedure, employing bromo-
cyclopropane 241i  (117 mg 1.00 eq, 0.50 mmol) and 4-pentene1-ol (87 mg, 1.00 eq, 0.50 
mmol).  Preparative column chromatography on Silica gel to afford the titled compound as a 
yellowish oil, Rf 0.50 (hexane/EtOAc 2:1).  Yield 117 mg (0.49 mmol, 89%).  
1H NMR (400.13 
MHz, CDCl3) δ 5.75 (ddt, J = 17.2 Hz, 10.1 Hz, 6.6 Hz, 1H), 4.97 (dq, J = 17.2 Hz, 1.7 Hz, 1H), 
4.92 (ddt, J = 10.1 Hz, 2.0 Hz, 1.3 Hz, 1H), 3.63 (dq, J = 14.3 Hz, 7.1 Hz, 1H), 3.50-3.33 (m, 
4H), 3.24 (dq, J = 13.6 Hz, 7.1 Hz, 1H), 3.20 (dd, J = 5.6 Hz, 3.5 Hz, 1H), 2.06-1.98 (m, 2H), 
1.60-1.50 (m, 2H), 1.20 (t, J = 7.1 Hz, 3H), 1.19 (s, 3H), 1.17 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 1.07 
(t, J = 7.1 Hz, 3H), 0.57 (t, J = 5.8 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 170.7, 138.2 (+), 
114.6 (-), 69.4 (-), 62.9 (+), 40.9 (-), 38.5 (-), 30.2 (-), 28.6 (-), 27.4, 20.5 (+), 18.3 (-), 14.0 (+), 
12.3 (+);  FT IR (cm-1, film): 3078, 2970, 2935, 2872, 1641, 1462, 1443, 1425, 1258, 1219, 
1165, 1128, 1090, 1005, 960, 912, 636;  HRMS (TOF ES): found 262.1774, calculated for 
C14H25NO2Na (M+Na) 262.1783 (3.4 ppm). 
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 ((1S*,2R*)-1-Methyl-2-(pent-4-enyloxy)cyclopropyl)(pyrrolidin-1-
yl)methanone (242h): Was prepared according to Typical Procedure, employing (2-bromo-1-
methylcyclopropyl)(pyrrolidin-1-yl)methanone (241f) (250 mg, 1.07 mmol) and pent-4-en-1-ol 
(138 mg, 1.61 mmol, 1.50 equiv).  Preparative column chromatography of a residue on silica gel 
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afforded the title compound as a yellow oil, Rf 0.30 (hexane/EtOAc 2:3). Yield 219 mg (0.98 
mmol, 92%).  1H NMR (400.13 MHz, CDCl3) δ 5.76 (ddt, J = 17.0 Hz, 10.3 Hz, 6.7 Hz, 1H), 
4.97 (ddt, J = 17.2 Hz, 1.8 Hz, 1.5 Hz, 1H), 4.92 (ddt, J = 10.4 Hz, 2.2 Hz, 1.2 Hz, 1H), 3.83 
(ddd, J = 10.1 Hz, 6.2 Hz, 3.7 Hz, 1H), 3.50-3.36 (m, 5H), 3.17 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 
2.02 (q, J = 7.3 Hz, 2H), 1.96-1.74 (m, 4H), 1.56 (quin J = 7.0 Hz, 2H), 1.23 (s, 3H), 1.19 (dd, J 
= 6.1 Hz, 3.5 Hz, 1H), 0.57 (dd, J = 6.1 Hz, 5.8 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 
170.0, 138.2 (+), 114.6 (-), 69.4 (-), 62.2 (+), 46.3 (-), 45.9 (-), 30.2 (-), 28.6 (-), 28.2, 26.2 (-), 
24.1 (-), 19.3 (+), 17.7 (-);  FT IR (cm-1, film): 3076, 2937, 2874, 1774, 1726, 1614, 1529, 1344, 
1252, 1157, 1090, 1040, 912, 874, 731, 644, 503;  HRMS (TOF ES): found 238.1815, calculated 
for C14H24NO2 (M+H) 238.1807 (3.4 ppm).   
 
 (1S*,2R*)-2-(Allyloxy)-N-hexyl-1-methylcyclopropanecarboxamide 
(243e):  Was prepared according to Typical Procedure, employing 2-
bromo-N-hexyl-1-methylcyclopropanecarboxamide (241d) (79 mg, 0.30 
mmol) and allylic alcohol (35 mg, 0.60 mmol, 2.0 equiv). The reaction was carried out at 60 oC 
for 12 hr.  Preparative column chromatography of a residue on silica gel fforded the title 
compound as a colorless oil, Rf 0.25 (hexane-EtOAc 5:1). Yield 59 mg (0.25 mmol, 82%).  
1H 
NMR (400.13 MHz, CDCl3) δ 6.37 (br. s., 1H), 5.91 (ddt, J = 17.2 Hz, 10.4 Hz, 5.8 Hz, 1H), 
5.30 (dq, J = 17.2 Hz, 1.5 Hz, 1H), 5.23 (dq, J = 10.4 Hz, 1.3 Hz, 1H), 4.12-3.99 (m, 2H), 3.36 
(dd, J = 6.6 Hz, 4.0 Hz, 1H), 3.25-3.16 (m, 2H), 1.50-1.39 (m, 2H), 1.34-1.22 (m, 6H), 1.20 (s, 
3H), 1.16 (dd, J = 6.3 Hz, 4.3 Hz, 1H), 0.94 (t, J = 6.6 Hz, 6.3 Hz, 1H), 0.87 (t, J = 6.7 Hz, 3H);  
13C NMR (100.67 MHz, CDCl3) δ 173.2, 133.3 (+), 117.9 (-), 72.3 (-), 64.5 (+), 39.3 (-), 31.5 (-), 
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29.5 (-), 26.7 (-), 25.2, 22.5 (-), 22.1 (-), 20.0 (+), 14.0 (+);  FT IR (NaCl, film, cm-1): 3360, 
3080, 2957, 2930, 2858, 1645, 1537, 1462, 1445, 1344, 1331, 1211, 1169, 1101, 1043, 991, 922;  
HRMS (TOF ES): found 240.1969, calculated for C14H26NO2 (M+H) 240.1964 (2.1 ppm). 
 
 ((1S*,2R*)-2-(Allyloxy)-1-methylcyclopropyl)(piperidin-1-yl)-
methanone (243h):  Was prepared according to Typical Procedure, 
employing (2-bromo-1-methylcyclopropyl)(piperidin-1-yl)methanone 
(241h) (79 mg, 0.30 mmol) and allylic alcohol (35 mg, 0.60 mmol, 2.0 equiv).  The reaction was 
carried out at 60 oC for 12 hr.  Preparative column chromatography of a residue on silica gel 
afforded the title compound as a colorless oil, Rf 0.20 (hexane-EtOAc 3:1). Yield 61 mg (0.27 
mmol, 91%).  1H NMR (400.13 MHz, CDCl3) δ 5.87 (dddd, J = 17.2 Hz, 10.4 Hz, 5.9 Hz, 5.1 
Hz, 1H), 5.23 (dq, J = 17.2 Hz, 1.8 Hz, 1H), 5.14 (dq, J = 10.4 Hz, 1.5 Hz, 1H), 4.03 (ddt, J = 
13.1 Hz, 5.1 Hz, 1.8 Hz, 1 H), 3.96 (ddt, J = 13.1 Hz, 5.9 Hz, 1.3 Hz, 1H), 3.68-3.54 (m, 3H), 
3.54-3.43 (m, 1H), 3.30 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 1.69-1.51 (m, 6H), 1.23 (s, 3H), 1.20 (dd, J 
= 6.1 Hz, 3.5 Hz, 1H), 0.63 (app. t, J = 6.1, 5.8 Hz, 1H); 13C NMR (100.67 MHz, CDCl3) δ 
169.9, 134.5 (+), 116.4 (-), 71.2 (-), 62.9 (+), 46.7 (-), 43.0 (-), 27.3, 24.7 (-), 20.5 (-), 18.0 (+);  
FT IR (NaCl, film, cm-1): 3080, 2999, 2934, 2854, 1730, 1643, 1516, 1439, 1350, 1310, 1277, 
1256, 1236, 1209, 1163, 1132, 1126, 1090, 1043, 1014, 989, 955, 924, 854, 758, 689, 604, 532, 
507, 417;  HRMS (TOF ES): found 224.1653, calculated for C13H22NO2 (M+H) 224.1651 (0.8 
ppm). 
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 ((1S*,2R*)-2-(Allyloxy)-1-methylcyclopropyl)(morpholino)methanone 
(243c):  Was prepared according to Typical Procedure, employing(2-bromo-1-methylcyclo-
propyl)(morpholino)methanone (241g) (74 mg, 0.30 mmol) and allylic alcohol (35 mg, 0.60 
mmol, 2.0 equiv). The reaction was carried out at 60 oC for 12 hr.  Preparative column 
chromatography of a residue on silica gel afforded the title compound as a colorless oil, Rf 0.23 
(hexane-EtOAc 1:1). Yield 59 mg (0.26 mmol, 88%).  1H NMR (400.13 MHz, CDCl3) δ 5.85 
(dddd, J = 17.2 Hz, 10.4 Hz, 5.8 Hz, 5.1 Hz, 1H), 5.23 (dq, J = 17.2 Hz, 1.7 Hz, 1H), 5.15 (dq, J 
= 10.4 Hz, 1.4 Hz, 1H), 4.03 (ddt, J = 12.6 Hz, 5.1 Hz, 1.5 Hz, 1H), 3.95 (ddt, J = 12.6 Hz, 5.8 
Hz, 1.3 Hz, 1 H), 3.79-3.53 (m, 7H), 3.41-3.31 (m, 1H), 3.29 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 1.23 
(s, 3H), 1.21 (dd, J = 6.1 Hz, 3.5 Hz, 1H), 0.65 (app. t, J = 6.1 Hz, 5.8 Hz, 1H);  13C NMR 
(100.67 MHz, CDCl3) δ 170.0, 134.2 (+), 116.8 (-), 71.3 (-), 67.3 (-), 66.9 (-), 62.5 (+), 46.3 (-), 
42.5 (-), 26.8, 20.2 (+), 17.7 (-);  FT IR (KBr, film, cm-1): 3269, 3182, 3080, 2962, 2926, 2899, 
2858, 2359, 2125, 1732, 1614, 1514, 1429, 1358, 1310, 1242, 1204, 1198, 1161, 1113, 1068, 
1034, 991, 945, 926, 858, 847, 804, 690, 621, 559, 515;  HRMS (TOF ES): found 226.1438, 
calculated for C12H20NO3 (M+H) 226.1443 (2.2 ppm). 
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 (1S*,2R*)-2-(allyloxy)-N,N,1-trimethylcyclopropanecarboxamide 
(243f):  Was prepared according to Typical Procedure, employing 2-bromo-N,N,1-
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trimethylcyclopropanecarboxamide (241e) (103 mg, 0.50 mmol) and allylic alcohol (35 mg, 0.60 
mmol, 2.0 equiv).  The reaction was carried out at 50 oC for 12 hr. Preparative column 
chromatography of a residue on silica gel afforded the title compound as a colorless oil, Rf 0.35 
(hexane-EtOAc 2:1). Yield 93.8 mg (0.46 mmol, 91%).  1H NMR (400.13 MHz, CDCl3) δ ppm 
5.84 (dddd, J = 17.3 Hz, 10.4 Hz, 5.8 Hz, 5.1 Hz, 1H), 5.19 (dq, J = 17.3 Hz, 1.6 Hz, 1H), 5.11 
(dq, J = 10.4 Hz, 1.5 Hz, 1H), 4.01 (ddt, J = 13.1 Hz, 5.1 Hz, 1.5 Hz, 1H), 3.94 (ddt, J = 13.1 Hz, 
5.8 Hz, 1.3 Hz, 1H), 3.27 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 3.13 (s, 3H), 2.92 (s, 3H), 1.22 (s, 3H), 
1.16 (dd, J = 6.1 Hz, 3.5 Hz, 1H), 0.60 (app. t, J = 6.1, 5.8 Hz, 1H);  13C NMR (100.67 MHz, 
CDCl3) δ ppm 171.4, 134.4 (+), 116.3 (-), 71.2 (-), 62.5 (+), 37.1 (+), 35.4 (+), 27.2, 20.0 (+), 
17.9 (-);  FT IR (NaCl, film, cm-1): 3547, 3464, 3080, 3001, 2959, 2934, 2872, 1643, 1634, 1497, 
1454, 1396, 1379, 1350, 1265, 1167, 1124, 1101, 1086, 1059, 1043, 991, 964, 926, 858, 704, 
606, 575, 569, 517, 492;  HRMS (TOF ES): found 206.1156, calculated for C10H17NO2Na 
(M+Na) 206.1157 (0.5 ppm). 
 
 (1S*,2R*)-N,N,1-Trimethyl-2-((3-methylbut-2-en-1-yl)oxy)-
cyclopropanecarboxamide (243b):  Was prepared according to Typical 
procedure, employing 2-bromo-N,N,1-trimethylcyclopropanecarboxamide 
(241e) (62 mg, 0.30 mmol) and 3-methylbut-2-en-1-ol (28 mg, 0.33 mmol, 1.1 equiv).  The
reaction was carried out at 60 oC for 12 hrs.  Preparative column chromatography of a residue on 
silica gel afforded the title compound as a colorless oil, Rf 0.40 (hexane-EtOAc 2:3).  Yield 59 
mg (0.28 mmol, 93%).  1H NMR (400.13 MHz, CDCl3) δ ppm 5.25 (t-sept, J = 6.9 Hz, 1.3 Hz, 
1H), 4.03-3.91 (m, 2H), 3.22 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 3.11 (s, 3H), 2.92 (s, 3H), 1.71 (s, 
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3H), 1.64 (s, 3H), 1.21 (s, 3H), 1.16 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 0.59 (t, J = 5.8 Hz, 1H);  13C 
NMR (100.67 MHz, CDCl3) δ ppm 171.5, 136.5, 120.8 (+), 66.9 (-), 62.2 (+), 37.2 (+), 35.4 (+), 
27.2, 25.7 (+), 20.1 (+), 17.97 (-), 17.96 (+);  FT IR (NaCl, film, cm-1): 3082, 2962, 2932, 1643, 
1448, 1394, 1157, 1126;  HRMS (TOF ES): found 212.1653, calculated for C12H22NO2 (M+H) 
212.1651 (0.9 ppm).   
 
 (1S*,2R*)-2-(((E)-3,7-Dimethylocta-2,6-dien-1-yl)oxy)-N,N,1-
trimethylcyclopropanecarboxamide (243a):  Was prepared 
according to Typical Procedure, 2-bromo-N,N,1-trimethylcyclopropanecarboxamide (241e) (102 
mg, 0.60 mmol) and geraniol (93 mg, 0.66 mmol, 1.1 equiv).  The reaction was carried out at 60 
oC for 12 hrs.  Preparative column chromatography of a residue on silica gel afforded the title 
compound as a colorless oil, Rf 0.40 (hexane-EtOAc 2:3). Yield 149 mg (0.53 mmol, 89%).  
1H 
NMR (400.13 MHz, CDCl3) δ 5.31-5.22 (m, 1H), 5.11-5.03 (m, 1H), 4.00 (d, J = 6.8 Hz, 2H), 
3.23 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 3.12 (s, 3H), 2.92 (s, 3H), 2.13-1.97 (m, 4H), 1.67 (s, 3H), 
1.64 (s, 3H), 1.59 (s, 3H), 1.21 (s, 3H), 1.17 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 0.59 (t, J = 5.8 Hz, 
1H);  13C NMR (100.67 MHz, CDCl3) δ 171.5, 139.8, 131.5, 123.9 (+), 120.6 (+), 66.9 (-), 62.2 
(+), 39.5 (-), 37.2 (+), 35.4 (+), 27.2, 26.2 (-), 25.6 (+), 20.1 (+), 18.0 (-), 17.6 (+), 16.3 (+);  FT 
IR (KBr, cm-1): 2964, 2928, 2872, 2858, 1645, 1495, 1450, 1394, 1360, 1126, 1101, 1084, 1041, 
986;  HRMS (TOF ES): found 302.2084, calculated for C17H29NO2Na (M+Na) 302.2096 (4.0 
ppm).  
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2.4.6. Addition to Carboxylates 
 
(1R*,2S*)-Allyl 2- tert-butoxy-1-methylcyclopropanecarboxylate (250f): 
Typical procedure, A mixture of t-BuOK (14.5 g, 129 mmol, 2.6 equiv), 18-
crown-6 (1.32 g, 5 mmol), and potassium 1-methyl-2-bromocyclopropane 
carboxylate (10.85 g, 50 mmol) in anhydrous THF (200 mL) was stirred at 80
oC for 8 hrs, then cooled down to room temperature and freshly distilled allyl bromide (13 mL, 
18 g, 150 mmol, 3 equiv.) was added dropwise.  The resulting mixture was stirred for 1 hr, then 
poured in ice-cold water (300 mL) and extracted with diethyl ether (3 x 100 mL).  Combined 
ethereal extracts were washed with brine (50 mL), dried with MgSO4, filtered and concentrated.  
The residue was distilled in vacuum to afford allyl 2-tert butoxy-1-methylcyclopropane-
carboxylate as colorless oil, bp 61 oC (1 mm Hg).  Yield 8.61 g (40.6 mmol, 81%).  1H NMR 
(CDCl3, 400.13 MHz) δ 5.93 (ddt, J = 17.2 Hz, 10.6 Hz, 5.8 Hz, 1H), 5.34 (ddt, J = 17.2 Hz, 1.5 
Hz, 1.5 Hz, 1H),  5.20 (ddt, J = 10.6 Hz, 1.5 Hz, 1.5 Hz, 1H), 4.65-4.53 (m, 2H), 3.24 (dd, J = 
7.1 Hz, 4.8 Hz, 1H), 1.74 (dd, J = 6.1 Hz, 4.8 Hz, 1H), 1.25 (s, 3H), 1.18 (s, 9H), 0.87 (dd, J = 
7.1 Hz, 6.1 Hz, 1H);  13C NMR (CDCl3, 100.67 MHz) δ172.0, 132.4 (+), 117.7 (-), 74.9, 65.1 (-), 
60.5 (+), 27.7 (+, 3C), 26.1, 20.2 (-), 18.7 (+);  1H NOE NMR (CDCl3, 500.13 MHz) δ 1.25 (8%) 
upon irradiation at 3.24 ppm;  TLC: Rf 0.7 (hexane-EtOAc 1:1); GC: Rt 8.80 min; HRMS (TOF 
ES) found 213.1491, calcd for C12H21O3 (M + H) 213.1491 (0.0 ppm). 
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(1R*,2S*)-Methyl 2-tert-butoxy-1-methylcyclopropanecarboxylate (250c): was 
obtained according to the protocol described for preparation of 250f, employing 
methyl iodide (7 mL, 16 g, 112 mmol, 2.24 equiv) instead of allyl bromide.  Yi ld 
7.38 g (39.68 mmol, 79%), colorless oil, bp 64 oC (7 mm Hg).  1H NMR (CDCl3, 400.13 MHz) δ 
3.70 (s, 3H), 3.25 (dd, J = 7.3 Hz, 5.1 Hz, 1H), 1.74 (dd, J = 6.1 Hz, 5.1 Hz, 1H), 1.25 (s, 3H), 
1.20 (s, 9H), 0.89 (dd, J = 7.3 Hz, 6.1 Hz, 1H);  13C NMR (CDCl3, 100.67 MHz) δ 172.9, 74.9, 
60.6 (+), 51.6 (+), 27.8 (+, 3C), 26.2, 20.1 (-), 18.7 (+);  GC: Rt 7.54 min;  HRMS (TOF ES) 
found 209.1147, calcd for C10H18O3Na (M + Na) 209.1154 (3.3 ppm). 
 
(1R*,2S*)-Methyl 1-methyl-2-propoxycyclopropanecarboxylate (250h): A 
mixture of t-BuOK (193 mg, 1.72 mmol, 1.5 equiv), 18-crown-6 (30 mg, 0.11 
mmol), and potassium 1-methyl-2-bromocyclopropane carboxylate (250 mg, 1.15 
mmol) in anhydrous THF (5 mL) was stirred overnight at 80 oC, then quenched 
with methyl iodide (180 µL, 411 mg, 2.88 mmol). The mixture was partitioned between water 
and diethyl ether, the ethereal phase was washed with brine, dried with MgSO4, filtered and 
concentrated.  Methyl 2-n propoxy-1-methylcyclopropanecarboxylate (Rf 0.9, hexane-EtOAc 
1:1) was purified by flash column chromatography on silica gel. Yield 163 mg (0.95 mmol, 
83%).  1H NMR (CDCl3, 400.13 MHz) δ 3.70 (s, 3H), 3.45 (dt, J = 9.4 Hz, 6.6 Hz, 1H), 3.32 (dt, 
J = 9.4 Hz, 6.6 Hz, 1H), 3.27 (dd, J = 6.6 Hz, 4.5 Hz, 1H), 1.77 (dd, J = 5.8 Hz, 4.5 Hz, 1H), 
1.55 (sextet, J = 6.8 Hz, 2H), 1.25 (s, 3H), 0.89 (t, J = 7.3 Hz, 3H), 0.86 (ps.-t, J = 6.6 Hz, 5.8 
Hz, 1H);  13C NMR (CDCl3, 100.67 MHz) δ 172.6, 73.1 (-), 66.1 (+), 51.9 (+), 25.8, 22.6 (-), 
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20.5 (-), 19.0 (+), 10.6 (+); GC: Rt 7.46 min; HRMS (TOF ES) found 173.1179, calcd for 
C9H17O3 (M + H) 173.1178 (0.6 ppm). 
 
 (1S*,2R*)-Methyl2-(benzyloxy)-1-methylcyclopropanecarboxylate 
(250b): Was prepared according to the Typical Procedure employing 
benzyl alcohol (83 mg, 0.77 mmol, 1.5 equiv) and MeI (93 µL, 213 mg, 
1.50 mmol, 3.00 equiv).  Preparative column chromatography on silica gel afforded the title 
compound as a clear oil, Rf 0.40 (hexane/EtOAc 10:1). Yield 100 mg (0.41 mmol, 82%).  
1H 
NMR (400.13 MHz, CDCl3) δ 7.39-7.30 (m, 5H), 4.53 (d, J = 11.6 Hz, 1H), 4.48 (d, J = 11.6 Hz, 
1H), 3.71 (s, 3H), 3.36 (dd, J = 6.6 Hz, 4.5 Hz, 1H), 1.85 (dd, J = 5.9 Hz, 4.7 Hz, 1H), 1.27 (s, 
3H), 0.90 (t, J = 6.6 Hz, 5.9 Hz, 1H);  13C NMR (100.67 MHz, CDCl3)   172.4, 137.1, 128.4 (+, 
2C), 128.1 (+, 2C), 127.9 (+), 73.4 (-), 65.6 (+), 52.0 (+), 26.1, 20.7 (-), 19.0 (+);  FT IR (film, 
cm-1): 3088, 3030, 3005, 2907, 2872, 1960, 1880, 1728, 1497, 1454, 1437, 1385, 1356, 1329, 
1286, 1269, 1254, 1194, 1155, 1107, 1045, 1028, 993, 943, 903, 866, 833, 795, 737, 698, 606, 
554, 490, 451;  HRMS (TOF ES): found 221.1188, calculated for C13H17NO3 (M+H) 221.1178 
(4.5 ppm).  
 
 (1S*,2R*)-Methyl1-methyl-2-(pent-4-en-1-yloxy)cyclopropane-
carboxylate (250d):  Was prepared according to the Typical Procedure 
employing pent-4-en-1-ol (64.5 mg, 0.75 mmol, 1.5 equiv) and MeI (93 µL, 213 mg, 1.50 mmol, 
3.00 equiv) was added dropwise.  Preparative column chromatography of a residue on silica gel 
afforded the title compound as a colorless oil, Rf 0.40 (hexane/EtOAc 20:1).  Yield 71 mg (0.36 
Me
O
O
O
Me
Me
O
O
O
151 
 
 
mmol, 72%).  1H NMR (400.13 MHz, CDCl3) δ 5.81 (ddt, J = 17.1 Hz, 10.3 Hz, 6.7 Hz, 1H), 
5.03 (dq, J = 17.1 Hz, 1.7 Hz, 1H), 4.97 (ddt, J = 10.2 Hz, 2.1 Hz, 1.2 Hz, 1H), 3.72 (s, 3H), 3.51 
(dt, J = 9.3 Hz, 6.6 Hz, 1H), 3.38 (dt, J = 9.3 Hz, 6.4 Hz, 1H), 3.28 (dd, J = 6.8 Hz, 4.5 Hz, 1H), 
2.16-2.01 (m, 2H), 1.77 (dd, J = 5.9 Hz, 4.7 Hz, 1H), 1.64 (quin, J = 7.0 Hz, 2H), 1.27 (s, 3H), 
0.87 (app. t, J = 6.8 Hz, 5.9 Hz, 1H); 13C NMR (100.67 MHz, CDCl3) δ 172.5, 138.1 (+), 114.8 
(-), 70.7 (-), 66.1 (+), 51.9 (+), 30.2 (-), 28.6 (-), 25.9, 20.6 (-), 19.1 (+);  FT IR (cm-1, film): 
3081, 2949, 2939, 1734, 1437, 1364, 1352, 1329, 1194, 1157, 1107, 1043, 995, 945, 912, 858, 
557, 444;  HRMS (TOF ES): found 221.1164, calculated for C11H18O3Na (M+Na) 221.1154 (4.5 
ppm). 
Me
O
O
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 (1S*,2R*)-Allyl1-methyl-2-(pent-4-en-1-yloxy)cyclopropanecarboxylate 
(250e): Was prepared according to the Typical Procedure  employing pe t-4-en-1-ol (65 mg, 
0.75 mmol, 1.5 equiv) and allyl bromide (130 µL, 182 mg, 1.50 mmol, 3.00 equiv).  Preparative 
column chromatography of a residual oil on silica gel afforded the title compound as a clear oil, 
Rf 0.40 (hexane/EtOAc 20:1). Yield 76 mg (0.34 mmol, 68%).  
1H NMR (400.13 MHz, CDCl3) 
δ 5.94 (dddd, J = 17.0 Hz, 10.5 Hz, 6.6 Hz, 5.6 Hz, 1H), 5.79 (ddt, J = 17.0 Hz, 10.3 Hz, 6.7 Hz, 
1H), 5.35 (dq, J = 17.3 Hz, 1.6 Hz, 1H), 5.23 (dq, J = 10.5 Hz, 1.4 Hz, 1H), 5.02 (ddt, J = 17.2 
Hz, 2.0 Hz, 1.5 Hz, 1H), 4.96 (ddt, J = 10.2 Hz, 2.0 Hz, 1.4 Hz, 1H), 4.62 (dt, J = 5.6 Hz, 1.4 Hz, 
2H), 3.50 (dt, J = 9.1 Hz, 6.6 Hz, 1H), 3.38 (dt, J = 9.4 Hz, 6.6 Hz, 1H), 3.29 (dd, J = 6.6 Hz, 4.5 
Hz, 1H), 2.12-2.03 (m, 2H), 1.78 (dd, J = 5.8 Hz, 4.6 Hz, 1H), 1.63 (quin, J = 6.9 Hz, 2H), 1.28 
(s, 3H), 0.87 (t, J = 6.5 Hz, 2H);  13C NMR (100.67 MHz, CDCl3) δ 171.6, 138.0 (+), 132.3 (+), 
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117.9 (-), 114.7 (-), 70.7 (-), 66.2 (+), 65.3 (-), 30.1 (-), 28.6 (-), 25.9, 20.6 (-), 19.0 (+);  FT IR 
(film, cm-1): 3078, 3005, 2962, 2937, 2874, 1730, 1641, 1462, 1441, 1385, 1364, 1321, 1261, 
1155, 1105, 1043, 1032, 989, 914, 858, 795, 768, 635, 557, 505;  HRMS (TOF ES): found 
247.1304, calculated for C13H20O3Na (M+Na) 247.1310 (2.4 ppm). 
  
 (1R*,2S*)-Methyl1-methyl-2-((E)-prop-1-enyloxy)cyclopropane-
carboxylate (250i): Was prepared according to the Typical Procedure 
employing allyl alcohol (51 µL, 44 mg, 0.75 mmol, 1.5 equiv) and MeI (93 µL, 213 mg, 1.50 
mmol, 3.00 equiv).  Preparative column chromatography of a residue on silica ge  afforded the 
title compound as a colorless oil, Rf 0.38 (hexane/EtOAc 20:1).  Yield 71 mg (0.42 mmol, 84%).  
1H NMR (500.13 MHz, CDCl3) δ 5.96 (dq, J = 6.0 Hz, 1.6 Hz, 1H), 4.45 (ps.-quintet, J = 6.9 Hz, 
6.0 Hz, 1H), 3.67 (s, 3H), 3.54 (dd, J = 6.6 Hz, 4.4 Hz, 1H), 1.85 (dd, J = 6.0 Hz, 4.4 Hz, 1H), 
1.51 (dd, J = 6.9 Hz, 1.6 Hz, 3H), 1.27 (s, 3H), 0.91 (ps.-t, J = 6.6 Hz, 6.0 Hz, 1H); 13C NMR 
(125.76 MHz, CDCl3) δ 171.7, 144.0 (+), 103.2 (+), 65.5 (+), 51.9 (+), 25.9, 20.0 (-), 18.8 (+), 
9.0 (+);  FT IR (NaCl, film, cm-1): 2949, 2873, 1729, 1641, 1462, 1437, 1362, 1329, 1261, 1194, 
1157, 1107, 1045, 995, 945, 912, 858, 793, 528;  HRMS (TOF ES): found 171.1016, calculated 
for C9H15O3 (M+H) 171.1021 (2.9 ppm). 
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 2.4.7. Addition to Enolizable Substrates 
 
 ((1R,2R)-2-(Allyloxy)cyclopropyl)(piperidin-1-yl)methanone (246b):  
 An oven-dried 10 mL Weaton vial was charged with (2-bromocyclopropyl)(piperidin-1-
yl)methanone (245a) (70 mg, 0.3 mmol, 1.0 equiv) and allylic alcohol (19.9 mg, 0.36 mmol, 1.2 
equiv). 18-crown-6 (13 mg, 50 µmol, 10 mol%), powdered KOH (62 mg, 1.1 mmol, 2.2 equiv.), 
and anhydrous THF (5 mL). The mixture was stirred at 85 °C for 12 hrs, then filtered through a 
fritted funnel and concentrated.  The residue was purified by flash chromatography on silica gel, 
eluting with hexane/EtOAc 2:1, Rf 0.40. Yield 59 mg (0.29 mmol, 95%). 
 1H NMR (400.13 MHz, CDCl3) δ 5.91 (ddt, J = 17.3 Hz, 10.4 Hz, 5.8 Hz, 1H), 5.28 (dq, J = 
17.3 Hz, 1.6 Hz, 1H), 5.19 (dq, J = 10.4 Hz, 1.3 Hz, 1H), 4.07 (ddt, J = 12.6 Hz, 5.6 Hz, 1.3 Hz, 
1H), 4.02 (m, J = 12.6 Hz, 5.8 Hz, 1.5 Hz, 1H), 3.63 (ddd, J = 6.3 Hz, 3.8 Hz, 2.3 Hz, 1H), 3.62-
3.52 (m, 4H), 1.97 (ddd, J = 9.5 Hz, 5.9 Hz, 2.0 Hz, 1H), 1.71-1.58 (m, 4H), 1.58-1.49 (m, 2H), 
1.29 (td, J = 6.3 Hz, 5.9 Hz, 5.3 Hz, 1H), 1.14 (ddd, J = 9.5 Hz, 5.3 Hz, 3.9 Hz, 1H); 13C NMR 
(100.67 MHz, CDCl3) δ 169.4, 134.0 (+), 117.5 (-), 72.0 (-), 60.2 (+), 46.7 (-), 43.1 (-), 26.6 (-), 
25.5 (-), 24.6 (-), 19.3 (+), 14.9 (-);  FT IR (KBr, cm-1): 3081, 2935, 2854, 1632, 1454, 1445, 
1352, 1250, 1225, 1169, 1136, 1128, 1094, 1053, 1014, 943, 924, 874;  HRMS (TOF ES): found 
210.1496, calculated for C12H20NO2 (M+H) 210.1494 (1.0 ppm). 
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 ((1R*,2R*)-2-(Cinnamyloxy)cyclopropyl)(piperidin-1-yl)-
methanone (246a):  Was prepared according to procedure for 246a, employing (2-bromo-
cyclopropyl)(piperidin-1-yl)methanone (245a) (62 mg, 0.30 mmol, 1.0 equiv) and cinnamyl 
alcohol (44 mg, 0.36 mmol, 1.2 equiv).  The reaction was carried out at 60 oC for 12 hrs.  
Preparative column chromatography of a residue on silica gel afforded the title compound as a 
colorless oil, Rf 0.40 (hexane/EtOAc 2:3). Yield 69 mg (0.24 mmol, 81%).  
1H NMR (400.13 
MHz, CDCl3) δ 7.43-7.37 (m, 2H), 7.37-7.30 (m, 2H), 7.30-7.23 (m, 1H), 6.63 (d, J = 15.9 Hz, 
1H), 6.30 (dt, J = 15.9 Hz, 6.2 Hz, 1H), 4.27 (ddd, J = 12.5 Hz, 5.9 Hz, 1.3 Hz, 1H), 4.20 (ddd, J 
= 12.4 Hz, 6.4 Hz, 1.4 Hz, 1H), 3.71 (ddd, J = 6.4 Hz, 4.0 Hz, 2.0 Hz, 1H), 3.66-3.47 (m, 4H), 
2.02 (ddd, J = 9.6 Hz, 5.9 Hz, 2.1 Hz, 1H), 1.70-1.49 (m, 6H), 1.33 (ddd, J = 6.4 Hz, 5.9 Hz, 5.3 
Hz, 1H), 1.19 (ddd, J = 9.5 Hz, 5.3 Hz, 3.9 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 169.5, 
136.4, 132.9 (+), 128.5 (+, 2C), 127.8 (+), 126.5 (+, 2C), 125.2 (+), 71.6 (-), 60.3 (+), 46.7 (-), 
43.1 (-), 26.6 (-), 25.5 (-), 24.6 (-), 19.5 (+), 14.9 (-);  FT IR (KBr, cm-1): 3059, 3024, 2935, 
2855, 1634, 1446, 1225;  HRMS (TOF ES): found 286.1801, calculated for C18H24NO2 (M+H) 
286.1807 (2.1 ppm).   
  (1R*,2R*)-N-(tert-Butyl)-2-(prop-2-yn-1-yloxy)cyclopropane-
carboxamide (246c):  Was prepared according to procedure for 246b, employing 2-bromo-N-
(tert-butyl)cyclopropanecarboxamide (245c) (66 mg, 0.30 mmol, 1.0 equiv) and propargyl 
alcohol (21 mg, 0.32 mmol, 1.2 equiv).  The reaction was carried out at 60 oC for 3 hrs.  
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Preparative column chromatography of a residual oil on silica gel fforded the title compound as 
a colorles oil, Rf 0.30 (hexane/EtOAc, 4:1). Yield 46 mg (0.23 mmol, 78%).  
1H NMR (500.13 
MHz, CDCl3) δ 5.46 (br. s., 1 H), 4.24-4.19 (m, 1H), 4.19-4.14 (m, 1H), 3.71 (ddd, J = 6.4 Hz, 
4.0 Hz, 2.2 Hz, 1H), 2.46 (t, J = 2.5 Hz, 1H), 1.55 (ddd, J = 9.6 Hz, 6.0 Hz, 2.0 Hz, 1H), 1.35 (s, 
9H), 1.24 (q, J = 6.0 Hz, 1H), 1.10 (ddd, J = 9.5 Hz, 5.6 Hz, 4.1 Hz, 1H);  13C NMR (100.67 
MHz, CDCl3) δ 170.0, 79.3, 74.7 (+), 59.4 (+), 58.2 (-), 51.3, 28.9 (+, 3C), 23.5 (+), 13.6 (-);  FT 
IR (NaCl, cm-1): 3308, 3078, 2968, 2930, 2870, 1724, 1643, 1549, 1537, 1479, 1454, 1394, 
1364, 1331, 1256, 1227, 1202, 1153, 1097, 1061, 1043, 1026, 995, 986, 955, 926, 910, 893, 878, 
764, 737, 665, 635;  HRMS (TOF ES): found 196.1341, calculated for C11H18NO2 (M+H) 
196.1338 (1.5 ppm). 
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2.4.8. Adition of Phenoxides 
 
Me
O
Et2N
O
OMe
  
Preparation of (1R*,2S*)-N,N-Diethyl-2-(4-methoxyphenoxy)-1-methylcyclopropane-
carboxamide (242m):  An oven dried 5 mL Wheaton vial was charged with bromocyclopropane 
241e (117 mg, 0.50 mmol), 4-methoxyphenol (62 mg, 0.50 mmol), potassium tert-butoxide (29 
mg. 0.50 mmol), 18-crown-6 (14 mg, 0.05 mmol, 10 mol%), and anhydrous THF (2 mL).  The 
mixture was stirred at 80 oC for 20 hrs, after which time GC analysis indicated ca. 40% 
conversion of the intermediate cyclopropene into a 1:1 mixture of aryl (242m) and tert-butyl 
(242e) ethers.  Attempts to achieve complete conversion by extending reaction time and/or 
increasing reaction temperature resulted in significant decomposition of the phenol ether 242m.  
Accordingly, the reaction was stopped at partial conversion and was quenched with water (10 
mL) and extracted with EtOAc (3 x 5 mL).  Combined organic extracts were dried with MgSO4, 
filtered, and concentrated in vacuum.  The residue was purified by column chromatography on 
Silica gel, eluting with hexane/EtOAc (1:1).  The titled compound was obtained as colorless oil, 
yield 28 mg (0.10 mmol, 20%). 
1H NMR (400.13 MHz, CDCl3) δ 6.87 (d, J = 9.1 Hz, 2H), 6.81(d, J = 9.1 Hz, 2H), 3.77 (s, 3H), 
3.69 (dd, J = 5.8 Hz, 3.5 Hz, 1H), 3.61-3.48 (m, 2H), 3.39-3.28 (m, 2H), 1.35 (s, 3H), 1.31 (dd, J 
= 6.1 Hz, 3.5 Hz, 1H), 1.30 (t, J = 7.3 Hz, 3H), 1.16 (t, J = 7.3 Hz, 3H), 0.93 (ps.-t, J = 6.1 Hz, 
5.8 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ169.9, 154.1, 152.3, 115.8 (+, 2C), 114.4 (+, 
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2C), 60.6 (+), 55.7 (+), 41.0 (-), 38.6 (-), 27.5, 20.4 (+), 19.5 (-), 14.1 (+), 12.3 (+);  1H NOE 
NMR (500.13 MHz, CDCl3) δ 1.35 (7%) and 0.95 (5%) upon irradiation at 3.68 ppm; 1.31 (7%), 
1.35 (3%), 3.68 (2%) upon irradiation at 0.95 ppm;  GC: Rt 12.69 min; HRMS (TOF ES): found 
278.1763, calculated for C16H24NO3 (M+H) 278.1756 (2.5 ppm).   
 
Scheme 106. Thermodynamic reversibility of phenoxide addition 
 
 
   
 An oven-dried 1.0 mL Wheaton vial was charged with phenoxycyclopropane 242m (17 
mg, 60 µmol), t-BuOK (17 mg, 150 µmol), 18-crown-6 (1.6 mg, 6 µmol, 10 mol%), and 
anhydrous THF (300 µL).  The mixture was stirred at 80 oC for 48 hrs.  No reaction occurred as 
judged by GC analysis.  Then the temperature was raised to 100 oC, and stirring was continued 
for another 48 hrs.  Notable decomposition of the starting material took place; however, no 
formation of tert-butyl ether 242e was detected (eq 18).   
 
2.4.9. Studies on Formal Substitution with Hydroxide and Silanolate 
  
 These experiments were performed in order to asses the possibility of direct addition of 
water en route to cyclopropanol 257 ( 
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Scheme 107).  Also, addition of sylanolate species was tested en route to cyclopropyl silyl ether 
258. Two sets of conditions were tested with each pronucleophile, using t-BuOK and KOH, 
respectively.  It was found that in the presence of water (T st 1 and Test 2), no reaction between 
bromocyclopropane 231a and a base to generate intermediate cyclopropene 91a was observed, 
suggesting that moisture adversely affected the first step, 1,2-dehydrobrominati n reaction. ( 
Scheme 107).  
 
Scheme 107. Addition of hydroxide species 
 
 
 
 In the presence of anhydrous lithium sylanolate, the 1,2-dehydrobromination of 231a 
proceeded smoothly with both bases affording cyclopropene 91a. However, no addition of 
sylanolate nucleophile to the cyclopropene was detected.  Thus, when t-BuOK was employed as 
a base, nucleophilic attack of tert-butoxide resulted in the formation of product 232c (Test 3), 
whereas in the presence of KOH the cyclopropene either remained intact or slowly decomposed 
at higher temperatures (Test 4). 
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Scheme 108. Attemted addition silanolates 
 
 
 
Test 1. An oven-dried 2 mL Wheaton vial was charged with bromocyclopropane 231a (63 mg, 
0.30 mmol), t-BuOK (50 mg, 0.45 mmol, 1.5 equiv), 18-crown-6 (7.9 mg, 30 µmol, 10 mol%), 
water (11 µL, 0.60 mmol, 2.0 equiv), and anhydrous THF (1 mL).  The mixture was stirred at 80 
oC overnight.  According to the GC/MS analysis of the crude reaction mixtures, no reaction took 
place, and bromocyclopropane 231a remained intact. 
Test 2. An oven-dried 2 mL Wheaton vial was charged with bromocyclopropane 231a (63 mg, 
0.30 mmol), KOH (25 mg, 0.60 mmol, 2.0 equiv), 18-crown-6 (7.9 mg, 30 µmol, 10 mol%), 
water (11 µL, 0.60 mmol, 2.0 equiv), and anhydrous THF (1 mL).  The mixture was stirred at 80 
oC overnight.  According to the GC/MS analysis of the crude reaction mixtures, no reaction took 
place, and bromocyclopropane 231a remained intact. 
Test 3. An oven-dried 2 mL Wheaton vial was charged with bromocyclopropane 231a (63 mg, 
0.30 mmol), t-BuOK (50 mg, 0.45 mmol, 1.5 equiv), 18-crown-6 (7.9 mg, 30 µmol, 10 mol%), 
lithium trimethylsylanolate (48 mg, 0.60 mmol, 2.0 equiv), and anhydrous THF (1 mL).  The 
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mixture was stirred at 80 oC overnight.  According to the GC/MS analysis of the crude reaction 
mixtures, tert-butyl ether 232c was formed as a sole product. 
Test 4. An oven-dried 2 mL Wheaton vial was charged with bromocyclopropane 231a (63 mg, 
0.30 mmol), KOH (25 mg, 0.60 mmol, 2.0 equiv), 18-crown-6 (7.9 mg, 30 µmol, 10 mol%), 
lithium trimethylsylanolate (48 mg, 0.60 mmol, 2.0 equiv), and anhydrous THF (1 mL).  The 
mixture was stirred at 60 oC overnight.  According to the GC/MS analysis of the crude reaction 
mixtures, cyclopropene 91a was formed as the sole product.  The temperature was gradually 
increased to 100 oC, at which point cycloisomerization of cyclopropene into 3-methyl-1H-indene 
(32) took place; while no desired addition products were detected. 
 
2.4.10.  Assignment of Relative Configuration 
 
 Relative configurations of products, 242c, were assigned based on 1D NOEDIFF 
experiments.  Relative configurations of other products were assigned by analogy. Assignment of 
the relative configuration of product 242c is provided in Figure 12 and Figure 13. 
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Figure 12. Observed NOEs upon irradiation at 3.27 ppm (blue), 1.03 ppm (red), 0.95 ppm 
(green) for compound 242c.  For color-coded spectral charts corresponding to these experiments, 
see Figure 13 
 
 
 
162 
 
 
3.0 2.5 2.0 1.5 1.0 0.5
ppm
3.27 ppm
1.03 ppm
0.95 ppm
 
 
Figure 13. 1D NOEDIFF spectra of 242c.  Chemical shifts of the irradiated multiplets are listed 
at the right side of each chart. 
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Chapter 3. Intromolecular fomal nucleophilic substitution of bromocyclopropanes as a 
method for the synthesis of medium size cyclopropyl fused heterocycles 
 
3.1. Introduction 
 
 The formal substitution of bromocyclopropanes 258 with O- and N-based nucleophiles 
allows for the efficient diastereoconvergent assembly of valuable, highly functionalized 
cyclopropyl scaffolds. In this transformation, bromocyclopropane 258 undergoes dehydrobrom-
ination to produce a highly reactive cyclopropene intermediate 259, which once formed is 
immediately trapped by an external nucleophile to afford cyclopropanol or cyclopropylamine 
derivative 260 (Scheme 109, eq 1).  
 We envisioned the intramolecular mode (Scheme 109, eq 1,2) of this reacton as a useful 
tool for the construction of novel types of medium heterocycles and a convenient probe 
investigating challenging nucleophilic exo- and endo-trig medium ring closures. It was expected 
that stringent enthalpic and entropic requirements would be met in this cyclization as the rigid 
cyclopropyl moiety in the molecule backbone would endow the system with sufficient 
constraints, whereas the strain energy release would allow for effective ring closure via the 
nucleophilic attack of a tethered heteroatom moiety (Scheme 109, eq 2, 3). Thus, generation of 
cyclopropene species 262 from bromocyclopropane 261 bearing a pronucleophilic moiety 
tethered through the quaternary carbon would invoke an xo-trig cyclization, leading to bicyclic 
scaffold 263 (Scheme 109, eq 2).  On the other hand, a more exotic endo-trig mode can be real-
ized by subjecting to the reaction a substrate of type 264 possessing a tertiary α-carbon.  In 
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contrast to cyclopropene 262 with a nucleophilic entity attached to C3 (Scheme 109, eq 2), the 
corresponding unstable, non-isolable, conjugate strained olefin 269 suitable for the endo-trig 
cyclization possesses a C1-linked nucleophile (Scheme 109, eq 3).    
 
Scheme 109. 
 
 
  
  
  The potential synthetic and medicinal value of this unique transformati n was quickly 
realized as it could allow access to several important classes of compounds including 
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cyclopropyl fused heterocycles which up to this point have been limited to 
oxabicyclo[3.1.0]hexane and heptane derivatives (Figure 14).  
 Incorporation of light weight isosteric cyclopropane fragments wi h unusual bond angles 
into the structure of biologically active compounds is used to fine tune the geometry of small 
molecules without affecting its binding ability and solvent affinity,115 which becomes very 
practical in investigation of binding mechanisms.116    
 The steric constraints imparted by a cyclopropane ring could be used to restrict rotational 
freedom and reinforce binding conformations, which helps achieve more selective interactions 
between the ligand and the receptor.117,118 The innate, high metabolic stability of the 
cyclopropyl-based molecules as compared to the open-chain analogs, can be used to improve the 
in vivo pharmaceutical profile of a drug candidate.119    
 
Figure 14. 
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 Over the last decade, cyclopropyl fused ethers have been th subject of intense study as 
potential nucleoside mimics,120,121 metabotropic glutamate receptor 4 (mGluR4) positive 
allosteric modulators,122 and mGluR2,3 agonists123 (Figure 14). However,  only a handful of 
methods have emerged allowing for access to medium sized cyclopropyl fused heterocycles. 
Accordingly, there is a pressing need for the development of alternative routes towards these 
heterocycles.  
 Aside from the potential of this methodology for furnishing functionalized oxabicyclo 
derivatives, the transformation serves as a possible pathway to medium size conformationaly 
restricted lactam derivatives. The abundance of medium sized lactams in nature and their 
position in drug discovery research, particularly as β-turn and β-strand peptidomimetics (Figure 
15),124 generate an increasing demand for efficient synthetic approaches towards there 
construction.  
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Figure 15. 
 
 
  
 While the incorporation of cyclopropyl scaffolds into small heterocycles has been an area 
of intense research and a plethora of biologically active compounds have been synthesized, 
examples of medium and large cyclopropane fused heterocycles have remained virtually 
unexplored. However, recent investigations have revealed potential; for example, cyclopropyl 
fused heterocycles of type 11 were found to be potent HCV protease inhibitors (Figure 16).125  
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Figure 16. 
 
 
3.1.1. Synthetic approaches for the synthesis of cyclopropyl fused ethers  
 
 The synthetic methods employed for the construction of cyclopropyl 
oxabicyclo[3.1.0]hexane derivatives) span a variety of cyclopropanation reactions with cyclic 
enol ethers.95 However, it is generally recognized that efficient stereoselective cyclopropanation 
of enol ethers represents a challenging task.126 Cyclopropanation reactions are generally sensitive 
to sterics and do not allow access to highly funtionalized cyclopropane units. Most of the 
cyclopropanation reactions involved in formation of cyclopropyl fused ethers are restricted by 
the availability of the corresponding dihydrofuran or dihydropyran derivatives. Notably 
cyclopropanation reactions involving dihalocarbenes, which are one of the most useful reactions 
for the synthesis of functionalized cyclopropane derivatives, often times cannot be utilized as 
corresponding enol ether undergoes ring opening.127 The synthesis of cyclopropyl fused cyclic 
ethers of ring size greater than six utilizing cyclopropanation reactions requires the preparation 
of medium sized cyclic enol ethers which poses a seperate synthetic c allenge. Some recent 
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examples employing classic cyclopropanation reactions as well as those which providing access 
to medium size scaffolds are discussed below.  
 Metal-catalyzed carbene transfer from diazo compounds to olefins is a straightforward 
method for preparation of cyclopropanes, and much effort has been devote  towards the 
development of highly effective steroselective cyclopropanations.128 Several methods have been 
developed involving [2+1] cycloadditions of diazo acetate derivatives with furans;129 however, 
most of the methods are limited in terms of substrate scope, and sensitivity to sterics leads to 
decreased yields and stereoselectivity (Scheme 110. eq 1).130 Nonetheless, recent advances have 
emerged allowing for the preparation of enantiomerically pure oxabicyclo cyclopropane 
derivatives (Scheme 110., eq. 2).131   
 
Scheme 110. 
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 The Simmons-Smith reaction132 is a powerful tool for the preparation of cyclopropane 
derivatives from alkenes. Similar to methods based on diazo carbene transfers, this protocol 
allows for access to cyclopropyl fused ethers upon reaction with cyclic enol ethers; however, it is 
less sensitive to sterics and often times provides excellent diastereoselectivities. This method is 
often employed in the synthesis of conformationally restricted nucleoside analogues.133 For 
example dihydrofuran 272 underwent diastereoselctive cyclopropanation to afford 
conformationally restricted sugar 273 in high yields. The most serious drawback of this 
methodology for the construction fused cyclopropyl scaffolds is its nherent inability to carry out 
a transfer of functionalized carbenoid equivalents (Scheme 111). 
 
Scheme 111. 
 
 
  
 Similarly, the Corey-Chaykovsky reaction134 utilizing trimethylsulfoxonium iodide 
provides a facile and stereoselective method for preparation of cyclopropyl fused heterocycles 
through cycloadditions involving cyclic enol ethers. (Scheme 112).135 
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Scheme 112. 
 
 
 
 As mentioned above, the exploration of oxabicyclocyclopropane derivitives as medicinal 
agents has, up to this point, been limited to oxabicyclo[3.1.0]hexane and heptanes derivatives, 
since [2+1] cycloadditions are primarily executed on dihydrofuran and dihydropyran scaffolds. 
There are only a handful of efficient methods available that afford bicycles of ring sizes greater 
than six. Rousseau and co-workers took advantage of easily accessible medium lactones 277 
which were converted to enol ethers 278 and subsequently were reacted in the presence of in situ 
generated carbenes to furnish medium size cyclopropyl fused heterocycles 279. This protocol 
allowed for the construction of synthetically useful 6, 7, 8, 9, and 10 membered heterocycles in 
good yields (Scheme 113). 
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Scheme 113 
 
  
 It was demonstrated that stannyl substituted acetals 281 are effective for intramolecular 
cyclopropanation via in situ transacetalization (Scheme 114).136 For example, the treatment of 
281 with Lewis acids such as TMSOTf and BF3OEt2 in the presence of olefinic alcohol 282 gave 
rise to facile formation of bicyclic cyclopropane 285 in good yields. The reaction seems to 
proceed by the initial transacetalization of 281 with 282 to give mixed acetal 283 which then 
undergoes acid promoted elimination of the ethoxy group to generate tin substituted carbocation 
284 (Scheme 114). The carbocation adds to the carbon-carbon double bond and the subsequent 
elimination of tin to achieve the intramolecular cyclopropanation which afforded 5, 6, 7, and 8 
membered rings 285 in good to excellent yields.  
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Scheme 114. 
 
 
 
 
3.1.2. Known approaches towards medium size heterocycles 
   
 
 
 One of the most exciting aspects of the development of a intramolecular nucleophilic 
substitution (Scheme 109, eq 2, 3) is the potential for construction of mediu  size heterocycles. 
Not only are they of medicinal and synthetic value, high yielding diastereoselective non metal-
assisted intramolecular substitutions  present a rare class of trans ormations. Medium and large 
ring closure is typically achieved via radical cyclizations137 (Scheme 115, eq 1), transition 
metals138 (Scheme 115, eq 2), and lactonizations139 (Scheme 115, eq. 3). While these are 
valuable tools, there is still much to be explored in the realm of medium ring closure as 
formation of these are generally unfavored, since the free energy of such cyclizations are 
typically positive due to a significant increase in the ring strain and loss of conformational 
freedom.  
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 Intramolecular nucleophilic attack by tethered pronucleophilic entitis s possible in the 
presence of transition metals or a Lewis acid activator and is a powerful tool in the synthetic 
arsenal available for construction of medium size heterocycles.140 While the enthalpic 
requirements for medium ring closure present serious challenges, kinetic barriers for direct 
intramolecular nucleophilic addition to unactivated olefins, epoxides, and alkyl halides do not 
allow for efficient ring closure. However, in the presence of transition metals both O- and N-
pronucleophiles add across olefins and alkynes. An excellent example of this type of 
methodolology involving hydroamination was recently reported by Schefer, who prepared a 
zirconium precatalyst with excellent reactivity for intramolecular hydroamination of alkenes. 
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This methodology furnishes 7-membered cyclic amines 287 via efficient 7-exo-trig cyclizations 
of unactivated olefins 286 (Scheme 116).141 
 
Scheme 116. 
 
 
  
 Unless certain conformational restraints are present in acyclic precursors, the generation 
of medium- and large-sized ring compounds greater than 7 is commonly problematic. Thus, it 
was shown that decreasing the degrees of rotational freedom via utiliz tion rotationally restricted 
tethers such as amides allows for intramolecular cyclizations of medium size heterocycles. For 
example, intramolecular copper catalyzed addition to ynamides 289 generated in situ via 
nucleophilic attack of conformationaly restricted  O-and N- pronculeophiles  288 furnished a 
variety of highly functionalized medium and large heterocycles  290(Scheme 117).142 
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Scheme 117. 
 
 
 Metal-assisted intramolecular nucleophilic cyclizations involving inherently more 
activated substrates such as carbonyls and epoxides are more common. Suzuki and co-workers 
developed an efficient method toward the stereoselective construction of medium-sized cyclic 
ethers 292 by cyclization of hydroxy epoxides 291 promoted by Eu(fod)3.
143 Stereochemistry 
was easily controlled since the reaction proceeds via an SN2 mechanism. The efficiency of the 
method was proven by employing it in the successful total synthesis of (+)-obtusenyne via an 
efficient 9-exo-tet cyclization (Scheme 118).144 
 
Scheme 118. 
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 Direct non metal-assisted transformations involving nucleophilic attacks are less 
common, since oftentimes these methods involve the in situ generation of a nucleophilic species 
followed by SN2 substitution, which is entropically unfavored. For example, tethered diio i es 
293 in the presence of one equivalent of Na2S/Al2O3 first generate the corresponding sulfide 
which may then undergo an intramolecular SN2 substitution to afford oxathianes 294 of various 
sizes (Scheme 119).145 Unfortunately, these intramolecular cyclizations suffered from poor yields 
due to intermolecular dimerization which is a common problem among such cyclizations. 
 
Scheme 119. 
 
  
  
 The necessity of restricting conformational freedom in such cylizations is evident in the 
following example. The reaction of the trialkylstannyl ether acet ls 297 in the presence of 2 
equivalents of TiC13 gives intramolecular cyclizations furnishing vinyl cyclic ether of type 298 
(Scheme 12). The reaction works very well for the formation of pyran derivatives however 
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formations of rings larger than six required the incorporation of a cyclohexane ring into the 
carbon back bone which enhanced the chemical yield of 298 rom 8 % to 30 % via decreasing 
the flexibility of the acyclic precursor. 
 
Scheme 120. 
 
 
 
   
3.2. Results and Discussion 
 
3.2.1. Scope and limitations 
 
 We embarked on our investigation of intramolecular formal nucleophilic substitution by 
first inquiring into the possible structure, length, and rigidity of the tethered moiety as all of these 
factors greatly influence the outcome of the reaction. It was expected that due to the 
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conformational restraints imposed by the cyclopropane moiety the employment of 
conformationaly unrestricted tethers would be possible.  
 
 
Scheme 121 
 
 
 
 Thus, bromocyclopropane 303 was synthesized from 301 via a simple protocol shown in 
(Scheme 121). Disappointingly subjection of 303 to our optimized conditions developed for the 
intermolecular mode of this reaction did not yield cyclization and 305 was not detected (Scheme 
121). Surprisingly attempts to induce intermolecular nucleophilic attack of t-BuOK to in situ 
generated intermediate 304 failed to give conclusive results. Increasing the reaction temperature 
only yielded a complex mixture as observed by GC/MS analysis.  Addition of 1.1 equivalents t-
BuOK at room temperature generated trace amounts of 304, nonetheless attempts at isolation 
failed.  
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 It was hypothesized that the installation of an amide or carboxylate functionality into the 
tether would provide additional conformational restraint in acyclic precursors 306 thereby 
circumventing possible entropic factors hindering intramolecular attack and providing 
heterocycles of type 308 ( 
 
Scheme 122). The directing effects of carboxylate and amide functionali es observed in the 
intermolecular addition of nucleophiles (Scheme 94)  were also expectd to greatly effect the 
outcome of cyclization by not only providing rotational constaints, but also to serve as part of a 
preorganized template 307 for cyclization. This template would be based on coordination of 
potassium to both the carboxylate functionality and the in situ generated tethered nucleophile 
(Scheme 122).  
 
Scheme 122. 
 
 
 
  
 To test this hypothesis, monobromocyclopropane 309 was synthesized from the 
corresponding acid chloride 313. While it was observed that ester containing 
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bromocyclopropanes undergo decomposition upon subjection to t-BuOK, intramolecular 
nucleophilic addition was expected to outcompete the addition of t-BuOK to the carboxylate. 
Surprisingly, intramolecular addition did take place, however attack oc urred at the carbonyl 
rather than to the cyclopropene providing ylidene 311b in 68 % NMR yield via proposed 
intermediate 311 (Scheme 123). Unfortunately attempts to avoid this rearrangement at various 
temperatures and obtain dioxacanone 312 via an 8-exo-trig cyclization were unsuccessful. To 
address this issue we substituted the ester function with a more electron-rich carboxamide 
functionality.  It has previously shown that 2-bromocyclopropylcarboxamides can be readily 
converted into the corresponding cyclopropenes in the presence of nucleophilic reagents with 
complete preservation of the amide function.  
 
Scheme 123. 
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3.2.2. Medium Ring Closures 
  
 Accordingly, we set out to synthesis a library of ethanolamine and propanol amine 
derived acyclic precursors which upon cyclization would provide oxazepanones (n = 1) and 
oxazacanones (n = 2) via 7- and 8-exo trig cyclizations respectively. All amino alcohols reacted 
chemoselectively with acid chloride 313 in the presence of triethyl amine to furnish acyclic 
precursors 314a-e in reasonable yields (Scheme 124).  
 
Scheme 124. 
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 We performed test reactions employing 2-ethanolamine-derived substrates 314e-f. To our 
delight, the corresponding oxazepanones 316e-f were formed as sole products in high yield 
(Scheme 125). In both cases the cis-fused isomer was formed exclusively from a mixture of 
diastereomers. Notably no traces of the intermolecular addition of t-BuOK were detected by 
GC/MS analysis or by crude NMR analysis. Expectedly, the reaction times were shorter as 
compared to the intermolecular reaction. However, substrate 316f required heating to 80 oC in 
order to efficiently form cyclopropene intermediate 315. 
 Inspired by these results we set out to investigate the possibility of 8-exo trig cyclizations 
employing acyclic precursors 314a-c. Upon reaction of acyclic precursors 314a-c with 2-2.5 
equiv. of t-BuOK in the presence of 18-crown-6 in THF, oxazacanone derivatives were all 
obtained in good yields as single diastereomers. Interestingly, anthracenyl acycyclic precursor 
314d also reacted uneventfuly to provide oxazacanone 316d in 92% yield as a single diastreomer 
(Scheme 125). 
 
  
184 
 
 
Scheme 125.  
 
 
 
 The 8-exo-trig cyclizations were especially intriguing since classical Baldwin’s rules do 
not encompass ring closures larger than 7,146 and we wondered if this preorganized template 
proposed could induce cyclizations of longer tethers. Indeed oxazananones 318d and 318e were 
obtained as single diastereomers from acyclic precursors 317d and 317e via 9-exo-trig 
cyclizations. Remarkably acyclic precursors 317a-c underwent 10-exo-trig cyclizations affording 
oxazecanones 318a-c (Scheme 125), and dioxazecanone 318b in excellent yields. All described 
transformations proceeded in a highly diastereoselective fashion aff rding cis-fused bicyclic 
products starting from a diastereomeric mixture of bromocyclopropanes. 
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Scheme 126. 
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 The high degree of diastereoselectivity was observed even in 9- and 10-membered ring 
closures of very flexible substrates, possessing no additional stereo electivity-inducing elements 
in the tether.  Remarkably, the reactions did not require high dilutions and afforded consistently 
high yields in preparatively convenient 0.05-0.2 M concentration range. The unique feature of 
this sequential transformation, in which the reactive intermediate is generated in very low 
quantities, permitted carrying out the reaction at such unusually high for medium ring closure 
concentrations.  It should be mentioned that, despite the efficient assembly of 7-10 membered 
heterocycles we failed to obtain 11 and 12-membered rings via this approach. 
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 Having met success with the exo-trig ring closure, we tested a corresponding e do-trig 
cyclization.147 Our attempts to enable a 7-endo-trig ring closure were unsuccessful; however, 2-
bromocyclopropylcarboxamides 319 cyclized smoothly via an 8-endo-trig pathway upon 
exposure to powdered KOH in the presence of 18-crown-6 ether, to give the corresponding 
oxazacanones 320b-c high yields (Scheme 127).  Furthermore, under similar conditions bromo-
cyclopropane 319a bearing a tethered phenoxide pronucleophile, provided oxazacinone 320a in 
excellent yield. 8-endo-trig cyclization via 319 produced cis-fused heterocycles exclusively as 
equilibration to the trans-fused diastereomers 324 is unfavored unlike in the corresponding 
intermolecular nucleophilic additions to substrates of type 319 (Scheme 127). 
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Scheme 127 
 
 
 
3.2.3. Construction of chiral bicycles 
 
 To further showcase the synthetic potential of this methodology, we explored 
intramolecular addition of tethered chiral alcohols en route to nonracemic bicyclic products 
(Scheme 128). Acylation of chiral amino alcohols with a racemic acyl chloride 313 provided 
amides 325 and 326 as mixtures of four diastereomers, which were subjected to the 
dehydrobromination conditions. Gratifyingly, both reactions exhibited perfect site selectivity: the 
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intramolecular nucleophilic attack of the alkoxides in the cyclopropene intermediates 325’ and 
326’ proceeded at only one of the diastereotopic s 2-carbon atoms (a), efficiently producing the 
corresponding bicyclic oxazepinones 327a, b and 328 as sole products. 
 
Scheme 128. 
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 It was rationalized that the observed excellent diastereoselectivity results from a 
significant preference of the thermodynamically more favorable transition state TS327a with 
pseudo-equatorial orientation of the bulky substituents (Figure 17). The geometry of this 
transition state is very close to the most stable conformation of the obtained cyclic product, 
established by both NMR analysis and X-ray crystallography (Figure 17).148 To further examine 
how the  structure of the acyclic precursor affects the ster oh mical outcome of the reaction, (+)- 
Ephedrine was employed as a tether to ptovide acyclic precursor 326b, which upon cyclization 
gave 329 as a single diastereomer in 90% yield. (Figure 18). 
 
Figure 17. Thermodynamically most favored geometry of transition state TS327a (AM1) and X-
ray structure of 327a see Appendix Figure 28 
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Figure 18.  
 
 
 
 
3.3. Conclusion 
 
 In conclusion, we have developed a very facile and general exo-trig cyclization of seven- 
through ten-membered rings, achieved as a result of highly efficient pre-organization of 
conformationally constrained precursors and the strain energy release. The described 
transformation can be carried out in a highly diastereoselective fashion, affording a single cis-
fused bicyclic product starting from a diastereomeric mixture of bromocyclopropanes.  This 
being the case even for relatively flexible tethered substrates, leading to [9.1.0] and [10.1.0 ] 
bicyclic systems.  The developed transformation also involves a novel 8-endo-trig nucleophilic 
cyclizations and it was demonstrated that this reaction proceeds highly efficiently with both 
alkoxides and phenoxide nucleophiles. 
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3.4. Experimental Procedures 
3.4.1. General Information 
 
 See Chapter 1.4.1. for general remarks and list of instrumentation. Anhydrous 
triethylamine was obtained by distillation of ACS-grade commercially available materials over 
calcium hydride in a nitrogen atmosphere.   3-Benzylamino-1-propanol, 4-benzylamino-1-
butanol, 5-benzylamino-1-pentanol, and 2-cyclohexylamino-1-ethanol were purchased from TCI 
America and used as received.  All other commercially available reagents were purchased from 
Sigma-Aldrich or Acros Organics. 2-Bromo-cyclopropanecarbonyl chloride87 and 2-bromo-1-
methylcyclopropanecarbonyl chloride,113  Bromocyclopropanes 301 and 302 were prepared 
according to published procedures.  Preparation of other non-commercially av ilable starting 
materials is described below. 
 
3.4.2. Preparation of Amino Alcohols  
 
3-Cyclohexylamino-1-propanol:149 Three neck round bottom flask (250 
mL) equipped with a reflux condenser, a thermometer, and addition funnel 
(100 mL) was charged with LiAlH4 (1.30 g, 38.4 mmol, 1.50 eq) and anhydrous THF (30 mL).  
The resulting suspension was stirred at 0 oC and a solution of methyl 3-(cyclohexyl-
amino)propanoate150 (4.40 g, 23.2 mmol, 1.00 equiv) in dry THF (50 mL) was added drop wise 
over 30 min.   Once addition was complete the mixture was stirred at reflux overnight, then 
H
N
OH
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quenched at 0 oC consecutively with water (20 mL) and a concentrated aqueous solution of 
NaOH (5.0 g in 5 mL of water).  The resulting suspension was dilute with water (30 mL) and 
THF (50 mL) and filtered through a fritted funnel.  The filter cake was washed with THF (3 x 20 
ml), and the washing liquids were combined with the filtrate.  The resulting solution was 
saturated with NaCl and extracted with THF (3 x 20 ml). The combined organic phases were 
dried with Na2SO4, filtered, and concentrated. The crude product was purified by vacuum 
distillation (bp 60 oC at 15 torr) to afford the titled compound as colorless oil, solidifying upon 
standing. Yield 2.4 g (15.1 mmol, 65%). 
1H NMR (400.13 MHz, CDCl3) δ 3.80 (t, J = 5.2 Hz, 2H), 2.89 (t, J = 5.7 Hz, 2H), 2.41 (tt, J = 
10.3 Hz, 3.6 Hz, 1H), 2.05 (br. s, 2H), 1.97-1.79 (m, 2 H), 1.77-1.52 (m, 5H), 1.31-1.13 (m, 3H), 
1.11-0.99 (m, 2H);  13C NMR (100.67 MHz, CDCl3) δ 64.5 (-), 56.6 (+), 46.9 (-), 33.4 (-, 2C), 
31.2 (-), 26.0 (-), 24.9 (-, 2C); 1H NMR (400.13 MHz, CDCl3) δ 3.77 (t, J = 5.6 Hz, 2H), 2.84 (t, 
J = 5.8 Hz, 2H), 2.57 (t, J = 7.1 Hz, 2H), 1.67 (quin, J = 5.6 Hz, 2H), 1.44 (quin, J = 7.1 Hz, 2H), 
1.35-1.19 (m, 6H), 0.86 (t, J = 6.5 Hz, 3H);  13C NMR (100.67 MHz, CDCl3) δ 64.1 (-), 49.9 (-), 
49.8 (-), 31.6 (-), 30.7 (-), 29.8 (-), 26.9 (-), 22.5 (-), 13.9 (+);   
 
3-((Anthracen-9-ylmethyl)amino)propan-1-ol:151 To a stirred 
solution of anthracene-9-carbaldehyde (2.0 g, 9.6 mmol) in methanol 
(200 mL) was added 3-aminopropanol (800 mg, 10.7 mmol, 1.1 
equiv.).  The mixture was stirred for 30 min at room temperature, then cooled to 0 oC, and 
NaBH4 (547 mg, 14.4 mmol, 1.50 equiv) was added by small portions over 5 min.  The form d 
suspension was stirred for 3 hrs, then most of the solvent was removed in acuum, and the 
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residue was quenched with 2% aqueous KOH and extracted with dichloromethane (4 x 20 mL).  
Combined organic phases were dried with MgSO4, filtered and concentrated. Th  obtained 
yellow solid was recrystallized from hexane-EtOAc 10:1 mixture o afford the title compound as 
yellow needles, mp 82-83 oC, yield 1.8 g (6.78 mmol, 71%).   
1H NMR (400.13 MHz, CDCl3) δ 8.44 (s, 1H), 8.31 (d, J = 8.8 Hz, 2H), 8.03 (d, J = 8.3 Hz, 2H), 
7.59-7.54 (m, 2H), 7.50-7.47 (m, 2H), 4.76 (s, 2H), 3.84 (app. t, J = 5.2 Hz, 2H), 3.15 (app. t, J = 
5.7 Hz, 2H), 2.05 (br. s, 2H), 1.79 (quin, J = 5.6 Hz, 2H);  13C NMR (100.67 MHz, CDCl3) δ 
131.4 (2C), 130.7, 130.2 (2C), 129.2 (+, 2C), 127.4 (+), 126.2 
 
3-(Hexylamino)propan-1-ol:152  Three neck round bottom flask (250 mL) 
equipped with a reflux condenser, a thermometer, and addition funnel (100 ml) 
was charged with LiAlH4 (1.50 g, 38.4 mmol, 1.5 equiv) and anhydrous THF (30 mL).  The 
resulting suspension was stirred at 0 oC, a solution of methyl 3-(hexylamino)propanoate153 (4.80 
g, 25.6 mmol, 1.00 equiv) in dry THF (50 mL) and was added dropwise over 30 min.  Once 
addition was complete the mixture was stirred at reflux overnight, and then quenched 
consecutively with water (20 mL) and a concentrated solution of NaOH (5.00 g in 5 ml of water) 
at 0 oC.  The mixture was diluted with THF (50 mL) and of water (30 mL) and the resulting 
suspension was filtered through a fritted funnel.  The filter cake was washed with THF (3 x 20 
mL), and the washing liquid was combined with the filtrate.  The resulting filtrate was saturated 
with NaCl and extracted with THF (3 x 20 mL). The combined organic phases were dried with 
Na2SO4, filtered and concentrated. The resulting yellowish oil was purified by vacuum 
distillation to afford the titled compound as colorless oil. Yield 2.80 g (15.9 mmol, 62%). 1H 
HO NH
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NMR (400.13 MHz, CDCl3) δ 3.77 (t, J = 5.6 Hz, 2H), 2.84 (t, J = 5.8 Hz, 2H), 2.57 (t, J = 7.1 
Hz, 2H), 1.67 (quin, J = 5.6 Hz, 2H), 1.44 (quin, J = 7.1 Hz, 2H), 1.35-1.19 (m, 6H), 0.86 (t, J = 
6.5 Hz, 3H);  13C NMR (100.67 MHz, CDCl3) δ 64.1 (-), 49.9 (-), 49.8 (-), 31.6 (-), 30.7 (-), 29.8 
(-), 26.9 (-), 22.5 (-), 13.9 (+);   
 
2-(2-(Butylamino)ethoxy)ethanol:154 A two neck round bottom 
flask equipped with a reflux condenser and addition fummel (30 mL) was ch rged with neat n-
butylamine (7.00 g, 9.46 mL, 96.7 mmol, 3.00 equiv), and a 2-(2-chloroethoxy)ethanol (4.00 g, 
32.1 mmol, 1.00 equiv) in MeOH (20 ml) was added dropwise over 10 min.  Once addition was 
complete, the mixture was heated at reflux for 18 hrs. The solvent was removed in vacuum; the 
resulting salt was washed with hexane (3 × 10 mL) and dissolved in a solution of KOH (1.89 g, 
33.7 mmol) in water 10 (mL). The resulting slurry was partitioned betwe n THF (10 mL) and 
brine (10 mL) and extracted with THF (3 × 20 mL). The combined organic phases were dried 
with Na2SO4, filtered and concentrated to obtain the title compound as colorless oi, pure enough 
to be used in further transformation without additional purification.  Yield 3.60 g (22.8 mmol, 
71%).  1H NMR (400.13 MHz, CDCl3) δ 3.68 (t, J = 4.6 Hz, 2H), 3.58 (t, J = 5.2 Hz, 2H), 3.55 
(t, J = 4.6 Hz, 2H), 2.77 (t, J = 5.2 Hz, 2H), 2.58 (t, J = 7.3 Hz, 2H), 1.54 (quin, J = 7.3 Hz, 2H), 
1.31 (sxt, J = 7.3 Hz, 2H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (100.67 MHz, CDCl3) δ ppm 72.6 
(-), 70.1 (-), 61.5 (-), 49.5 (-), 49.3 (-), 32.0 (-), 20.4 (-), 14.0 (+);  
 
3-((Furan-2-ylmethyl)amino)propan-1-ol:155 To a stirred solution of O N
H
OH
O
N
H
HO
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furfural (5.00 g, 52.0 mmol, 1.00 equiv) in MeOH (30 mL) was added 3-aminopropan-1-ol (4.00 
g, 53.3 mmol, 1.00 equiv), and the mixture was stirred for 30 min at room temperature, then 
cooled to 0 oC and NaBH4 (2.90 g, 76.6 mmol, 1.50 equiv) was added by small portions over 10 
min.  The suspension was stirred for 4 hrs at room temperature and the solvent was removed in 
vacuum.  An aqueous solution of KOH (5.00 g, 47.8 mmol, 1.7 equiv in 20 mL of water) was 
added and the solution was partitioned between EtOAC and brine.  The aqueous layer was 
extracted with EtOAc (3 x 30 mL).  The combined organic phases were dried with Na2SO4, 
filtered, and concentrated. The resulting crude oil was distilled (130 oC) to afford the title 
compound as a colorless viscous oil. Yield 7.50 g (48.4 mmol, 93%).  
1H NMR (400.13 MHz, CDCl3) δ 7.32 (dd, J = 1.8 Hz, 0.8 Hz, 1H), 6.27 (dd, J = 3.2 Hz, 1.9 Hz, 
1H), 6.14 (d, J = 3.0 Hz, 1H), 3.74 (s, 2H), 3.71 (t, J = 5.6 Hz, 2H), 2.78 (t, J = 6.1 Hz, 2H), 1.66 
(quin, J = 5.9 Hz, 2H);  13C NMR (100.67 MHz, CDCl3) δ 153.2, 141.7 (+), 110.0 (+), 106.9 (+), 
63.0 (-), 48.0 (-), 45.7 (-), 30.9 (-);  
 
4-Hexylamino-1-butanol:156 Two neck round bottom flask equipped with a 
reflux condenser was charged with neat n-hexylamine (5.60 g, 55.2 mmol, 
3.00 equiv), and a solution of 4-chlorobutan-1-ol  (2.00 g, 18.4 mmol 1.00 equiv) and MeOH (20 
mL) was added dropwise over 30 min.  Once addition was complete the mixture was heated at 
reflux for 12 hr. The solvent was removed in vacuum and the resulting salt was washed with 
hexane (3 x 10 ml) and dissolved in a solution of KOH (3.10 g, 55.2 mmol, 3.00 equiv) in water 
(20 mL).  Then the mixture was partitioned between THF (20 ml) and bri e (20 ml) and the 
aqueous phase was extracted with THF (3 x 20 ml).  The combined organic ph ses were dried 
NH
HO
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with Na2SO4, filtered, and concentrated.  The resulting crude material was purified by vacuum 
distillation (100 oC at 1 torr) to afford the titled compound as colorless oil.  Yield 1.6 g (9.2 
mmol, 50 %). 
 
1H NMR (400.13 MHz, CDCl3) δ 3.75 (br.s, 2H), 3.55 (t, J = 6.0 Hz, 2H), 2.64 (t, J = 5.8 Hz, 
2H), 2.59 (t, J = 7.3 Hz, 2H), 1.88-1.80 (m, 2H), 1.67-1.59 (m, 4H), 1.48 (quin, J = 7.3 Hz, 2H), 
1.31-1.24 (m, 4H), 0.86 (t, J = 7.3 Hz, 3H);  13C NMR (100.67 MHz, CDCl3) δ 62.5 (-), 49.6 (-), 
49.5 (-), 32.6 (-), 31.7 (-), 29.6 (-), 28.8 (-), 26.9 (-), 22.5 (-), 14.0 (+);  
 
4-(Phenethylamino)butan-1-ol:157 Two neck round bottom flask 
equipped with a reflux condenser was charged with neat 2-
phenylethanamine (13.4 g, 110 mmol, 3.00 equiv), and a solution of 4-chlorobutan-1-ol (4.00 g, 
36.8 mmol, 1.00 equiv) in MeOH (30 mL) was added dropwise over 30 min. Once addition was 
complete the mixture was heated at reflux for 12 hr. The solvent was removed in vacuum, the 
resulting salt was washed with hexane (3 x 10 mL) and dissolved in a solution of KOH (6.2 g, 
110.4 mmol, 3 equiv) in water (30 mL).  The resulting mixture was partitioned between THF (20 
ml) and brine (20 ml) and extracted with THF (3 x 20 ml). The combined organic phases were 
dried with Na2SO4, filtered, and concentrated. The resulting greenish oil was purified by vacuum 
distillation (110 oC at 1 torr) to afford the titled compound as colorless oil. Yield 6.00 g (31.1 
mmol, 85 %).   
1H NMR (400.13 MHz, CDCl3) δ  7.33-7.25 (m, 2H), 7.24-7.07 (m, 3H), 3.57 (t, J = 5.3 Hz, 
2H), 2.90-2.84 (m, 2H), 2.84-2.77 (m, 2H), 2.64 (t, J = 5.8 Hz, 2H), 1.72-1.52 (m, 4H);  13C 
N
H
HO
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NMR (100.67 MHz, CDCl3) δ  139.4, 128.5 (+, 2C), 128.3 (+, 2C), 126.1 (+), 62.2 (-), 50.3 (-), 
49.3 (-), 35.7 (-), 32.1 (-), 28.2 (-);  
 
5-(Cyclohexylamino)pentan-1-ol:158 A two neck round bottom flak equipped 
with a reflux condenser was charged with neat  cyclohexylamine (3.00 g, 33.7 
mmol, 3.00 equiv), and a solution 5-chloropentan-1-ol (1.53 g, 12.5 mmol, 1.00 equiv) in MeOH
(10 ml) was added dropwise over 10 min. Once addition was complete the mixture was heated at 
reflux for 18 hrs.  The solvent was removed in vacuum; the resulting salt was washed with 
hexane (3 x 10 ml) and dissolved in a solution of KOH (1.89 g, 33.7 mmol) in water 10 (mL).  
The resulting mixture was partitioned between THF (10 mL) and brine (10 mL) and extracted 
with THF (3 x 20 mL). The combined organic phases were dried with Na2SO4, filtered, and 
concentrated.  The resulting oil was distilled (bp 115 oC at 1 torr) to afford the title compound as 
colorless oil. Yield 1.39 g (20.2 mmol, 60%).  
 
1H NMR (400.13 MHz, CDCl3) δ 3.64 (t, J = 6.4 Hz, 2H), 2.65 (t, J = 7.1 Hz, 2H), 2.42 (tt, J = 
10.6 Hz, 3.7 Hz, 1H), 2.05 (br. s., 2H), 1.97-1.83 (m, 2H), 1.80-1.68 (m, 2H), 1.68-1.48 (m, 4H), 
1.48-1.38 (m, 4H), 1.32-1.02 (m, 4H);  13C NMR (100.67 MHz, CDCl3) δ 62.4 (-), 56.9 (+), 46.6 
(-), 33.4 (-, 2C), 32.4 (-), 29.7 (-), 26.1 (-), 25.1 (-, 2C), 23.5 (-);   
 
2-(2-(Benzylamino)ethoxy)ethanol159: A solution of 2-(2-
chloroethoxy)ethanol (5.0 g, 40.1 mmol) in methanol (30 mL) was added to 
stirred neat benzylamine (12.9 g, 120.4 mmol, 3.0 equiv).  The mixture was heated at reflux 
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(bath temperature 100 oC) for 24 hr, then solvent was removed in vacuum.  The obtained 
crystalline residue was washed with hexane (3 x 50 mL) and dissolved in water (50 mL), basified 
with solid KOH (6.5 g), and extracted with EtOAc (3 x 80 mL).  Combined organic phases were 
dried with Na2SO4, filtered, and concentrated in vacuum.  The residue was distilled in vacuum, 
bp 110 oC (0.5 torr).  Yield 4.23 g (21.7 mmol, 54%).   
 
1H NMR (400.13 MHz, CDCl3) δ 7.37-7.21 (m, 5H), 3.79 (s, 2H), 3.68 (app. t, J = 4.6 Hz, 2H), 
3.59 (app. t, J = 5.2 Hz, 2H), 3.54 (app. t, J = 4.6 Hz, 2H), 2.80 (app. t, J = 5.2 Hz, 2H);  13C 
NMR (100.67 MHz, CDCl3) δ ppm 139.6, 128.3 (+, 2C), 128.1 (+, 2C), 126.9 (+), 72.4 (-), 70.0 
(-), 61.3 (-), 53.6 (-), 48.4 (-).   
 
 2-((tert-Butylamino)methyl)phenol160:  A solution of salicyl aldehyde (1.22 
g, 10.0 mmol, 1.00 equiv.) and tert-butyl amine (1.46 g, 20.0 mmol, 2.00 
equiv.) was stirred in dry MeOH (40 mL) for 1 hr. NaBH4 (600 mg, 16.0 mmol, 1.60 equiv.) was 
added causing a color change from yellow to clear over the course of 10 min,  after which the 
reaction was quenched with 5% aqueous HCl (15 mL).  The resulting mixture was then 
partitioned between Et2O (25 mL) and brine (25 mL). The aqueous layer was extracted with 
ether (3 x 20 mL). The combined organic layers were dried with MgSO4, filtered and 
concentrated. The obtained crystalline material was pure enough t be used for the following 
transformations without additional purification. Yield 1.45 g (8.01 mmol, 81%).   
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1H NMR (400.13 MHz, CDCl3) δ 7.17 (td, J = 8.0 Hz, 1.8 Hz, 1H), 6.98 (d, J = 7.3 Hz, 1H), 
6.84 (dd, J = 8.1 Hz, 1.0 Hz, 1H), 6.79 (td, J = 7.4 Hz, 1.1 Hz, 1H), 3.92 (s, 2H), 1.23 (s, 9H);  
13C NMR (100.67 MHz, CDCl3) δ ppm 158.3, 128.2 (+), 127.7 (+), 123.4, 118.6 (+), 116.2 (+), 
50.8, 45.8 (-), 28.3 (+);  HRMS (TOF ES): found 180.1383, calculated for C11H18NO (M+H) 
180.1388 (2.8 ppm). 
 
3.4.3. Syntheses of Bromocyclopropanes 
 
 
3-Hydroxypropyl 2-bromo-1-methylcyclopropanecarboxylate (309): To a 
stirred solution of 1,3-propanediol (520 µL, 551 mg, 7.24 mmol, 5.00 equiv) in anhydrous 
pyridine (2 mL) was added dropwise 2-bromo-1-methylcyclopropanecarbonyl chloride (200 µL, 
286 mg, 1.45 mmol).  The mixture was stirred for 2 hr at 0 oC, then quenched with water (20 
mL) and extracted with EtOAc (3 × 10 mL).  Combined organic phases were washed 
consequitively with 10% aqueous HCl (10 mL), saturated aqueous NaHCO3 (10 mL) and brine 
(10 mL), dried with MgSO4, filtered and concentrated in vacuum.  Preparative column 
chromatography of a residue (eluent hexane/EtOAc, gradient from 4:1 to 1:1) afforded two 
fractions.  Less polar fraction (Rf 0.50, eluent hexane/EtOAc 4:1) contained a mixture of 
diastereomeric propane-1,3-diyl bis(2-bromo-(methyl)cyclopropanecarboxylates) as a yellowish 
oil, yield 115 mg (0.29 mmol, 40%).  More polar fraction (Rf 0.50, eluent hexane/EtOAc 1:1) 
200 
 
 
represented a colorless oil which was identified as a title compound.  Yield 200 mg (0.84 mmol, 
58%).  1H NMR (400.13 MHz, CDCl3) δ [4.34-4.22 (m) & 4.19 (t, J = 6.3 Hz), ∑2H], [3.69 (t, 
J = 6.1 Hz) & 3.65 (t, J = 6.1 Hz), ∑2H], [3.48 (dd, J = 8.1 Hz, 5.3 Hz) & 2.94 (dd, J = 7.6 Hz, 
5.6 Hz), ∑1H], 2.43 (br. s, 1H), 1.91-1.74 (m, 3H), [1.44 (s) & 1.36 (s), ∑3H], [1.23 (dd, J = 7.6 
Hz, 6.6 Hz) & 0.99 (app. t, J = 6.1 Hz, 5.6 Hz), ∑1H];  13C NMR (100.67 MHz, CDCl3) δ major: 
173.5, 62.1 (-), 58.77 (-), 31.5 (-), 28.7 (+), 25.1 (-), 23.7, 16.7 (+);  minor: 171.3, 62.1 (-), 58.84 
(-), 31.6 (-), 26.6, 25.9 (+), 22.5 (-), 19.6 (+);  FT IR (NaCl, film, cm-1): 3427, 2961, 2887, 1726, 
1429, 1398, 1369, 1350, 1250, 1205, 1178, 1155, 1099, 1051, 922, 905, 590;  HRMS (TOF ES): 
found 258.9952, calculated for C8H13BrNaO3 (M+Na) 258.9946 (2.3 ppm).   
 
3-((2-bromo-1-methylcyclopropyl)methoxy)propan-1-ol (303): 
 
 
In a 2-neck 50 mL flask containing a stirred solution of 302 (1.8g, 8.7 mmol) in 20 mL of THF 
under N2 at 0 
oC was added 660 µL (8.8 mmol) of BH3SMe2. The solution was stirred for 2 hr at 
room temp when a solution of 1g of NaOH (3 equiv) in 2 mL of THF was added dropwise over 5 
min. Finally 3 mL of H2O2 was added via syring over 5 min at 0 
oC. The reaction was allowed to 
stir for one hour and 5 ml of water was added. The solution was extract d with 20 mL of EtOAC 
(20 mL) 3 times, washed with Na2CO3, dried with MgSO4 and filtered. The residue was purified 
by preparative column chromatography eluting with 3:1 EtOAC/hexanes. Yi ld: 1.64 g, 85% 
yield. 
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1H NMR (400.13 MHz, CDCl3) δ [3.75-3.62 (m) , ∑3H], [3.61-3.65 (m), ∑2H], [3.56-3.50 (m), 
∑2H], 4.44 (br. s, 1H), 3.3 (dd,  1.72 Hz) [3.2-3.17 (m), 1H], [2.97-2.92 m, 1H); 2.83-2.82 (m) 
1H; 1.85-1.74 m, 3H; 1.26 s, 3H; 1.15, s 3H; 1.13-1.08 m, 1H; 0.99 (t, J = 7.1 Hz 1H); 0.77 (t , J
= 7.5 Hz); 0.64 (t, J = 6.8 Hz. 13C NMR (100.67 MHz, CDCl3) δ major: 76.16 (+), 76.1 (+), 70.0 
(+), 69.52, (+) 67.77 (+), 32.05 (+) 27.57 (-), 28.48 (-), 27.20 (-), 20.92, 20.54 (-), 19.38 (+);  
HRMS (TOF ES): found 245.01.0153, calculated for C8H13BrNaO3 (M+Na) 245.01460 (2.3 
ppm).   
 
 
 
2-Bromo-N,N-bis(2-hydroxyethyl)-1-methylcyclopropanecarboxamide 
(31d): To a stirred solution of 2,2-diethanolamine (1.17 g, 11.2 mmol, 2.2 
equiv) in dry THF (4 mL) was added dropwise a solution of 2-bromo-1-
methylcyclopropanecarbonyl chloride (1.00 g, 5.1 mmol, 1.0 equiv) in dry THF (4 mL).  The 
mixture was stirred for 1 hr, then quenched with brine and extracted with EtOAc (3 x 25 mL).  
Combined organic phases were dried with MgSO4, filtered, and concentrated in vacuum.  Crude 
residue was purified by preparative column chromatography on silica gel (eluting with EtOAc) 
to afford the title compound.  Yield 1.09 g (4.08 mmol, 80%).     
 
1H NMR (400.13 MHz, CDCl3) δ 4.32 (br.s, 2H), 4.06-3.28 (m, 8H), [3.37 (dd, J = 8.2 Hz, 5.1 
Hz) & 2.99 (dd, J = 6.9 HZ, 4.7 Hz), Σ1H], [1.66 (ps.-t, J = 8.2 Hz, 6.9 Hz) & 1.54 (dd, J = 6.0 
Hz, 4.7 Hz), Σ1H], [1.47 (s) & 1.43 (s), Σ3H], [1.19 (ps.-t, J = 6.9 Hz, 6.0 Hz) & 0.89 (app. t, J = 
Br
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6.9 Hz, 5.1 Hz), Σ1H];  13C NMR (100.67 MHz, CDCl3) δ major: 174.0, 60.0 (-), 59.2 (-), 51.1 (-
), 48.6 (-), 27.9, 25.9 (+), 21.5 (-), 19.6 (+); minor: 172.5, 60.1 (-), 59.7 (-), 51.5 (-), 48.9 (-), 27.9 
(+), 25.7, 22.2 (-), 21.8 (+);  FT IR (cm-1, film): 3421, 2988, 2941, 2908, 2876, 2837, 2658, 
2621, 2442, 2363, 2332, 2230, 1757, 1610, 1290, 1232, 1213, 1132, 1088, 1020, 928, 862, 831, 
712, 685, 650, 604, 523, 473; HRMS (TOF ES): found 266.0388, calculated for C9H17NO3Br 
(M+H) 266.0392 (1.5 ppm).    
 
2-Bromo-N-cyclohexyl-N-(2-hydroxyethyl)-1-methylcyclopropane-
carboxamide (314e):  To a stirred solution of 2-(cyclohexylamino)ethanol 
(158 mg, 1.10 mmol, 1.10 equiv) and triethylamine (422 µL, 308 mg, 3.00 
mmol, 3.00 equiv) in dry THF (10 mL) was added (dropwise over 10 min) a solution of 2-
bromo-1-methylcyclopropanecarbonyl chloride (200 mg, 1.01 mmol, 1.0 equiv) in dry THF (10 
mL).  The resulting suspension was stirred for 30 min at room temperatur  and then filtered 
through a fritted funnel.  The filter cake was washed with EtOAc (3 x 10 mL). The combined 
organic solution was concentrated in vacuum. Preparative column chromatography of a crude 
residual oil on silica gel afforded the title compound as a clear oil, Rf 0.30 (hexane-EtOAc, 1:2).  
Yield 196 mg (0.65 mmol, 65 %).  
1H NMR (400.13 MHz, CDCl3) δ [3.99 (br. s.) & 3.83-3.68 (m) & 3.67-3.43 (m) & 3.39-3.25 
(m), Σ5H], [3.11 (dd, J = 8.2 Hz, 4.9 Hz) & 2.99 (dd, J = 7.5 Hz, 4.7 Hz), Σ1H], [2.05 (d, J = 
11.4 Hz) & 1.81 (br. s.) & 1.73-1.58 (m) & 1.58-1.50 (m) & 1.49-1.27 (m), Σ11Η], [1.38 (s) & 
1.31 (s), Σ3H], [1.22-1.00 (m) & 0.86 (dd, J = 6.8 Hz, 5.1 Hz, 1H), Σ2Η];  13C NMR (100.67 
MHz, CDCl3) δ 173.4, 171.6, 62.6 (-), 62.5 (-), 57.4 (+), 57.2 (+), 45.5 (-), 44.8 (-), 32.6 (-), 31.9 
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(-), 31.6 (-), 31.4 (-), 28.1, 27.0 (+), 25.8, 25.7 (-), 25.6 (-), 25.52 (-), 25.47 (-), 25.3 (+), 25.04 (-
), 25.02 (-), 23.0 (-), 21.6 (+), 21.2 (-), 19.5 (+); FT IR (cm-1, film): 3402, 2932, 2856, 1618, 
1470, 1454, 1423, 1375, 1319, 1298, 1197, 1163, 1144, 1074, 1053, 894, 731, 623, 509;  HRMS 
(TOF ES): found 304.0913, calculated for C13H23NOBr (M+H) 304.0912 (0.3 ppm).   
 
2-Bromo-N-cyclohexyl-N-(3-hydroxypropyl)-1-methylcycloprop-
anecarboxamide (314c):  To a stirred solution of 3-(cyclohexyl-
amino)propan-1-ol (4c) (580 mg, 3.80 mmol, 1.10 equiv) and 
triethylamine (1.45 mL, 1.06 g, 10.5 mmol, 3.00 equiv) in dry THF (25 mL) a solution of 2-
bromo-1-methylcyclopropanecarbonyl chloride (620 mg, 3.14 mmol, 0.90 equiv) in THF (20 
mL) was added dropwise over 10 min.  The resulting suspension was stirred for 30 min at room 
temperature and then filtered through a fritted funnel. The filter cake was washed with EtOAc (3 
x 10 ml). The combined filtrates were concentrated in vacuum.  Preparative column 
chromatography of the residual crude oil on silica gel afforded th  title compound as a yellowish 
crystalline solid, Rf 0.45 (hexane-EtOAc 1:1).  Yield 946 mg (2.90 mmol, 85 %). 
1H NMR (500.13 MHz, CDCl3) δ 3.96-3.76 (m, 2H), 3.61-3.38 (m, 3H), 3.34-3.22 (m, 1H), 
[3.13 (dd, J = 8.2 Hz, 4.7 Hz) & 3.02 (dd, J = 7.6 Hz, 4.7 Hz), Σ1H], 1.94-1.79 (m, 2H), 1.79-
1.64 (m, 4H), 1.64-1.48 (m, 4H), [1.43 (s) & 1.35 (s), Σ3H], 1.48-1.42 (m, 1H), 1.41-1.33 (m, 
1H), 1.13 (tt, J = 13.0 Hz, 3.7 Hz, 1H), 0.90 (dd, J = 6.6 Hz, 5.4 Hz, 1H); 13C NMR (125.76 
MHz, CDCl3) δ major 172.8, 59.0 (-), 57.6 (+), 37.9 (-), 33.2 (-), 32.1 (-), 31.8 (-), 27.2 (+), 26.1, 
26.0 (-), 25.8 (-), 25.3 (-), 21.4 (-), 19.8 (+); minor: 170.9, 59.0 (-), 58.0 (+), 38.4 (-), 33.4 (-), 
33.2 (-), 32.4 (s, 1 C), 28.5 (+), 26.0, 25.3 (-), 24.4 (-), 23.6 (-), 22.0 (-), 19.8 (+);  FT IR (cm-1, 
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film): 3400, 2932, 2856, 1616, 1472, 1454, 1425, 1369, 1350, 1325, 1298, 1269, 1240, 1197, 
1157, 1144, 1059, 986, 933, 897, 870, 756, 733, 623, 509;  HRMS (TOF ES): found 340.0886, 
calculated for C14H24NO2BrNa (M+Na) 340.0888 (0.6 ppm);   
 
2-Bromo-N-hexyl-N-(3-hydroxypropyl)-1-methylcyclopropane-
carboxamide (314b):  To  a stirred solution of 3-(hexylamino)propan-1-
ol (500 mg, 3.15 mmol, 1.00 equiv) and triethylamine (1.30 mL, 950 mg, 
9.50 mmol, 3.00 equiv) in dry THF (25 ml) a solution of 2-bromo-1-methylcyclopropane-
carbonyl chloride (620 mg, 3.14 mmol, 0.90 equiv) in dry THF (20 mL was added dropwise over 
10 min. The resulting suspension was stirred for 30 min at room temperature and then filtered 
through a fritted funnel. The filter cake was washed with EtOAc (3 x 10 ml), and the combined 
filtrates were concentrated in vacuum.  Preparative column chromatography of the residual crude 
oil on silica gel afforded the title compound as a colorless oil, Rf 0.40 (hexane-EtOAc, 1:1). 
Yield 736 mg (2.30 mmol, 73%). 
1H NMR (400.13 MHz, CDCl3) δ 3.66 (br. s., 1H), 3.63-3.52 (m, 1H), 3.52-3.31 (m, 4H), 3.19 
(dd, J = 8.2 Hz, 4.9 Hz, 1H), 1.75-1.67 (m, 3H), 1.66-1.57 (m, 2H), 1.49 (s, 3H), 1.36 (m, 7H), 
0.99-0.84 (m, 4H);  13C NMR (100.67 MHz, CDCl3) δ 173.2, 58.2 (-), 47.5 (-), 40.3 (-), 31.5 (-), 
30.2 (-), 28.4 (-), 27.4, 26.6 (+), 26.0 (-), 22.5 (-), 21.6 (-), 19.8 (+), 13.9 (+);  FT IR (cm-1, film): 
3410, 2934, 2874, 1614, 1497, 1472, 1454, 1427, 1379, 1358, 1325, 1298, 1271, 1236, 1184, 
1078, 1057, 1030, 1001, 933, 870, 825, 739, 698, 625, 573, 544, 490, 463; HRMS (TOF ES): 
found 342.1043, calculated for C14H26NO2BrNa (M+Na) 342.1045 (0.6 ppm);   
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N-Benzyl-2-bromo-N-(3-hydroxypropyl)-1-methylcyclopropane-
carboxamide (314a): To a stirred solution of 3-(benzylamino)propan-1-
ol ( 850 mg, 5.10 mmol, 1.02 equiv) and triethylamine (2.06 mL, 1.50 g, 15.0 mmol, 3.00 equiv) 
in dry THF (25 mL) a solution of 2-bromo-1-methylcyclopropanecarbonyl chloride  (1.0 g, 5.0 
mmol, 1.0 equiv) in dry THF (20 mL) was added dropwise over 10 min. The resulting 
suspension was stirred for 30 min at room temperature and filtered through a fritted funnel. The 
filter cake was washed with EtOAc (3 x 10 mL). The combined organic filtrates were 
concentrated in vacuum.  Preparative column chromatography of a resulting crude oil on silica 
gel afforded the title compound as a colorless oil, Rf 0.30 (hexane-EtOAc, 1:3). Yield 1.30 g 
(4.00 mmol, 80%) 
1H NMR (400.13 MHz, CDCl3) δ 7.39-7.15 (m, 5H), [5.12 (d, J = 16.9 Hz) & 4.71 (d, J = 16.4 
Hz), Σ1H], [4.66 (d, J = 16.4 Hz) & 4.45 (d, J = 16.9 Hz), Σ1H], 4.00-2.90 (m, 5H), 1.75-1.57 
(m, 3H), [1.49 (s) & 1.33 (s), Σ3H], [1.21 (ps.-t, J = 7.3 Hz, 6.8 Hz) & 0.92 (dd, J = 6.8 Hz, 5.1 
Hz), Σ1H];  13C NMR (100.67 MHz, CDCl3) δ 173.5, 172.1, 135.7, 135.6, 128.9 (+, 2C), 128.8 
(+, 2C), 127.7 (+), 127.5 (+), 126.6 (+, 2C), 126.5 (+, 2C), 58.3 (-), 58.2 (-), 50.4 (-, 2C), 40.9 (-
), 40.7 (-), 29.3 (-), 29.2 (-), 28.0, 27.0 (+), 25.9 (+), 25.8 (+), 22.4, 21.7 (+), 21.6 (-), 19.8 (-);  
FT IR (cm-1, film): 3400 (br), 3075, 2985, 1624, 1421, 1265, 1186, 894, 739, 704;  HRMS (TOF 
ES): found 246.1501, calculated for C15H20NO2 (M-Br) 246.1494 (2.8 ppm).  
 
N-(Anthracen-9-ylmethyl)-2-bromo-N-(3-hydroxypropyl)-1-
methylcyclopropanecarboxamide (314d):  To a stirred solution of 3-
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((anthracen-9-ylmethyl)amino)propan-1-ol (295 mg, 1.11 mmol, 1.11 equiv) and triethylamine 
(420 µL, 307 mg, 3.03 mmol, 3 equiv.) in dry THF (20 mL) was added dropwise a solution of  2-
bromo-1-methylcyclopropanecarbonyl chloride (200 mg, 1.01 mmol, 1 equiv) in dry THF (10 
mL).  The mixture was stirred overnight, then concentrated in vacuum.  The residue was 
quenched with brine and extracted with EtOAc (3 x 15 mL).  Combined organic phases were 
dried with MgSO4, filtered and concentrated. Preparative column chromatography of the residual 
crude oil on silica gel afforded the title compound as yellowish solid, Rf 0.15 and 0.35 (hexane-
EtOAc 1:1).  Yield 276 mg (0.65 mmol, 64%).  
 1H NMR (400.13 MHz, CDCl3) δ [8.51 (s) & 8.41 (s), Σ1H], 8.26 (d, J = 8.8 Hz, 2H), [8.06 (d, J
= 8.8 Hz) & 7.98 (d, J = 8.1 Hz), Σ2H], 7.60-7.43 (m, 4H), [5.93 (d, J = 14.4 Hz) & 5.88 (d, J = 
15.4 Hz), Σ1H], [5.72 (d, J = 14.4 Hz) & 5.65 (d, J = 15.4 Hz), Σ1H], 3.43-2.96 (m, 5H), [1.86-
1.82 (m) & 1.71-1.57 (m), Σ3H], [1.82 (s) & 1.37 (s), Σ3H], [1.44 (app. t, J = 7.1 Hz) & 1.28 
(app. t, J = 7.1 Hz), Σ1H];  13C NMR (100.67 MHz, CDCl3) δ major: 170.5, 131.2 (2C), 130.9 
(2C), 129.1 (+, 2C), 128.2 (+), 127.3, 126.3 (+, 2C), 125.0 (+, 2C), 124.3 (+, 2C), 59.9 (-), 43.1 
(-), 40.3 (-), 32.1 (-), 28.3, 25.9 (+), 23.3 (s, 1 C), 21.9 (+);  minor: 172.2, 131.6 (2C), 131.2 
(2C), 129.5 (+, 2C), 129.2 (+), 127.0 (+, 2C), 125.1 (+, 2C), 124.4, 123.4 (+, 2C), 58.1 (-), 44.5 
(-), 40.3 (-), 31.6 (-), 28.5, 25.9 (+), 23.9 (-), 21.7 (+);  FT IR (cm-1, film): 3397, 3053, 2957, 
2932, 2876, 1718, 1672, 1626, 1614, 1429, 1377, 1285, 1229, 1173, 1159, 1095, 1055, 932, 854, 
735, 700; HRMS (TOF ES): found 448.0894, calculated for C23H24NO2BrNa (M+Na) 448.0888 
(1.3 ppm);    
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2-Bromo-N-hexyl-N-(4-hydroxybutyl)-1-methylcyclopropane-
carboxamide (317e): A 25 ml round-bottomed flask was charged with 4-
(hexylamino)butan-1-ol (88 mg, 0.56 mmol, 1.1 equiv), triethylamine 
(212 µL, 154 mg, 1.53 mmol, 3.00 equiv), and dry THF (5 mL).  The mixture was stirred, and a 
solution of 2-bromo-1-methylcyclopropanecarbonyl chloride (100 mg, 0.51 mmol, 1.00 equiv) in 
THF (5 mL) was added dropwise over 5 min.  The resulting suspension was stirred for 30 min at 
room temperature, then filtered through a fritted funnel.  The filtercake was washed with EtOAc 
(3 x 10 ml).  The combined filtrates were concentrated in vacuum.  Preparative column 
chromatography of a residue on silica gel afforded the title compound as a colorless oil, Rf 0.2 
(Hexane-EtOAc 1:1).  Yield 128 mg (0.38 mmol, 75%). 
1H NMR (400.13 MHz, CDCl3) δ ppm 3.77-3.61 (m, 2H), 3.48-3.29 (m, 3H), 3.28-3.11 (m, 2H), 
2.42 (br. s, 1H), 1.71-1.43 (m, 8H), 1.45 (s, 3H), 1.41-1.31 (m, 3H), 1.28 (br. s., 2H), 0.98-0.81 
(m, 4H);  13C NMR (100.67 MHz, CDCl3) δ major: 171.7, 62.1 (-), 47.5 (-), 44.2 (-), 31.5 (-), 
29.5 (-), 28.5 (-), 27.5 (+), 26.6 (-), 26.0, 23.6 (-), 22.5 (-, 2C), 21.4 (-), 14.0 (+); minor: 171.4, 
62.1 (-), 47.0 (-), 44.4 (-), 31.5 (-), 29.9 (-), 28.5 (-), 27.7 (+), 27.0 (-), 26.0, 24.9 (-), 22.5 (-, C), 
21.4 (-), 19.7 (+);  FT IR (cm-1, film): 3418, 3404, 2932, 2860, 1622, 1462, 1429, 1377, 1325, 
1178, 1130, 1082, 1068, 1034, 615;  HRMS (TOF ES): found 334.1388, calculated for 
C15H29NO2Br (M+H) 334.1382 (1.8 ppm);   
 
2-Bromo-N-(4-hydroxybutyl)-1-methyl-N-phenethylcyclo-
propanecarboxamide (317d):  To  a stirred solution of 4-(phenethyl-
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amino)butan-1-ol (250 mg, 1.29 mmol, 1.00 equiv) and triethylamine (550 µL, 400 mg, 3.96 
mmol, 3.0 equiv) in dry  THF (10 ml) a solution of 2-bromo-1-methylcyclopropanecarbonyl 
chloride (260 mg, 1.29 mmol, 1.00 equiv) in dry THF (10 mL) was added dropwise over 10 min.  
The resulting suspension was stirred for 30 min at room temperature and filtered through a fritted 
funnel.  The filter cake was washed with EtOAc (3 x 10 mL).  The combined filtrates were 
concentrated in vacuum.  Preparative column chromatography o f the crud  residual oil on silica 
gel afforded the title compound as a colorles oil, Rf 0.20 (hexane-EtOAc, 1:1). Yield 300 mg 
(0.85 mmol, 66%), mixture of diastereomers 1:1). 
1H NMR (400.13 MHz, CDCl3) δ 7.37-7.21 (m, 5H), 3.72-3.58 (m, 4H), 3.45-3.11 (m, 2H), 
2.90-2.85 (m, 2H), 1.84 (br. s, 1H), 1.73-1.55 (m, 6H), [1.44 (s) & 1.42 (s), Σ3H], 0.90-0.84 (m, 
1H);  13C NMR (100.67 MHz, CDCl3) δ ppm 171.9, 171.6, 138.8, 137.6, 128.7 (+, 4C), 128.6 (+, 
2C), 128.3 (+, 2C), 126.8 (+),126.3 (+), 61.9 (-), 61.8 (-), 48.8 (-), 47.5 (-), 46.1 (-), 44.1 (-), 34.5 
(-), 33.2 (-), 29.7 (+), 29.4 (+), 27.4, 27.2, 25.9 (-), 25.8 (-), 24.7 (-), 23.4 (-), 21.3 (-), 21.2 (-), 
19.6 (+, 2C);  FT IR (cm-1, film):  3416, 2935, 2870, 2361, 2341, 1622, 1454, 1427, 1171, 1068, 
1032, 750, 700;  HRMS (TOF ES): found 354.1060, calculated for C17H25NO2Br (M+H) 
354.1069 (2.5 ppm);  
 
2-Bromo-N-cyclohexyl-N-(5-hydroxypentyl)-1-methylcyclopropane-
carboxamide (317c), mixture of diastereomers, 1.1:1.  25 ml round-
bottomed flask was charged with 5-(cyclohexylamino)pentan-1-ol (122 
mg, 0.66 mmol, 1.10 equiv) and triethylamine (246 µL, 179 mg, 1.77 mmol, 3.00 equiv), and dry 
THF (5 mL).  A solution of 2-bromo-1-methylcyclopropanecarbonyl chloride (116.5 mg, 0.59 
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mmol, 1.00 equiv) in THF (5 mL) was added dropwise over 5 min. The resulting suspension was 
stirred for 30 min at room temperature, and then filtered through a fritted funnel.  The filter cake 
was washed with EtOAc (3 x 10 mL). The combined filtrates were concentrated in vacuum.  
Preparative column chromatography of a residue on silica gel afforded the title compound as a 
colorless oil, Rf 0.30 (Hexane-EtOAc 1:2). Yield 143 mg (0.41 mmol, 70%). 
1H NMR (400.13 MHz, CDCl3) δ [3.85-3.70 (m) & 3.62 (t, J = 6.4 Hz), 3.28-3.09 (m) & 3.09-
2.97 (m), Σ7H], [2.11 (d, J = 13.1 Hz) & 1.93-1.78 (m) & 1.78-1.66 (m) & 1.62-1.53 (m), 
Σ10H], [1.42 (s) & 1.34 (s), Σ3H], [1.52-1.41 (m) & 1.39-1.33 (m) & 1.27-1.23 (m) & 1.21-1.09 
(m) & 0.91-0.81 (m), Σ8H];  13C NMR (100.67 MHz, CDCl3) δ 171.2, 169.4, 62.0 (-), 61.9 (-), 
57.3 (+), 57.0 (+), 42.7 (-), 42.2 (-), 32.6 (-), 32.1 (-), 31.98 (-), 31.96 (-), 31.7 (-), 31.5 (-), 28.5 
(-), 28.4,  28.3 (-), 28.2 (+), 27.2 (+), 25.9 (-), 25.8 (-), 25.7 (-), 25.6 (-), 25.4, 25.2 (-), 25.1 (-), 
23.3 (-), 23.3 (-), 23.0 (-), 21.8 (+), 21.1 (-), 19.5 (+);  FT IR (cm-1, film): 3434, 2978, 2934, 
2860, 2797, 2642, 2621, 2492, 1732, 1614, 1568, 1553, 1539, 1454, 1423, 1385, 1306, 1188, 
1161, 1084, 764, 613, 579, 519, 471;  HRMS (TOF ES): found 368.1209, calculated for 
C16H28BrNO2Na (M+Na) 368.1201 (2.2 ppm). 
 
N-Benzyl-2-bromo-N-(5-hydroxypentyl)-1-methylcyclopropane-
carboxamide (417a): To a stirred solution of 5-(benzylamino)pentan-1-ol 
(700 mg, 3.60 mmol, 1.10 equiv) and triethylamine (1.47 mL, 1.07 g, 10.6 
mmol, 3.00 equiv) in dry THF (25 mL) a solution of 2-bromo-1-
methylcyclopropanecarbonyl chloride (640 mg, 3.20 mmol, 1.00 equiv) in dry THF (20 mL) was 
added dropwise over 10 min.  The resulting suspension was stirred for 30 min at room 
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temperature and filtered through a fritted funnel. The filter cake was washed with EtOAc (3 x 10 
ml).  The combined filtrates were concentrated in vacuum.  Preparative column chromatography 
of the residual crude oil on silica gel afforded the title compound as a colorless oil, Rf 0.20 
(hexane-EtOAc, 1:3). Yield 882 mg (2.50 mmol, 78%). 
1H NMR (400.13 MHz, CDCl3) δ [7.47-7.34 (m) & 7.34-7.19 (m), Σ5H], [5.09 (d, J = 17.2 Hz) 
& 4.86 (d, J = 15.2 Hz), Σ1H], [4.50 (d, J = 16.9 Hz) & 4.48 (d, J = 15.2 Hz), Σ1H], [3.80 (dddd, 
J = 13.9 Hz, 9.6 Hz, 5.8 Hz, 1.2 Hz) & 3.57-3.51 (m), Σ1H], 3.61 (t, J = 6.6 Hz) & 3.57 (t, J = 
6.6 Hz), Σ2H], [3.25 (ddd, J = 14.1 Hz, 11.4 Hz, 4.8 Hz) & 2.77 (ddd, J = 13.5 Hz, 9.8 Hz, 5.3 
Hz), Σ1H], 2.95 - 3.10 (m, 1H), 2.18 (br. s., 2H), 1.87-1.72 (m, 1H), 1.72-1.46 (m, 4H), [1.41 (s) 
& 1.31 (s), Σ3H], 1.37-1.26 (m, 1H), 1.26-1.11 (m, 1H);  13C NMR (100.67 MHz, CDCl3) δ 
major: 170.7, 136.5, 128.7 (+, 2C), 127.4 (+), 126.6 (+, 2C), 62.4 (-), 50.6 (-), 45.3 (-), 32.2 (-), 
27.9, 26.0 (-), 25.9 (+), 23.1 (-), 22.4 (-), 21.7 (+); minor: 170.6, 137.1, 128.3 (+, 2C), 128.0 (+, 
2C), 127.1 (+), 62.3 (-), 47.5 (-), 46.7 (-), 32.2 (-), 28.0 (-), 27.9, 25.9 (+), 23.3 (-), 22.5 (-), 21.8 
(+);  FT IR (cm-1, film): 3412, 2934, 2849, 1628, 1495, 1452, 1427, 1373, 1358, 1323, 1300, 
1236, 1205, 1184, 1076, 1041, 1030, 1003, 957, 939, 735, 698, 609, 461;  HRMS (TOF ES): 
found 376.0888, calculated for C17H24NO2BrNa (M+Na) 376.0888 (0.0 ppm);  
 
N-Benzyl-2-bromo-N-(2-(2-hydroxyethoxy)ethyl)-1-methylcyclo-
propanecarboxamide (317b): mixture of diastereomers 1.1:1.  25 mL 
round bottomed flask was charged with 2-(2-(benzylamino)ethoxy)ethanol 
(110 mg, 0.56 mmol, 1.1 equiv), triethylamine (152 mg, 1.50 mmol, 3.0 
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equiv) and anhydrous THF (5 mL).  A solution of 2-bromo-1-methylcyclopropanecarbonyl 
chloride (100 mg, 0.51 mmol, 1.0 equiv) in dry THF (5 mL) was added dropwise over 10 min.  
The resulting suspension was stirred for 30 min at room temperatur, nd then filtered through a 
fritted funnel.  The filter cake was washed with EtOAc (3 x 10 mL). The combined filtrates were 
concentrated in vacuum.  Preparative column chromatography of a residue on silica gel afforded 
the title compound as a colorless oil, Rf 0.25 (Hexane-EtOAc 1:1). Yield 89 mg (0.25 mmol, 
50%). 
1H NMR (400.13 MHz, CDCl3) δ 7.40-7.27 (m, 3H), 7.20-7.16 (m, 2H), [4.86-4.76 (m) & 4.52-
4.45 (m), Σ2H], 3.72-3.67 (m, 2H), 3.63-3.57 (m, 2H), 3.54-3.45 (m, 4H), 3.26-3.20 (m, 1H), 
2.27-2.18 (m, 1H), 1.80-1.73 (m, 1H), 1.51 (m, 3H), 0.96-0.91 (m, 1H); 13C NMR (100.67 MHz, 
CDCl3) δ ppm 172.8 (2C), 137.2, 136.3, 128.9 (+, 2C), 128.6 (+, 2C), 127.6 (+, 4C), 126.6 (+, 
2C), 72.4 (-), 72.2 (-), 68.3 (-), 67.9 (-), 61.7 (-, 2C), 51.6 (-), 47.6 (-), 46.5 (-), 44.3 (-), 28.5 (+), 
27.2 (+), 26.0, 25.8, 21.6 (-, 2C), 19.7 (+, 2C);  FT IR (cm-1, film): 3435, 2926, 1634, 1452, 
1423, 1188, 1124, 1070, 1030, 737, 698, 625, 604, 571;  HRMS (TOF ES): found 356.0862, 
calculated for C16H23BrNO3 (M+H) 356.0861 (0.3 ppm). 
 
 
 
N-Benzyl-2-bromo-N-(3-hydroxypropyl)cyclopropanecarboxamide 
(319c): To a stirred solution of (3-benzylamino)propane-1-ol (550 mg, 
3.3 mmol, 1.1 equiv) and triethylamine (610 mg, 6 mmol, 2 equiv) in 
dry THF (30 mL) was added 2-bromocyclopropanecarbonyl chloride (550 mg, 3.0 mmol).  The 
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mixture was stirred for 1 hr at room temperature, then the solvent was removed in vacuum. The 
residue was partitioned between 10% aqueous HCl (20 mL) and EtOAc (20 mL). The organic 
layer was separated and washed consecutively with 10% aqueous HCl (3 x 10 mL) and 4N 
aqueous NaOH (5 mL), dried with MgSO4, filtered, and concentrated.  The title compound was 
obtained as colorless oil, mixture of diastereomers, 2:1. This material was pure enough to be 
used for the following transformations without additional purification. Yield 690 mg (2.22 
mmol, 74%).  
1H NMR (400.13 MHz, CDCl3) δ ppm [7.48-7.36 (m) & 7.36-7.27 (m) & 7.26-7.19 (m), Σ5H], 
[4.74 (d, J = 17.2 Hz) & 4.65 (d, J = 14.9 Hz), Σ1H], [4.66 (d, J = 17.4 Hz) & 4.54 (d, J = 14.9 
Hz), Σ1H], 3.88 (br. s., 1 H), 3.71-3.42 (m, 4H), [3.30 (ddd, J = 7.6 Hz, 4.6 Hz, 3.0 Hz) & 3.27 
(ddd, J = 7.8 Hz, 4.8 Hz, 3.0 Hz), Σ1H], [2.37 (ddd, J = 9.2 Hz, 5.9 Hz, 3.0 Hz) & 2.17 (ddd, J = 
9.2 Hz, 5.9 Hz, 3.2 Hz), Σ1H], [1.83 (tt, J = 7.1 Hz, 6.1 Hz) & (1.78-1.64 (m), Σ3H], [1.37 (ddd, 
J = 9.4 Hz, 5.6 Hz, 4.8 Hz) & 1.33 (ddd, J = 9.1 Hz, 5.6 Hz, 4.8 Hz), Σ1H];  13C NMR (100.67 
MHz, CDCl3) δ major: 171.9, 136.0, 128.9 (+, 2C), 127.8 (+), 126.2 (+, 2C), 58.2 (-), 51.0 (-), 
42.8 (-), 29.8 (-), 22.6 (+), 19.9 (+), 18.3 (-), minor: 170.4, 137.3, 128.4 (+, 2C), 127.9 (+, 2C), 
127.3 (+), 58.9 (-), 49.0 (-), 43.9 (-), 31.5 (-), 22.3 (+), 20.2 (+), 18.1 (-);  FTIR (NaCl, film, cm1) 
3387, 2930, 2874, 1620, 1450, 1215, 1055, 731, 698, 581; HRMS (TOF ES): found 334.0217, 
calculated for C14H18NO2BrNa (M+Na) 334.0419 (0.6 ppm);   
 
2-Bromo-N-hexyl-N-(3-hydroxypropyl)cyclopropanecarboxamide 
(319b): mixture of diastereomers, 5:1. To a solution of (3-
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hexylamino)propan-1-ol (350 mg, 2.2 mmol, 1.1 equiv) and triethylamine (410 g, 4.0 mmol, 2.0 
equiv)  in dry THF (15 mL) stirred at 0 oC was added a solution of 2-bromocyclopropane-
carbonyl chloride (370 mg, 2.0 mmol, 1.0 equiv.) in dry THF (15 mL).  The mixture was stirred 
for 5 hr at RT, then the solvent was removed in vacuum. The residue was partitioned between 
10% aqueous HCl (20 mL) and EtOAc (20 mL). The organic layer was separated and washed 
consecutively with 10% aqueous HCl (3 x 10 mL) and 4N aqueous NaOH (5 mL), dried with 
MgSO4, filtered, and concentrated. The title compound was obtained as colorless oil, mixture of 
diastereomers, 5:1.  This material was pure enough to be used for the f llowing transformations 
without additional purification. Yield 527 mg (1.72 mmol, 86%).  
1H NMR (400.13 MHz, CDCl3) δ 3.90 (br. s., 2H), [3.68 (t, J = 5.7 Hz) & 3.56 (sxt, J = 6.8 Hz) 
& 3.49 (td, J = 6.1 Hz, 2.3 Hz) & 3.44 (t, J = 5.3 Hz) & 3.41-3.34 (m) & 3.34-3.23 (m) & 3.20 
(ddd, J = 7.8 Hz, 4.7 Hz, 3.2 Hz), Σ7H], [2.26 (ddd, J = 9.2 Hz, 5.9 Hz, 3.0 Hz) & 2.12 (ddd, J = 
9.2 Hz, 6.0 Hz, 3.0 Hz), Σ1H], [1.85 (quin, J = 6.3 Hz) & 1.77-1.56 (m) & 1.56-1.43 (m), Σ5H], 
1.43-1.19 (m, 7H), [0.89 (t, J = 7.1 Hz) & 0.86 (t, J = 6.8 Hz), Σ3H];  13C NMR (100.67 MHz, 
CDCl3) δ major: 171.2, 58.0 (-), 48.2 (-), 42.6 (-), 31.3 (-), 30.2 (-), 29.4 (-), 26.4 (-), 22.5 (+), 
22.4 (-), 19.9 (+), 18.1 (-), 13.9 (+); minor: 169.7, 59.0 (-), 46.7 (-), 44.7 (-), 32.0 (-), 31.5 (-), 
27.6 (-), 26.5 (-), 22.4 (+), 22.3 (-), 20.2 (+), 17.8 (-), 13.9 (+);  FT IR (NaCl, film cm1) 3408, 
2955, 2930, 2858, 1620 1462, 1377, 1229, 1190, 1057, 725, 588;  HRMS (TOF ES): found 
328.0887, calculated for C13H24BrNO2Na (M+Na) 328.0888 (0.3 ppm); 
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2-Bromo-N-(furan-2-ylmethyl)-N-(3-hydroxypropyl)cyclo-
propanecarboxamide (319d):  To a stirred solution of 3-((furan-2-
ylmethyl)amino)propan-1-ol (282 mg, 1.81 mmol, 1.10 equiv) and 
triethylamine (686 µL, 500 mg, 4.95 mmol, 3.00 equiv) in dry THF (5 mL) a solution of 2-
bromo-1-methylcyclopropanecarbonyl chloride (300 mg, 1.65 mmol, 1.00 equiv) in dry THF (5 
mL) was added dropwise over 10 min.  The resulting suspension was stirred for 30 min at room 
temperature, and then filtered through a fritted funnel.  The filter cake was washed with EtOAc 
(3 x 10 ml).  Combined organic solution was concentrated in vacuum.  Preparative column 
chromatography of a crude residue on silica gel afforded the title compound as a colorless oil, Rf 
0.50 (DCM-EtOAc, 3:1). Yield 310 mg (1.02 mmol, 62%), mixture of two diastereomers, 2:1. 
1H NMR (400.13 MHz, CDCl3) δ [7.36 (s) & 7.29 (s), Σ1H], [6.35-6.28 (m) & 6.25 (d, J = 3.0 
Hz) & 6.19 (d, J = 3.0 Hz), Σ2H], [4.59 (d, J = 16.9 Hz) & 4.53 (d, J = 15.4 Hz) & 4.53 (d, J = 
16.9 Hz) & 4.48 (d, J = 15.4 Hz), Σ2H], [3.63-3.53 (m) & 3.54-3.44 (m) & 3.40 (t, J = 5.6 Hz) & 
3.20 (ddd, J = 7.5 Hz, 4.7 Hz, 2.9 Hz), Σ4H], [2.35 (ddd, J = 9.1 Hz, 5.9 Hz, 3.2 Hz) & 2.28 
(ddd, J = 9.1 Hz, 5.9 Hz, 3.2 Hz), Σ1H), [1.76 (quin, J = 6.5 Hz) & 1.69-1.55 (m), Σ3H], [1.34 
(dt, J = 9.1 Hz, 5.6 Hz, 1H) & 1.29 (dt, J = 9.1 Hz, 5.3 Hz), Σ1H);  13C NMR (100.67 MHz, 
CDCl3) δ major: 171.5, 149.5, 142.6 (+), 110.3 (+), 108.2 (+), 58.0 (-), 44.7 (-), 42.8 (-), 29.8 (-), 
22.6 (+), 19.7 (+), 18.1 (-);  minor: 170.1, 150.6, 141.9 (+), 110.2 (+), 108.4 (+), 58.6 (-), 44.3 (-
), 42.1 (-), 31.4 (-), 22.1 (+), 20.1 (+), 18.0 (-);  FT IR (NaCl, film, cm1): 3414, 3117, 2932, 
2876, 2341, 1626, 1504, 1477, 1454, 1373, 1356, 1229, 1188, 1072, 1055, 1013, 922, 741, 598, 
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586;  HRMS (TOF ES): found 302.0391, calculated for C12H17NO3Br (M+H) 302.0392 (0.3 
ppm);  
 
2-Bromo-N-(tert-butyl)-N-(2-hydroxybenzyl)cyclopropanecarboxamide 
(319a) A solution of Me3SiCl (261 mg, 2.40 mmol, 1.20 equiv), NEt3 (708 
mg, 975 µL, 7.00 mmol, 3.50 equiv), and 2-((tert-butylamino)-
methyl)phenol (394 mg, 2.20 mmol, 1.10 equiv) was stirred in dry THF (30 mL) overnight under 
a nitrogen atmosphere. Then cyclopropylmonobromo acid chloride (367 mg, 2 mmol, 1 equiv)  
was added and allowed to stir for 3 hours. The solvent was removed by rotar  evaporation and 
then partitioned between 10 mL 5% HCl & 10 mL EtOAc. The organic layer was washed with 
5% HCl (3 x 15 mL) then dried with MgSO4, filtered, and concentrated. The obtained crystalline 
material (mp 165-168 oC) was pure enough for the following transformation with no additional 
purification. Yield 583 mg (1.78 mmol, 89%).     
 
1H NMR (500.13 MHz, CD3OD) δ ppm 7.04 (d, J = 7.6 Hz, 1H), 6.99 (t, J = 7.6 Hz, 1H), 6.76 
(t, J = 7.6 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H), 4.67 (d, J = 19.2 Hz, 1H), 4.62 (d, J = 19.2 Hz, 1H), 
3.04 (ddd, J = 7.6 Hz, 4.4 Hz, 3.2 Hz, 1H), 1.88 (ddd, J = 9.0 Hz, 6.0 Hz, 3.0 Hz, 1H), 1.41 (ddd, 
J = 7.6 Hz, 6.0 Hz, 5.0 Hz, 1H), 1.29 (s, 9H), 1.09 (dt, J = 9.5 Hz, 5.0 Hz, 1H);  13C NMR 
(125.76 MHz, CD3OD) δ ppm 174.0, 155.4, 129.2 (+), 127.7 (+), 126.6, 120.8 (+), 116.0 (+), 
59.3, 45.4 (-), 28.8 (+, 3C), 26.6 (+), 20.4 (+), 18.6 (-);  FT IR (NaCl, film, cm1): 3300, 
2964,2930,1622,1595,1456,1427,1364, 1227, 1192, 754;  HRMS (TOF ES): found 325.0670, 
calculated for C15H20BrNO2 (M
+) 325.0677 (2.2 ppm).  
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Scheme 129.  Synthesis of 326 
 
 
 
O
N
H
OH
Br  2-Bromo-N-((R)-2-hydroxy-1-phenylethyl)-1-methylcyclopropane-
carboxamide: (R)-phenylglycinol (871 mg, 6.35 mmol) and triethylamine (2.55 mL, 1.84 g, 18.2 
mmol) were stirred in anhydrous THF (20 mL) at room temperature, and a solution of racemic 
acylchloride 5 (1.26 g, 6.35 mmol) in dry THF (35 mL) was added dropwise.  The reaction 
mixture was stirred for 2 hrs, followed by filtration through a Buchner funnel.  The precipitate 
was rinsed with THF, dissolved in water and extracted with EtOAc.  The organic phases were 
combined with THF filtrate and concentrated in vacuum.  Preparative column chromatography 
on Silica gel eluting with hexane-EtOAc 1:1 afforded three fractions (Rf 0.38, 0.19, and 0.13; 
eluent hexane-EtOAc 1:3).   NMR spectra were recorded for these individual fractions.  For 
further transformation the fractions were combined to afford a mixture of four diastereomeric 
amides as white crystalline material, 1.74 g (5.84 mmol, 92%).  HRMS (TOF ES) found 
298.0439, calcd for C13H17BrNO2 (M+H) 298.0443 (1.3 ppm). 
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Fraction 1: Rf 0.38 (eluent: hexane-EtOAc 1:1); 
 1H NMR (CDCl3, 400.13 MHz) δ 7.41-7.38 
(m, 2H), 7.35-7.31 (m, 1H), 7.31-7.32 (m, 2H), 6.63 (br.d, J = 6.1 Hz, 1H), 5.05 (dt, J = 6.1 Hz, 
5.1 Hz, 1H), 3.90 (d, J = 5.1 Hz, 2H), 3.55 (dd, J = 8.1 Hz, 5.3 Hz, 1H), 2.33 (br.s, 1H), 1.88 (dd, 
J = 8.1 Hz, 5.6 Hz, 1H), 1.58 (s, 3H), 0.95 (ps.-t, J = 5.6 Hz, 5.3 Hz, 1H); 13C NMR (CDCl3, 
100.67 MHz) δ 172.7, 138.8, 129.0 (+, 2C), 128.0 (+), 126.5 (+, 2C), 66.4 (-), 56.1 (+), 29.1 (+), 
24.5 (-), 24.0, 17.2 (+);  
Fraction 2:  Rf 0.19 (eluent: hexane-EtOAc 1:1); 
1H NMR (CDCl3, 400.13 MHz) δ 7.43-7.39 
(m, 2H), 7.36-7.32 (m, 1H), 7.32-7.30 (m, 2H), 6.60 (br.d, J = 6.8 Hz, 1H), 5.05 (dt, J = 6.8 Hz, 
5.1 Hz, 1H), 3.90 (d, J = 5.1 Hz, 2H), 3.52 (dd, J = 8.1 Hz, 5.3 Hz, 1H), 2.36 (br.s, 1H), 1.91 (dd, 
J = 8.1 Hz, 5.8 Hz, 1H), 1.58 (s, 3H), 0.98 (ps.t, J = 5.8 Hz, 5.1 Hz, 1H);  13C NMR (CDCl3, 
100.67 MHz) δ 172.7, 138.7, 129.0 (+, 2C), 128.0 (+), 126.5 (+, 2C), 66.5 (-), 56.2 (+), 29.0 (+), 
24.7 (-), 24.0, 17.1 (+);  
Fraction 3: Rf 0.13 (eluent: hexane-EtOAc 1:1);  
1H NMR (CDCl3, 400.13 MHz) δ 7.40-7.29 
(m, 5H), 6.58-6.56 (br.m, 1H), 5.16-5.08 (m, 1H), 3.93-3.89 (m, 2H), [2.94 (dd, J = 7.6 Hz, 5.1 
Hz) & 2.93 (dd, J = 7.6 Hz, 5.1 Hz), Σ1H], 2.60 (br.s, 1H), [1.74 (dd, J = 6.6 Hz, 5.1 Hz) & 1.70 
(dd, J = 6.6 Hz, 5.1 Hz), Σ1H], 1.44 (s, 3H), 1.24-1.19 (m, 1H);  13C NMR (CDCl3, 100.67 MHz) 
δ [170.5 & 170.3], [138.9 & 138.8], [128.78 (+) & 128.73 (+), Σ2C], 127.8 (+), [126.8 (+) & 
126.7 (+), Σ2C], 66.2 (-), [56.2 (+) & 56.0 (+)], 27.8, [25.32 (+) & 25.27 (+)], [21.6 (-) & 21.5 (-
)], [20.9 (+) & 20.8 (+)]. 
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Scheme 130. Synthesis of Pseudoephedrine analog 326 
 
 
 
2-Bromo-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N,1-dimethylcyclopropanecarbo-
xamide (326): (R,R)-(-)-pseudoephedrine  (1.00 g, 6.05 mmol) and triethylamine (2.55 mL, 1.84 
g, 18.2 mmol) were stirred in anhydrous THF (20 mL) at room temperatur , and solution of 
racemic acylchloride 5 (1.26 g, 6.35 mmol) in dry THF (35 mL) was added dropwise.  The 
reaction mixture was stirred for 2 hrs, and then filtered through a Buchner funnel.  The 
precipitate was rinsed with THF, dissolved in water and extracted with EtOAc.  The organic 
phases were combined with THF filtrate and concentrated in vacuum.  Preparative column 
chromatography on Silica gel eluting with hexane-EtOAc 1:1 (two sp ts are resolved: Rf 0.42, 
0.29, eluent hexane-EtOAc 1:3) afforded 1.91 g (5.85 mmol, 97%) of mixture of four 
diastereomeric amides as colorless glass.  GC: Rt 13.18 min, 13.32 min, 13.36 min (three peaks 
are resolved).  1H NMR (CDCl3, 400.13 MHz) δ 7.55-7.28 (m, 5H), 4.78-4.14 (m, 2H), 3.75-2.98 
(m, 1H), [3.07 (s) & 2.97 (s), & 2.92 (s), & 2.86 (s), Σ3H], 1.87-0.89 (m, 3H), [1.47 (s) & 1.39 
(s), & 1.37 (s), & 1.35 (s), Σ3H], [1.19 (s) & 1.18 (s), & 1.17 (s), & 1.15 (s), Σ3H];  13C NMR 
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(CDCl3, 100.67 MHz) δ [173.2 & 173.0, & 172.7, & 172.2], [141.97 & 141.95, & 141.9, & 
141.6], 128.4, 128.3, 128.03, 127.98, 127.9, 127.3, 127.2, 127.0, 126.3, 126.0, 125.9, 125.8, 
75.4, 75.3, 74.8, 74.7, 58.3 (br), 57.64, 57.59, 56.9 (br), 32.0, 29.4, 28.1, 28.0, 27.5, 27.3, 26.9, 
26.6, 26.1, 25.8, 25.70, 25.67, 25.5 21.7, 21.5, 21.2, 20.3, 20.0, 19.7, 18.3, 15.4, 15.0, 13.8, 13.7, 
13.5;  HRMS (TOF ES) found 326.0757, calcd for C15H21BrNO2 (M+H) 326.0756 (0.3 ppm). 
 
2-bromo-N-((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)-N,1-
dimethylcyclopropanecarboxamide (326b):  D-ephedrine  (500 mg, 6.05 mmol) and 
triethylamine (766 mg, 7.6 mmol) were stirred in anhydrous THF (20 mL) at room temperature, 
and solution of racemic acylchloride 5 (418mg, 2.53 mmol) in dry THF (20 mL) was added 
dropwise.  The reaction mixture was stirred for 2 hrs, and then filtred through a Buchner funnel.  
The precipitate was rinsed with EtOAc, and concentrated in vacuum.  Preparative column 
chromatography on Silica gel eluting with hexane-EtOAc 2:1 (three spots are resolved: Rf 0.43, 
0.30, 0.2 eluent hexane-EtOAc 2:1) afforded 536 mg (5.85 mmol, 65%) of mixture of four 
diastereomeric amides as a white powder. 1H NMR (CDCl3, 400.13 MHz) δ 7.42-7.23 (m, 5H), 
4.65 (d, J = 7.0 Hz, 1H), 4.13 (br, 1H), 3.05 (m, 1H), 2.95 (s, 3H), 1.59 (dd, J = 4.8 Hz, 6.95 Hz, 
1H), 1.26 (d, J = 6.8 Hz, 1H), 1.26 (d, J = 6.8 Hz, 3H); 13C NMR (C6D6, 100.67 MHz) δ 172.4, 
142.3, 128.2 (+, 2C), 127.22 (+), 126.14 (+), 75.86 (+), 58.3 (-), 28.46, 25.95 (+), 21.86 (-), 
20.34 (+), 13.96 (+);  HRMS (TOF ES) found 348.0567, calcd for C15H20NO2Na (M + Na) 
348.0575 (2.3 ppm) FT IR (cm-1, film): 3382, 3226, 3045, 1633, 1384, 891, 784, 709. 
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1H NMR (CDCl3, 400.13 MHz) δ 7.43-7.21 (m, 5H), 4.67 (d, J = 7.0 Hz, 1H), 4.21 (br, 1H), 3.10 
(s, 3H), 3.10 (dd, J = 4.3 Hz, 7.2 Hz, 1H), 1.59 (dd, J = 4.8 Hz, 6.9 Hz, 1H), 1.32 (s, 3H) 1.12 (d, 
J = 6.8 Hz, 3H), 0.99 (m, 1H) 0.86 (d, J = 4.8 Hz, 6.7 Hz, 1H); 13C NMR (C6D6, 100.67 MHz) δ 
171.75, 142.0, 128.4 (+, 2C), 127.72 (+), 126.59 (+), 75.83 (+), 58.02 (-) 28.36, 25.90 (+), 21.87 
(-), 20.66 (+), 13.0 (+). 
1H NMR (CDCl3, 400.13 MHz) δ 7.45-7.22 (m, 5H), 4.64 (d, J = 7.2 Hz, 1H), 4.52 (br, 1H), 3.06 
(s, 3H), 2.98 (dd, J = 4.7 Hz, 7.4 Hz, 1H), 1.57 (dd, J = 4.6 Hz, 6.8 Hz, 1H), 1.35 (s, 3H) 1.13 (d, 
J = 6.9 Hz, 3H), 1.01 (m, 1H) 0.88 (d, J = 5.3 Hz, 6.8 Hz, 1H); 13C NMR (C6D6, 100.67 MHz) δ 
171.77, 141.9, 128.41 (+, 2C), 127.45 (+), 126.58 (+), 75.91 (+), 58.1 (-) 27.45, 25.87 (+), 21.89 
(-), 20.69 (+), 14.07 (+). 
 
 
 
3.4.4. Medium Size Ring Cyclizations 
 
(1R,4R,7S)-7-methyl-4-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one 
(327b): A mixture of bromocyclopropane 325a (mixture of four diastere-
omers, 100 mg, 0.34 mmol), 18-crown-6 (8.9 mg, 0.03 mol, 10 mol%), 
and potassium tert-butoxide (120 mg, 1.07 mmol, 3.2 equiv.) was stirred in dry THF (2.5 mL) at 
80 oC overnight.  The mixture was quenched with brine (10 mL) and extracted with EtOAc (3 x 
10 mL).  Combined organic phases were dried with MgSO4, filtered and condensed in vacuum.  
Column chromatography on Silica gel (eluent hexane-EtOAc 1:1, Rf 0.23) afforded the title 
(R)O
HN
(R)
O
Me
(S)
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compound as a colorless solid material, yield 51 mg (0.23 mmol, 71%).  1H NMR (CDCl3, 
500.13 MHz) δ 7.43 (t, J = 7.5 Hz, 2H), 7.39 (t, J = 7.3 Hz, 1H), 7.34 (d, J = 7.2 Hz, 2H), 5.91 
(br.s, 1H), 5.00 (dt, J = 11.7 Hz, 5.4 Hz, 1H), 3.85 (dd, J = 11.0 Hz, 5.1 Hz, 1H), 3.66 (ps.-t, J = 
11.4 Hz, 1H), 3.19 (dd, J = 6.0 Hz, 2.8 Hz, 1H), 1.34 (s, 3H), 1.22 (dd, J = 6.6 Hz, 2.8 Hz, 1H), 
0.89 (ps.-t, J = 6.3 Hz, 1H); 13C NMR (CDCl3, 125.76 MHz) δ 174.1, 135.7, 129.3 (+, 2C), 128.9 
(+), 127.1 (+, 2C), 71.4 (-), 56.8 (+), 55.0 (+), 26.1, 17.88 (+), 17.85 (+);  HRMS (TOFES) 
found 218.1181, calcd for C13H16NO2 (M + H) 218.1181 (0.0 ppm); [α]
25
D = +43.2
o (c 0.5, 
CH2Cl2); 
 
 
 (1R,4R,7S)-4-benzyl-1-methyl-3-azabicyclo[5.1.0]octan-2-one (327b):  
A mixture of amide 325b (100 mg, 0.32 mmol), t-BuOK (72 mg, 0.64 
mmol, 2.0 equiv), 18-crown-6 ether (9 mg, 0.03 mmol, 10 mol%) was stirred in anhydrous THF 
(4 mL) at 60 oC overnight.   Then the mixture was partitioned between water (10 mL) and EtOAc 
(10 mL), and extracted with EtOAc (3 x 5 mL).  Combined organic phases were dried with 
Na2SO4, filtered and concentrated.  Preparative column chromatography on Silica gel afforded 
the title compound as yellowish oil, Rf 0.1 (hexane-EtOAc 2:3).  Yield 58 mg (0.25 mmol, 78%).    
1H NMR (400.13 MHz, CDCl3) δ 7.33-7.22 (m, 5H), 6.64 (d, J = 5.3 Hz, 1H), 4.22-4.12 (m, 
1H), 3.69 (dd, J = 10.9 Hz, 4.5 Hz, 1H), 3.39 (t, J = 11.1 Hz, 1H), 3.02 (dd, J = 6.1 Hz, 2.8 Hz, 
1H), 2.79 (d, J = 7.1 Hz, 2H), 1.28-1.23 (m, 1H), 1.20 (s, 3H), 1.12 (dd, J = 6.6 Hz, 2.7 Hz, 1H); 
13C NMR (100.67 MHz, CDCl3) δ 174.9, 136.6, 128.6 (+, 4C), 126.9 (+), 70.5 (-), 56.7 (+), 51.5 
O
NH
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(+), 36.3 (-), 26.2, 17.8 (-), 17.6 (+);  HRMS (TOF ES): found 232.1335, calculated for 
C14H18NO2 (M+H) 232.1338 (1.3 ppm). 
 
 (1R,3R,4R,7S)-4,5,7-trimethyl-3-phenyl-2-oxa-5-azabicyclo[5.1.0]-
octan-6-one (328): the mixture of bromocyclopropane 328b (200 mg, 
0.61 mmol), 18-crown-6 (16.1 mg, 0.06 mmol, 10 mol%), and 
potassium tert-butoxide (144 mg, 1.28 mmol, 2.0 equiv.) was stirred in anhydrous THF (8 mL) at 
room temperature for 12 hrs.  The mixture was filtered and concentrat d in vacuum to afford the 
title compound as a yellowish viscous oil.  Yield 123 mg (0.50 mmol, 82%).  1H NMR (C6D6, 
400.13 MHz) δ 7.29-7.21 (m, 5H), 4.59 (dq, J = 10.6 Hz, 7.1 Hz, 1H), 4.22 (d, J = 10.6 Hz, 1H), 
3.08 (dd, J = 6.3 Hz, 2.8 Hz, 1H), 2.87 (s, 3H), 1.47 (dd, J = 6.3 Hz, 2.8 Hz, 1H), 1.18 (s, 3H), 
0.76 (d, J = 7.1 Hz, 3H), 0.63 (ps.-t, J = 6.3 Hz, 6.3 Hz, 1H);  13C NMR (C6D6, 100.67 MHz) δ 
172.9, 138.4, 129.0 (+, 2C), 128.58 (+), 128.55 (+, 2C), 80.2 (+), 54.0 (+), 51.4 (+), 26.9 (+), 
26.5, 19.4 (-), 18.0 (+), 14.7 (+);  HRMS (TOF ES) found 268.1310, calcd for C15H20NO2 (M + 
H) 268.1313 (0.8 ppm). [α]25D = +18.6
o (c 1.32, MeOH); 
 
 (1R,3S,4R,7S)-4,5,7-trimethyl-3-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-
one (329): the mixture of bromocyclopropane 328b (100 mg, 0.31 mmol), 18-crown-6 (8 mg, 
0.03 mmol, 10 mol%), and potassium tert-butoxide (72 mg, .65 mmol, 2.0 equiv.) was stirred in 
anhydrous THF (4 mL) at room temperature for 12 hrs.  The mixture was filtered and 
(R)
(S) Me
O
N(R)
Me
(R)
Me
O
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concentrated in vacuum. Preparative column chromatography on Silica ge afforded the title 
compound as white powder, Rf 0.2 (hexane-EtOAc 1:1).  Yield 66 mg (0.27 mmol, 90%).  
1H NMR (C6D6, 400.13 MHz) δ 7.46-7.35 (m, 5H), 4.82 (dq, J = 10.8 Hz, 7.0 Hz, 1H), 4.22 (d, J 
= 10.8 Hz, 1H), 3.08 (dd, J = 6.2 Hz, 2.8 Hz, 1H), 2.96 (s, 3H), 1.37 (s, 3H), 1.18 (d, J = 7.0 Hz, 
3H), 1.11 (dd, J = 6.5 Hz, 2.8 Hz, 1H), 0.83 (ps t, J = 6.4 Hz);  13C NMR (C6D6, 100.67 MHz) δ 
173.7, 137.2, 129.0 (+, 2C), 128.85 (+), 128.16 (+, 2C), 80.2 (+), 53.6 (+), 51.4 (+), 27.3 (+), 
26.4, 19.1 (-), 18.1 (+), 15.0 (+);  HRMS (TOF ES) found 268.1310, calcd for C15H20NO2 (M + 
Na) 268.1313 (1.1 ppm) FT IR (cm-1, film): 3389, 2955, 1643, 1274, 763, 750. 
 
 
 (1S*,7R*)-5-(2-Hydroxyethyl)-7-methyl-2-oxa-5-azabicyclo[5.1.0]octan-
6-one (316d):  To a mixture of t-BuOK (155 mg, 1.38 mmol, 2.00 equiv), 
18-crown-6 ether (18.2 mg, 0.70 mmol, 10 mol%) in THF (5 mL) was 
added bromocyclopropane 314d (186 mg, 0.70 mmol, 1.00 equiv). The mixture was stirred for 1 
hr at 40 oC. Then the mixture was partitioned between water (10ml) and EtOAc (10ml), and 
extracted with EtOAc (3 x 10 ml). The combined organic phases were dried with Na2SO4, 
filtered and concentrated. No further purification was necessary. Yield 93 mg (0.50 mmol, 72%). 
1H NMR (400.13 MHz, CDCl3) δ 4.16 (ddd, J = 15.4 Hz, 12.6 Hz, 5.1 Hz, 1H), 3.75-3.73 (m, 
2H), 3.67 (dd, J = 11.1 Hz, 5.1 Hz, 1H), 3.56 (dt, J = 14.2 Hz, 5.8 Hz, 1H), 3.48 (dt, J = 14.4 Hz, 
4.8 Hz, 1H), 3.22 (dd, J = 15.2 Hz, 4.6 Hz, 1H), 2.97 (dd, J = 5.8 Hz, 2.8 Hz, 1H), 1.24 (s, 3H), 
1.06 (dd, J = 6.8 Hz, 2.8 Hz, 1H), 0.82 (ps.-t, J = 6.8 Hz, 5.8 Hz, 1H);  13C NMR (100.67 MHz, 
CDCl3) δ 174.3, 64.2 (+), 61.7 (+), 56.5 (-), 50.3 (+), 47.1 (+), 26.3, 18.1 (+), 17.8 (-);  FT IR 
O
N
O
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(cm-1, film): 3389, 2955, 2920, 2866, 1626, 1481, 1439, 1371, 1209, 1153, 1097, 1056, 1040, 
789, 700, 660;  HRMS (TOF ES): found 229.1677, calculated for C12H23NO3 (M
+) 229.1678 (0.4 
ppm);  
 
(1S*,7R*)-5-Cyclohexyl-7-methyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one 
(316e):  To a mixture of t-BuOK (82 mg, 0.73 mmol, 2.4 equiv), 18-crown-6 
ether (13.2 mg, 0.03 mmol, 10 mol%) in THF (3 mL) was added 
bromocyclopropane 314e (92 mg, 0.3 mmol, 1.0 equiv). The mixture was stirred for 4 hrs at 80 
oC. The KBr precipitate was filtered off on a fritted funnel and the solvent was removed in 
vacuum. Flash column chromatography of the residue through a silica plug in EtOAc afforded 
the title compound as a yellowish oil, Yield 60 mg (0.27 mmol, 91%). 
1H NMR (400.13 MHz, CDCl3) δ ppm 4.38 (tt, J = 12.0 Hz, 3.6 Hz, 1H), 3.80 (ddd, J = 15.4 Hz, 
12.6 Hz, 4.8 Hz, 1H), 3.71 (dd, J = 11.0 Hz, 4.9 Hz, 1H), 3.56 (ddd, J = 12.4 Hz, 11.1 Hz, 4.5 
Hz, 1H), 3.21 (dd, J = 15.3 Hz, 4.7 Hz, 1H), 2.92 (dd, J = 6.1 Hz, 2.8 Hz, 1H), 1.83-1.60 (m, 
4H), 1.44-1.22 (m, 6H), 1.20 (s, 3H), 1.09-1.02 (m, 1H), 0.80 (t, J = 6.2 Hz, 1H);  13C NMR 
(100.67 MHz, CDCl3) δ ppm 172.1, 66.4 (-), 56.5 (+), 51.6 (+), 39.7 (-), 30.5 (-), 26.6, 25.5 (-), 
25.32 (-), 25.29 (+), 17.8 (-);  FT IR (cm-1, film): 2930, 2856, 1645, 1472, 1423, 1379, 1366, 
1329, 1263, 1236, 1211, 1196, 1157, 1140, 1092, 1040, 789, 665;  HRMS (TOF ES): found 
246.1441, calculated for C13H21NO2Na (M+Na) 246.1470 (2.4 ppm). 
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(1S*,8R*)-6-Cyclohexyl-8-methyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one 
(316c): To a mixture of t-BuOK (139 mg, 1.25 mmol, 2.5 equiv), 18-crown-6 
ether (13 mg, 0.05 mmol, 10 mol%) in dry THF (5 mL) was added 
bromocyclopropane 314c (160 mg, 0.5 mmol, 1.0 equiv).  The mixture was stirred for 12 hrs at 
80 oC. The KBr precipitate was filtered and the solvent was removed in vacuum. Preparative 
column chromatography on silica gel afforded the title compound as a colorless oil, Rf 0.30 
(hexane-EtOAc 2:1).  Yield 105 mg (0.45 mmol, 89%). 
 
1H NMR (400.13 MHz, CDCl3) δ 4.38 (ddt, J = 15.1 Hz, 7.7 Hz, 3.6 Hz, 1H), 4.09 (dd, J = 12.5 
Hz, 5.2 Hz, 1H), 3.80 (dd, J = 15.7 Hz, 9.9 Hz, 1H), 3.61 (td, J = 12.7 Hz, 3.2 Hz, 1H), 3.42 (dd, 
J = 15.7 Hz, 7.3 Hz, 1H), 3.18 (dd, J = 7.2 Hz, 3.9 Hz, 1H), 2.02-1.84 (m, 3H), 1.84-1.54 (m, 
5H), 1.51-1.28 (m, 4H), 1.18 (s, 3H), 1.12 (dd, J = 6.4 Hz, 3.9 Hz, 1H), 0.75 (t, J = 6.8 Hz, 1H);  
13C NMR (100.67 MHz, CDCl3) δ 172.1, 72.8 (-), 67.7 (+), 53.8 (+), 41.8 (-), 33.4 (-), 31.5 (-), 
30.3 (-), 27.9, 26.0 (-), 25.7 (-), 25.6 (-), 20.1 (+), 16.8 (-);  FT IR (cm-1, film): 2932, 2856, 2360, 
2351, 1612, 1458, 1421, 1325, 1198, 1057, 986;  HRMS (TOF ES): found 238.1804, calculated 
for C14H24NO2 (M+H) 238.1807 (1.3 ppm);  
 
(1S*,8R*)-6-Hexyl-8-methyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one 
(316b): To a mixture of t-BuOK (72.9 mg, 0.65 mmol, 2.0 equiv), 18-
crown-6 ether (8.6 mg, 0.033 mmol, 10 mol%) in THF (3 mL) was added 
bromocyclopropane 314b (103 mg, 0.33 mmol, 1.0 equiv).  The mixture was stirred for 12 hrs at 
80 oC.  The KBr precipitate was filtered off on a fritted funnel and the solvent was removed in 
O
N
O
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vacuum.  Preparative column chromatography on silica gel afforded the title compound as a clear 
oil, Rf 0.35 (hexane-EtOAc 1:1). Yield 65.3 mg (0.27 mmol, 84%). 
1H NMR (400.13 MHz, CDCl3) δ 4.08 (dd, J = 12.6 Hz, 5.3 Hz, 1H), 3.97 (dd, J = 15.3 Hz, 10.5 
Hz, 1H), 3.93-3.78 (m, 1H), 3.61 (td, J = 12.7 Hz, 3.2 Hz, 1H), 3.27 (dd, J = 15.2 Hz, 7.1 Hz, 
1H), 3.15 (dd, J = 7.3 Hz, 3.8 Hz, 1H), 2.73 (ddd, J = 13.6 Hz, 8.2 Hz, 5.9 Hz, 1H), 1.92 (dddd, J 
= 15.1 Hz, 12.7 Hz, 10.1 Hz, 5.3 Hz, 1H), 1.62 (ddd, J = 15.2 Hz, 7.1 Hz, 3.0 Hz, 1H), 1.58-1.46 
(m, 2H), 1.26 (br. s., 6H), 1.19 (s, 3H), 1.09 (dd, J = 6.6 Hz, 3.8 Hz, 1H), 0.90-0.79 (m, 3H), 
0.68 (t, J = 6.9 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ ppm 171.9, 72.6 (-), 67.5 (+), 46.1 (-
), 45.7 (-), 31.5 (-), 30.5 (-), 27.4 (-), 27.3, 26.4 (-), 22.4 (-), 19.7 (+), 16.7 (-), 13.9 (+);  FT IR
(cm-1, film): 2955, 2930, 2858, 1637, 1481, 1464, 1441, 1423, 1364, 1325, 1250, 1203, 1150, 
1132, 1103, 1070, 1045, 1009, 733, 559, 500, 424;  HRMS (TOF ES): found 262.1785, 
calculated for C14H25NO2Na (M+Na) 262.1783 (0.8 ppm);  
 
 (1S*,8R*)-6-benzyl-8-methyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one 
7crown-6 ether (13.2 mg, 0.05 mmol, 10 mol%) in THF (5 mL) was added 
bromocyclopropane 4e (163 mg, 0.50 mmol, 1.00 equiv). The mixture was stirred for 2 hrs at 80 
oC.  The KBr precipitate was filtered off on a fritted funnel and the solvent was removed in 
vacuum. Filtration of the residue through a silica plug in EtOAc afforded the title compound as a 
crystalline solid, Yield 93 mg (0.38 mmol, 76%). 
1H NMR (400.13 MHz, CDCl3) δ 7.37-7.20 (m, 5H), 5.32 (d, J = 14.9 Hz, 1H), 4.13 (dd, J = 
12.8 Hz, 5.4 Hz, 1H), 3.96 (dd, J = 15.7 Hz, 10.9 Hz, 1H), 3.90 (d, J = 14.9 Hz, 1H), 3.64 (td, J 
= 12.7 Hz, 3.2 Hz, 1H), 3.28-3.18 (m, 2H), 2.07-1.86 (m, 1H), 1.59 (ddd, J = 15.2 Hz, 7.1 Hz, 
O
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3.0 Hz, 1H), 1.29 (s, 3H), 1.21 (dd, J = 6.8 Hz, 3.8 Hz, 1H), 0.79 (t, J = 6.9 Hz, 1H);  13C NMR 
(100.67 MHz, CDCl3) δ 172.6, 137.5, 128.5 (+, 2C), 127.7 (+, 2C), 127.2 (+), 72.6 (-), 67.5 (+), 
48.3 (-), 45.3 (-), 29.9 (-), 27.1, 19.7 (+), 16.8 (-);  FT IR (cm-1, film): 2982, 2962, 2943, 2908, 
2874, 1738, 1697, 1636, 1479, 1423, 1393, 1373, 1300, 1244, 1103, 1047, 1001, 916, 849, 733, 
700, 648, 635, 608, 461;  HRMS (TOF ES): found 246.1490, calculated for C15H20NO2 (M+H) 
246.1494 (1.6 ppm).   
 
(1S*,8R*)-6-(Anthracen-9-ylmethyl)-8-methyl-2-oxa-6-azabi-
cyclo[6.1.0]nonan-7-one (316d): To a stirred suspension of t-BuOK (62 
mg, 0.55 mmol, 2.5 equiv), 18-crown-6 (6.0 mg, 22 µmol, 10 mol%) in 
anhydrous THF (3 mL) was added bromocyclopropane 314d (94 mg, 0.22 mmol, 1.0 equiv).  
The resulting dark-brown mixture was stirred for 6 hrs at 60 oC.  The KBr precipitate was filtered 
off and the filtrate was concentrated in vacuum.  Preparative column chromatography of a 
residue on silica gel afforded the title compound as an orange solid, Rf 0.20 (hexane-EtOAc 1:1).  
Yield 70.0 mg (0.20 mmol, 92%). 
1H NMR (400.13 MHz, CDCl3) δ ppm 8.48 (s, 1H), 8.33 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.3 Hz, 
2H), 7.55 (ddd, J = 8.4 Hz, 6.6 Hz, 1.5 Hz, 2H), 7.49 (dd, J = 7.3 Hz, 6.8 Hz, 2H), 6.33 (d, J = 
15.2 Hz, 1H), 5.10 (d, J = 15.2 Hz, 1H), 4.12 (dd, J = 12.6 Hz, 5.1 Hz, 1H), 3.64 (dd, J = 15.5 
Hz, 10.0 Hz, 1H), 3.56 (td, J = 12.9 Hz, 3.0 Hz, 1H), 3.20 (dd, J = 7.2 Hz, 3.7 Hz, 1H), 2.91 (dd, 
J = 15.7 Hz, 7.3 Hz, 1H), 2.23-2.09 (m, 1H), 1.48 (dd, J = 16.5 Hz, 6.9 Hz, 1H), 1.37 (dd, J = 6.6 
Hz, 3.8 Hz, 1H), 1.14 (s, 3H), 0.83 (t, J = 6.8 Hz, 1H);  13C NMR (125.76 MHz, CDCl3) δ 172.6, 
131.5 (2C), 131.4 (2C), 129.2 (+, 2C), 128.24 (+), 128.17, 126.5 (+, 2C), 125.1 (+, 2C), 124.0 (+, 
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2C), 72.7 (-), 67.7 (+), 43.3 (-), 39.1 (-), 30.5 (-), 27.9, 19.5 (+), 16.8 (-);  FT IR (cm-1, fil ): 
2957, 2928, 2868, 1634, 1445, 1423, 1362, 1312, 1244, 1202, 1188, 1146, 1109, 1070, 966, 928, 
891, 854, 762, 737;  HRMS (TOF ES): found 346.1806, calculated for C23H24NO2 (M+H) 
346.1807 (0.3 ppm). 
 
(1S*,9R*)-7-Hexyl-9-methyl-2-oxa-7-azabicyclo[7.1.0]decan-8-one (318e):  To 
a mixture of t-BuOK (65.1 mg, 0.56 mmol, 2.00 equiv), 18-crown-6 ether (8 mg, 
0.03 mmol, 10 mol%) in THF (3 mL) was added bromocyclopropane 317  (92.2 
mg, 0.29 mmol, 1.00 equiv). The mixture was stirred for 3 hrs at 80 oC. The KBr 
precipitate was filtered off on a fritted funnel and the solvent was removed in vacuum. 
Preparative column chromatography on silica gel afforded the title compound as a colorless oil, 
Rf 0.40 (hexane-EtOAc 1:1). Yield 97.0 mg (0.24 mmol, 84%). 
1H NMR (400.13 MHz, CDCl3) δ 4.19 (dd, J = 12.8 Hz, 7.2 Hz, 1H), 4.11 (td, J = 13.9 Hz, 2.8 
Hz, 1H), 3.86 (m, J = 14.0 Hz, 8.2 Hz, 7.8 Hz, 0.8 Hz, 1H), 3.35 (dd, J = 14.1 Hz, 4.3 Hz, 1H), 
3.28 (dd, J = 12.8 Hz, 6.7 Hz, 1H), 3.11 (dd, J = 7.1 Hz, 3.5 Hz, 1H), 2.77 (ddd, J = 13.7 Hz, 8.8 
Hz, 5.3 Hz, 1H), 2.01-1.90 (m, 1H), 1.84-1.70 (m, 2H), 1.66-1.38 (m, 4H), 1.35-1.26 (m, 6H), 
1.21 (s, 3H), 1.23 (dd, J = 6.4 Hz, 3.7 Hz, 1H), 0.89 (t, J = 6.8 Hz, 3H), 0.72 (t, J = 6.8 Hz, 3H);  
13C NMR (100.67 MHz, CDCl3) δ 171.6, 71.6 (-), 65.7 (+), 43.5 (-), 42.5 (-), 31.5 (-), 27.7, 27.3 
(-), 26.8 (-), 26.5 (-), 25.4 (-), 22.6 (-), 20.3 (+), 17.0 (-), 14.0 (+);  FT IR (cm-1, film): 2953, 
2930, 2870, 1636, 1468, 1427, 1194, 1159, 1099;  HRMS (TOF ES): found 276.1937, calculated 
for C15H27NO2Na (M+Na) 276.1939 (0.7 ppm).  
 
O
NO
229 
 
 
 
(1S,9R)-9-methyl-7-phenethyl-2-oxa-7-azabicyclo[7.1.0]decan-8-one (318d):  To a mixture of 
t-BuOK (62.7 mg, 0.56 mmol, 2.00 equiv), 18-crown-6 ether (7.4 mg, 0.028 mmol, 10 mol%) in 
THF (3 mL) was added bromocyclopropane 317d (100 mg, 0.28 mmol, 1.00 equiv). The mixture 
was stirred for 6 hrs at 60 oC.  The KBr precipitate was filtered off on a fritted funnel and the 
filtrate was concentrated in vacuum. Preparative column chromatography on silica gel afforded 
the title compound as a colorless oil, Rf 0.36 (hexane-EtOAc 1:1). Yield 65.0 mg (0.24 mmol, 
86%). 
  
1H NMR (400.13 MHz, CDCl3) δ 7.33-7.18 (m, 5H), 4.17 (dd, J = 12.8 Hz, 6.9 Hz, 1H), 4.13-
4.05 (m, 1H), 4.00 (td, J = 14.0 Hz, 2.9 Hz, 1H), 3.24 (dd, J = 12.8 Hz, 6.9 Hz, 1H), 3.09 (dd, J = 
6.8 Hz, 3.3 Hz, 1H), 3.12-3.04 (m, 1H), 3.04-2.94 (m, 2H), 2.90-2.81 (m, 1H), 2.01-1.86 (m, 
1H), 1.81-1.71 (m, 1H), 1.49-1.31 (m, 2H), 1.24 (dd, J = 6.6 Hz, 3.5 Hz, 1H), 1.13 (s, 3H), 0.71 
(t, J = 6.8 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ 171.7, 139.3, 128.8 (+, 2C), 128.3 (+, 
2C), 126.2 (+), 71.5 (-), 65.6 (+), 44.3 (-), 44.2 (-), 33.2 (-), 27.6, 27.3 (-), 25.3 (-), 20.1 (+), 16.8 
(-);  FT IR (cm-1, film): 3084, 3024, 2932, 2870, 2359, 1637, 1468, 1441, 1425, 1362, 1280, 
1192, 1167, 1099, 1047, 983, 748, 702, 505; HRMS (TOF ES): found 296.1618, calculated for 
C17H23NO2Na (M+Na) 296.1626 (2.7 ppm);  
 
(1S*,10R*)-8-cyclohexyl-10-methyl-2-oxa-8-azabicyclo[8.1.0]undecan-9-one 
(318c):  To a mixture of t-BuOK (67.3 mg, 0.60 mmol, 2.00 equiv), 18-crown-6 
O
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ether (8 mg, 0.03 mmol, 10 mol%) in THF (3 mL) was added bromocyclopropane 317c (104 mg, 
0.30 mmol, 1.00 equiv).  The mixture was stirred overnight at 80 oC. The KBr precipitate was 
filtered off on a fritted funnel and the filtrate was concentrated in vacuum. Preparative column 
chromatography on silica gel afforded the title compound as a colorless oil, Rf 0.25 (hexane-
EtOAc 1:1). Yield 69.3 mg (0.42 mmol, 87%). 
 
 
1H NMR (400.13 MHz, CDCl3) δ ppm 3.94 (ddd, J = 14.4 Hz, 11.4 Hz, 4.9 Hz, 
1H), 3.85 (ddd, J = 11.2 Hz, 7.6 Hz, 3.7 Hz, 1H), 3.70-3.60 (m, 2H), 3.26 (ddd, J 
= 14.2 Hz, 4.9 Hz, 3.4 Hz, 1H), 3.06 (dd, J = 7.6 Hz, 4.3 Hz, 1H), 1.97-1.79 (m, 
4H), 1.78-1.54 (m, 6H), 1.40 (dd, J = 6.6 Hz, 4.6 Hz, 1H), 1.47-1.23 (m, 5H), 1.20 (s, 3H), 1.22-
1.07 (m, 1H), 0.68 (t, J = 6.9 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ ppm 172.1, 70.4 (-), 
65.6 (+), 57.4 (+), 43.7 (-), 30.9 (-), 30.0 (-), 28.6, 27.9 (-), 26.9 (-), 26.4 (-), 26.3 (-), 25.8 (-), 
21.4 (+), 17.7 (-), 17.2 (-);  FT IR (cm-1, film): 2930, 2854, 1630, 1448, 1420, 1367, 1360, 1327, 
1306, 1259, 1192, 1173, 1148, 1136, 1105, 1051, 1020, 785, 710, 503; HRMS (TOF ES): found 
288.1944, calculated for C16H27NO2Na (M+Na) 288.1939 (1.7 ppm);   
 
(1S*,10R*)-8-Benzyl-10-methyl-2-oxa-8-azabicyclo[8.1.0]undecan-9-one 
(318a): To a mixture of t-BuOK (140 mg, 1.25 mmol, 2.50 equiv), 18-crown-6 
ether (13.2 mg, 0.05 mmol, 10 mol%) in THF (3 mL) was added 
bromocyclopropane 317a (177 mg, 0.50 mmol, 1.00 equiv). The mixture was 
stirred for 4 hrs at 80 oC.  The KBr precipitate was filtered off on a fritted funnel and the solvent 
O
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was removed in vacuum. Preparative column chromatography on silica ge afforded the title 
compound as a colorless oil, Rf 0.40 (hexane-EtOAc 1:3). Yield 97 mg (0.35 mmol, 70%). 
 
1H NMR (400.13 MHz, CDCl3) δ 7.37-7.30 (m, 2H), 7.30-7.22 (m, 3H), 5.53 (d, J = 14.9 Hz, 
1H), 3.98 (td, J = 13.1 Hz, 4.6 Hz, 1H), 3.92 (td, J = 6.3 Hz, 4.3 Hz, 1H), 3.72 (d, J = 14.9 Hz, 
1H), 3.66 (ddd, J = 11.3 Hz, 8.8 Hz, 2.8 Hz, 1H), 3.12 (dd, J = 7.6 Hz, 4.3 Hz, 1H), 3.10 (ddd, J 
= 13.9 Hz, 5.2 Hz, 2.1 Hz, 1H), 2.07-1.93 (m, 1H), 1.82-1.70 (m, 1H), 1.49 (dd, J = 6.6 Hz, 4.3 
Hz, 1H), 1.58-1.38 (m, 3H), 1.27 (s, 3H), 1.34 - 1.22 (m, 1H), 0.78 (dd, J = 7.3 Hz, 6.6 Hz, 1H);  
13C NMR (100.67 MHz, CDCl3) δ ppm 172.5, 137.3, 128.5 (+, 2C), 127.9 (+, 2C), 127.1 (+), 
70.2 (-), 65.3 (+), 45.4 (-), 43.5 (-), 27.8, 27.4 (-), 24.7 (-), 20.7 (+), 17.3 (-), 16.3 (-);  FT IR (cm-
1, film): 3026, 2930, 2874, 1630, 1441, 1425, 1356, 1236, 1192, 1150, 1105, 1051, 1032, 739, 
700;  HRMS (TOF ES): found 296.1621, calculated for C17H23NO2Na (M+Na) 296.1626 (1.7 
ppm).  
 
(1S*,10R*)-8-Benzyl-10-methyl-2,5-dioxa-8-azabicyclo[8.1.0]undecan-9-one 
(318b):  To a mixture of t-BuOK (37 mg, 0.33 mmol, 2.5 equiv), 18-crown-6 
(3.5 mg, 13 µmol, 10 mol%) in THF (2 mL) was added bromocyclopropane 
317b (49 mg, 0.13 mmol, 1.0 equiv).  The resulting mixture was stirred at 50 oC for 12 hrs.  The 
KBr precipitate was filtered off and the filtrate was concentrated in vacuum.  Preparative column 
chromatography of a residue on silica gel afforded the title compound as a colorless oil, Rf 0.20 
(hexane-EtOAc 1:1). Yield 29 mg (0.10 mmol, 80%). 
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1H NMR (500.13 MHz, CDCl3) δ ppm 7.35-7.30 (m, 2H), 7.29-7.23 (m, 3H), 5.44 (d, J = 15.4 
Hz, 1H), 4.35-4.21 (m, 1H), 4.04-3.90 (m, 3H), 3.76-3.62 (m, 3H), 3.29 (d, J = 12.3 Hz, 1H), 
3.15 (dd, J = 7.3 Hz, 4.1 Hz, 1H), 2.98 (br. s., 1H), 1.73 (dd, J = 6.6 Hz, 4.1 Hz, 1H), 1.34 (s, 
3H), 0.76 (dd, J = 7.3 Hz, 6.6 Hz, 1H);  13C NMR (125.76 MHz, CDCl3) δ ppm 172.0, 137.5, 
128.6 (+, 2C), 127.8 (+), 127.2 (+, 2C), 70.0 (-), 66.8 (-), 65.3 (+), 64.7 (-), 47.1 (-), 44.4 (-), 
27.5, 21.2 (+), 18.4 (-);  FT IR (cm-1, film): 2957, 2922, 2860, 2359, 2339, 2330, 1634, 1448, 
1425, 1263, 1146, 1115, 741, 698;  HRMS (TOF ES): found 298.1422, calculated for 
C16H21NO3Na (M+Na) 298.1422 (1.0 ppm). 
 
 
 (1S*,8R*)-6-Benzyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (320c):  An 
oven-dried 50 mL round bottom flask was charged with 
bromocyclopropane 319c (140 mg, 0.45 mmol, 1.0 equiv), 18-crown-6 
(11.8 mg, 0.045 mmol, 10 mol%), KOH ( 88 mg, 1.57 mmol, 3.5 equiv) and anhydrous THF (10 
mL). The mixture was stirred at RT for 2.25 hrs. The solvent was removed by rotary evaporation.  
The residue was purified by flash column chromatography on silica gel (Rf 0.28, eluent EtOAc) 
to obtain a title compound as a colorless crystalline solid, mp 51-55 oC.  Yield 91 mg (0.40 
mmol, 88%)  
 1H NMR (500.13 MHz, CDCl3) δ ppm 7.29-7.23 (m, 2H), 7.23-7.17 (m, 3H), 5.24 (d, J = 14.8 
Hz, 1H), 3.85 (d, J = 15.1 Hz, 1H), 3.60 (td, J = 12.8 Hz, 3.2 Hz, 1H), 3.45 (ddd, J = 6.9 Hz, 6.1 
Hz, 4.1 Hz, 1H), 3.17 (dd, J = 15.4 Hz, 6.9 Hz, 1H), 1.96 - 1.80 (m, 1H), 1.63 (dt, J = 10.2 Hz, 
6.5 Hz, 1H), 1.53 (ddd, J = 15.2 Hz, 7.2 Hz, 3.2 Hz, 1H), 1.17 (td, J = 6.9 Hz, 3.9 Hz, 1H), 1.03 
O
N
O
233 
 
 
(dt, J = 10.2 Hz, 7.1 Hz, 1H);  13C NMR (125.76 MHz, CD3Cl) δ 169.7, 137.5, 128.5 (+, 2C), 
128.1 (+, 2C), 127.3 (+), 72.8 (-), 61.0 (+), 48.6 (-), 46.0 (-), 30.1 (-), 22.7 (+), 10.5 (-);  FTIR 
(NaCl, film, cm1) 2928, 2870, 1634, 1481, 1439, 1229, 1080, 735, 698;  HRMS (TOF ES): found 
232.1332, calculated for C14H18NO2 (M+H) 232.1338 (2.6 ppm). 
 
(1S*,8R*)-6-Hexyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (320b):  An 
oven-dried 50 mL round bottom flask was charged with 
bromocyclopropane 319b (165 mg, 0.53 mmol, 1.0 equiv), 18-crown-6 (14 
mg, 0.053 mmol, 10 mol%), KOH (74 mg, 1.33 mmol, 2.5 equiv.) and anhydrous THF (10 mL). 
The mixture was stirred at RT for 2.25 hrs. The solvent was removed by rotary evaporation.  The 
residue was purified by flash column chromatography on silica gel, eluting first with mixture 
EtOAc/hexane 3:1, and then with mixture EtOAc/MeOH 3:1, to obtain a title compound as a 
colorless amorphous solid, Rf  0.83 EtOAc/MeOH 3:1. Yield 107 mg (90%, 0.48 mmol). 
1H NMR (400.13 MHz, CDCl3) δ ppm 4.22-4.06 (m, 2H), 3.88 (dddd, J = 13.4 Hz, 8.1 Hz, 6.6 
Hz, 1.0 Hz, 1H), 3.66 (td, J = 12.7 Hz, 3.2 Hz, 1H), 3.48 (td, J = 6.7 Hz, 4.0 Hz, 1H), 3.28 (dd, J 
= 15.3 Hz, 6.9 Hz, 1H), 2.76 (ddd, J = 13.9 Hz, 8.8 Hz, 5.6 Hz, 1H), 2.02-1.86 (m, 1H), 1.71-
1.43 (m, 4H), 1.13-1.21 (m, 6H), 1.15 (td, J = 6.8 Hz, 3.8 Hz, 1H), 1.03 (dt, J = 10.2 Hz, 7.0 Hz, 
1H), 0.88 (t, J = 6.4 Hz, 3H);  13C NMR (100.67 MHz, CDCl3) δ 169.1, 72.8 (-), 61.0 (+), 46.8 (-
), 45.9 (-), 31.6 (-), 30.7 (-), 27.6 (-), 26.6 (-), 22.9 (+), 22.6 (-), 14.0 (+), 10.3 (-);  FTIR (NaCl, 
film, cm1) 2955, 2930, 2858, 1626, 1485, 1462, 1373, 1225, 1095, 725;  HRMS (TOF ES): found 
226.1807, calculated for C13H24NO2 (M+H) 226.1807 (0.0 ppm). 
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(1S*,8R*)-6-(Furan-2-ylmethyl)-2-oxa-6-azabicyclo[6.1.0]nonan-7-one 
(320d): To a stirred suspension of powdered KOH (46 mg, 0.83 mmol, 2.5 
equiv) and 18-crown-6 ether (8.7 mg, 0.033 mmol, 10 mol%) in dry THF (3 
mL) was added bromocyclopropane 320d (100 mg, 0.33 mmol, 1.0 equiv).  The mixture was 
vigorously stirred at 25 oC for 3 hrs.  The KBr precipitate was filtered off on a fritted funnel and 
the filtrate wa concentrated in vacuum. Preparative column chromatography of a residual oil on 
silica gel afforded the title compound as a crystalline solid, Rf 0.30 (CH2Cl2-EtOAc, 3:1). Yield 
69 mg (0.31 mmol, 95%). 
1H NMR (400.13 MHz, CDCl3) δ ppm 7.37 (d, J = 1.0 Hz, 1H), 6.37-6.31 (m, 1H), 6.29 (d, J = 
3.3 Hz, 1H), 5.06 (d, J = 15.4 Hz, 1H), 4.22-4.08 (m, 2H), 3.68 (td, J = 12.6 Hz, 3.3 Hz, 1H), 
3.55-3.48 (m, 1H), 3.41 (dd, J = 15.4 Hz, 6.8 Hz, 1H), 1.95-1.80 (m, 1H), 1.74-1.59 (m, 3H), 
1.22 (td, J = 6.9 Hz, 3.9 Hz, 1H), 1.08 (dt, J = 10.2 Hz, 6.9 Hz, 1H);  13C NMR (100.67 MHz, 
CDCl3) δ ppm 169.5, 151.0, 142.1 (+), 110.5 (+), 108.6 (+), 72.8 (-), 60.9 (+), 46.4 (-), 41.7 (-), 
30.2 (-), 22.7 (+), 10.4 (-);  FT IR (NaCl, film, cm1): 3115, 2959, 2932, 2872, 1728, 1634, 1504, 
1479, 1464, 1423, 1393, 1362, 1337, 1281, 1248, 1225, 1200, 1165, 1148, 1121, 1107, 1080, 
1041, 1011, 982, 964, 932, 885, 833, 762, 743, 600, 540, 417;  HRMS (TOF ES): found 
222.1129, calculated for C12H16NO3 (M+H) 222.1130 (0.5 ppm).   
 
(1aR*,9aS*)-3-(tert-Butyl)-1,3,4,9a-tetrahydrobenzo[b]cyclopropa[g]-
[1,5]oxazocin-2(1aH)-one (320a): An oven-dried 50 mL round bottom flask 
was charged with bromocyclopropane 319b (184mg, 0.56 mmol, 1 equiv), 18-
crown-6 (14.9 mg, 0.056 mmol, 10 mol%), KOH (78.6 mg, 1.4 mmol, 2.5 equiv.) and anhydrous 
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THF (15 mL). The mixture was stirred at 50 oC for 12 hrs. The solvent was removed by rotary 
evaporation.  The residue was absorbed onto silica gel and then purified by flash column 
chromatography on silica gel being flushed (eluent EtOAc/hexane 1:2 Rf :.3 product). Yield 129 
mg (93%, 0.52 mmol) clear crystalline solid, mp 115-116 oC. 
1H NMR (400.13 MHz, CDCl3) δ 7.24 (td, J = 7.6 Hz, 1.8 Hz, 1H), 7.15 (dd, J = 7.6 Hz, 1.5 Hz, 
1H), 7.09-7.03 (m, 2H), 5.59 (d, J = 17.2 Hz, 1H), 4.35 (d, J = 16.9 Hz, 1H), 3.79 (td, J = 6.2 Hz, 
3.0 Hz, 1H), 2.22 (dt, J = 10.1 Hz, 6.3 Hz, 1H), 1.41 (td, J = 6.9 Hz, 3.2 Hz, 1H), 1.35 (s, 9H), 
1.15 (dt, J = 10.1 Hz, 6.7 Hz, 1H);  13C NMR (100.67 MHz, CDCl3) δ ppm 169.9, 157.5, 130.8 
(+), 128.9 (+), 128.7, 123.6 (+), 121.8 (+), 57.7, 56.9 (+), 48.9 (-), 28.5 (+, 3C), 26.6 (+), 10.4 (-
);  FT IR (NaCl, film, cm1): 3456, 2993, 2966, 2924, 1651, 1489, 1408, 1358, 1225, 1194, 1111, 
754;  HRMS (TOF ES): found 268.1311, calculated for C15H19NO2Na (M+Na) 268.1313 (0.7 
ppm). 
 
3.5. Assignment of Relative Configurations  
 
3.5.1 Assignment of relative configurations for compounds 316d, 318d, and 318c 
 
 1H NOE DIFF experiments unambiguously confirmed cis-configurations of cyclopropane 
moiety in representative products, obtained in 8-exo-trig (316d), 9-exo-trig (318d), and 10-exo-
trig (318c) cyclizations.  The corresponding spectral charts and 3D molecular structures 
showcasing the significant NOE responses are shown below.  In each case NOE responses have 
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been detected between the corresponding methyl group and a set of two hydrogen atoms in 
cyclopropane, one of them being a deshielded proton next to ethereal oxygen.  R lative 
configurations of the products obtained in exo-trig cyclizations were assigned by analogy.   
 
 
 
 
Figure 19.  MM2-Optimized 3D molecular structures of three cyclization products: 316d (A), 
318d (B), and 318c (C).  NOE responses, imperative for the assignment of the relative 
configuration are shown as red arrows connecting the corresponding hydrogen atoms. 
237 
 
 
 
ba0465_noe_004001r
ba0465_noe_006001r
ba0465_noe_010001r
ba0465_noe_013001r
ba0465_noe_001001r
3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
A
B
C
D
E
 
Figure 20.   NOE experiments performed for compound 316d  All spectra were registered at 
500.13 MHz.  The charts represent: (A) – reference 1H NMR spectrum; (B) NOE DIFF 
experiment with excitation at 3.21 ppm and mixing time 100 ms; (C) - NOE DIFF experiment 
with excitation at 1.39 ppm and mixing time 1.0 s; (D) -  NOE DIFF experiment with excitation 
at 1.16 ppm and mixing time 500 ms; (E) -  NOE DIFF experiment with excitation at 0.84 ppm 
and mixing time 1 s. 
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Figure 21.  NOE experiments performed for compound 318d.  All spectra were registered at 
500.13 MHz.  The charts represent: (A) – reference 1H NMR spectrum; (B) – NOE DIFF 
experiment with excitation at 1.26 ppm and mixing time 1 s; (C) - NOE DIFF experiment with 
excitation at 1.15 ppm and mixing time 1.0 s; (D) -  NOE DIFF experiment with excitation at 
0.72 ppm and mixing time 1 s. 
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Figure 22. NOE experiments performed for compound 318c.  All spectra were registered at 
500.13 MHz.  The charts represent: (A) – reference 1H NMR spectrum; (B) – NOE DIFF 
experiment with excitation at 1.51 ppm and mixing time 1 s; (C) - NOE DIFF experiment with 
excitation at 1.28 ppm and mixing time 1.0 s; (D) -  NOE DIFF experiment with excitation at 
0.79 ppm and mixing time 1 s. 
 
 
 
Relative configurations of all the products obtained 
in 8-endo-trig cyclizations were assigned based on 
analysis of the coupling constants in the multiplets 
corresponding to the cyclopropyl methine nex to 
ethereal oxygen.  Signal at 3.45 ppm in the 1H NMR 
HBHD
HC
3J cis (AB) = 6.94 Hz
3J trans (AD) = 6.10 Hz
3J trans (AC) = 4.10 Hz
HA
O
O N
Ph
240 
 
 
spectrum of compound 316c is the representative example that is discussed below.  Coupling 
constant values were determined by multiplete simulation using ACD/SpecManager 11.01 
(Figure 23).  The observation of two cis-3J coupling constants (6.94 Hz, 6.10 Hz) and only one 
trans-3J coupling constant (4.10 Hz) allowed for unambiguous assignment of the cis-
configuration to product 316c. 
 
 
 
 
Figure 23. Analysis of coupling constants in 1H NMR signal of proton A in compound 316a. 
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3.5.2. Assignment of relative configurations for compounds 327a and 328 
 
 Structure elucidations were performed for compounds 327a, and 328 are provided below.  
The minimum energy conformation for the fused 2-oxa-5-azabicyclo[5.1.0]octan-6-one system is 
depicted in Figure 24 and  Figure 25.  Relative stability of these conformations is governed by 
the pseudo-equatorial phenyl group at position 4 for compound 327a, and both the equatorial 
phenyl at position 3 and the equatorial methyl group at position 4 for compound 328.  The 
observed 1H-1H NOE effects are listed in Figure 24 and Figure 25, the corresponding color-
coded spectral charts are shown in Figure 26 and Figure 27.   
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Figure 24. Observed NOEs upon irradiation at 5.91 ppm (blue), 5.00 ppm (red), 3.86 ppm 
(lilac), 3.66 ppm (green), 3.19 ppm (orange), 1.21 ppm (pink), 0.89 ppm (brown) for compound 
327a.  For color-coded spectral charts corresponding to these experiments, s e Figure 26.  Atom 
numbering in the seven-membered ring is provided according to IUPAC nomenclature. 
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Figure 25.  Observed NOEs upon irradiation at 7.24 ppm (blue), 4.58 ppm (green), 4.21 ppm 
(terracotta), 3.08 ppm (pink), 2.87 ppm (red), 1.46 ppm (spruce), 1.18 ppm (brown) for 
compound 328.  For color-coded spectral charts corresponding to these experiments, s e Figure 
27.  Atom numbering in the seven-membered ring is provided according to IUPAC 
nomenclature. 
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Figure 26.  1D NOEDIFF spectra of 327a.  Chemical shifts of the irradiated multiplets are listed 
at the left side of each chart 
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Figure 27.  1D NOEDIFF spectra of 328.  Chemical shifts of the irradiated multiplets are listed 
at the left side of each chart. 
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Appendix 
A.1. 1H and 13C Specta for 94 A 
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A.2. 1H-13C HSQC spectrum of trans-94a 
 
Acquisition Time (sec) (0.0614, 0.1597) Comment Imported from UXNMR/XWINNMR
Date 30 Apr 2008 15:29:40
File Name \ba0139A-2D-Minor\5\pdata\1\2rr
Frequency (MHz) (100.61, 400.13) Nucleus (13C, 1H)
Number of Transients 2 Original Points Count (1024, 1024)
Points Count (1024, 1024) Pulse Sequence hsqcetgpsisp2
Solvent CDCl3 Sweep Width (Hz) (16666.67, 6410.26)
Temperature (degree C) 23.160
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A.3. 1H-13C HSQC spectrum of cis-94a-d2 
 
Acquisition Time (sec) (0.0614, 0.1597) Comment Imported from UXNMR/XWINNMR
Date 30 Apr 2008 15:34:40
File Name \\SERVER1\GROUP\CHEM\MAR_GRP\Sam\NMR DATA\ba0141f2\5\pdata\1\2rr
Frequency (MHz) (100.61, 400.13) Nucleus (13C, 1H) Number of Transients 2
Original Points Count (1024, 1024) Points Count (1024, 1024) Pulse Sequence hsqcetgpsisp2
Solvent CDCl3 Sweep Width (Hz) (16666.67, 6410.26) Temperature (degree C) 23.160
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3JPH(cis) = 19.7 Hz
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A.4. 1H and 13C spectra of trans and cis 94e 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
ppm
12.003.143.005.56
0.
00
1.
60
1.
63
1.
63
1.
67
2.
11
2.
15
2.
19
2.
19
2.
20
2.
22
2.
23
3.
86
7.
49
7.
52
7.
53
7.
55
7.
56
7.
61
7.
61
7.
63
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
ppm
19
.4
5
21
.9
2
23
.7
8
23
.8
0
24
.3
4
24
.4
4
24
.6
4
34
.6
3
53
.0
2
76
.6
8
77
.0
0
77
.3
2
87
.5
8
88
.1
7
12
7.
85
12
7.
90
13
0.
77
13
4.
19
17
3.
25
MeOOC
P
O
OO
MeOOC
P
O
OO
 
249 
 
 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
ppm
5.771.013.002.99
1.
42
1.
45
1.
53
1.
53
1.
57
1.
58
1.
60
1.
61
1.
64
2.
16
2.
17
2.
21
2.
23
3.
71
7.
29
7.
31
7.
31
7.
33
7.
42
7.
44
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
ppm
18
.3
3
21
.7
8
23
.6
2
23
.8
3
24
.1
5
24
.3
2
24
.5
4
24
.5
8
36
.6
4
36
.6
8
52
.7
4
76
.6
8
77
.0
0
77
.3
2
87
.9
2
12
7.
79
12
8.
32
12
9.
30
13
8.
04
13
8.
07
17
0.
60
MeOOC
P O
OO
MeOOC
P O
OO
250 
 
 
A.5. 1H and 13C spectra of 94f 
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A.6. 1H and 13C spectra of 242c 
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A.7. 1H and 13C spectra for 327a 
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A.8. 1H and 13C spectra for 316d 
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A.9. 1H and 13C for 318d. 
ba0430_002001r
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A.10. 1H and 13C for 318c 
Ba0389B_002001r
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
16
.3
3
17
.3
1
20
.6
9
24
.6
6
27
.4
1
27
.7
6
43
.4
9
45
.4
0
65
.3
3
70
.2
1
76
.6
9
77
.0
0
77
.3
2
12
7.
10
12
7.
93
12
8.
48
13
7.
31
17
2.
53
O
NO
Ba0389B_001001r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
1.014.491.022.000.971.991.003.13
0.
76
0.
78
0.
80
1.
27
1.
43
1.
43
1.
44
1.
45
1.
48
1.
49
1.
50
1.
51
1.
75
1.
76
3.
08
3.
11
3.
11
3.
12
3.
13
3.
14
3.
66
3.
66
3.
71
3.
74
3.
92
3.
93
3.
94
3.
99
5.
51
5.
55
7.
24
7.
26
7.
28
7.
29
7.
32
7.
33
7.
35
7.
35
O
NO
CH4
. 
256 
 
 
A.11.  Crystallographic Data for 327a 
 To a solution of compound 327a (25 mg) in dichloromethane (10 mL) was added hexane 
(10 mL) and the mixture was left overnight in the flask, closed with a cotton ball to ensure slow 
evaporation of the solvents.  Well-formed colorless needles were obtained, which were collected, 
washed with hexane, and analyzed by single crystal X-ray crystallography. 
 
 Colorless crystals of C13H15NO2 are, at 100(2) K, orthorhombic, space group P212121– 
D2
4 (No. 19) with a = 8.6537(6) Å, b = 9.4166(6) Å, c = 13.4394(9) Å, V = 1095.2(1) Å and Z =  
4 molecules {dcalcd = 1.318 g/cm
3; µa(MoKα) = 0.089 mm
-1}.   A full hemisphere of diffracted 
intensities (1850 20-second frames with a ω scan width of 0.30°) was measured for a single-
domain specimen using graphite-monochromated MoKα radiation (λ= 0.71073 Å) on a Bruker 
SMART APEX CCD Single Crystal Diffraction System.  X-rays were provided by a fine-focus 
sealed x-ray tube operated at 50kV and 30mA.  Lattice constants were determined with the 
Bruker SAINT software package using peak centers for 3007 reflections.  A total of 13228 
integrated reflection intensities having 2θ((MoKα)< 60.99° were produced using the Bruker 
program SAINT; 3298 of these were unique and gave Rint = 0.050 with a coverage which was 
99.4% complete. The data were corrected empirically for variable sorption effects using 
equivalent reflections; the relative transmission factors ranged from 0.951 to 1.000.  The Bruker 
software package SHELXTL was used to solve the structure using“direct methods” techniques.  
All stages of weighted full-matrix least-squares refinement were conducted using Fo
2 data with 
the SHELXTL Version 6.10 software package. 
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 The final structural model incorporated anisotropic thermal parameters for all 
nonhydrogen atoms and isotropic thermal parameters for all hydrogen atoms.  All hydrogen 
atoms were located in a difference Fourier and included in the structural model as independent 
isotropic atoms whose parameters were allowed to vary in least-squares refinement cycles.  A 
total of 205 parameters were refined using no restraints, 3298 data and weights of w = 1/ [σ
2
(F
2
) 
+ (0.0465 P)
2
], where P = [Fo
2
 + 2Fc
2
] / 3.  Final agreement factors at convergence are:  
R1(unweighted, based on F) = 0.050 for 3043 independent absorption-corrected “observed” 
reflections having 2θ(MoKα)<  60.99° and I>2σ(I);  R1(unweighted, based on F) = 0.056 and 
wR2(weighted, based on F
2) = 0.100 for all 3298 independent absorption-corrected reflections 
having 2θ(MoKα)< 60.99°.  The largest shift/s.u. was 0.000 in the final refinement cycle.  The
final difference map had maxima and minima of 0.36 and -0.26 e-/Å
3
, respectively.  With oxygen 
being the heaviest atom present, the absolute structure could not be reliably determined 
experimentally.  The absolute configuration for the molecule was therefore assigned using the 
known configuration at carbon atom C(6).  
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Figure 28.  ORTEP drawing of 327a, showing the atom-numbering scheme; 50% probability 
amplitude displacement ellipsoids are shown.  The asymmetric unit co tains one C13H15NO2 
molecule.    
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Figure 29.  Packing of 327a molecules in the crystalline lattice cell. 
  
260 
 
 
Table 3. Crystal data and structure refinement for C13H15NO2. 
 
Empirical formula  C13H15NO2 
Formula weight  217.26 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121– D2
4 (No. 19) 
Unit cell dimensions a = 8.6537(6) Å α = 90.000° 
 b = 9.4166(6) Å β = 90.000° 
 c = 13.4394(9) Å γ = 90.000° 
Volume 1095.2(1) Å
3
 
Z 4 
Density (calculated) 1.318 g/cm
3
 
Absorption coefficient 0.089 mm
-1
 
F(000) 464 
Crystal size 0.24 x 0.22 x 0.04 mm
3
 
Theta range for data collection 2.64° to 30.50° 
Index ranges -12 ≤ h ≤ 12, -13 ≤ k ≤ 13, -19 ≤ l ≤ 19 
Reflections collected 13228 
Independent reflections 3298 [Rint = 0.050] 
Completeness to theta = 30.50° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.951 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3298 / 0 / 205 
Goodness-of-fit on F
2
 1.057 
Final R indices [I>2sigma(I)] R1 = 0.050, wR2 = 0.098 
R indices (all data) R1 = 0.056, wR2 = 0.100 
Absolute structure parameter 0.5(12) 
Largest diff. peak and hole 0.36 and -0.26 e-/Å
3
 
------------------------------------------------------------------------------------------------------------------------ 
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R1 = Σ ||Fo| - |Fc|| / Σ |Fo|  
wR2 = { Σ [w(Fo
2
 - Fc
2
)
2
] / Σ [w(Fo
2
)
2
] }
1/2
  
 
Table 4. Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2 x 103) for C13H15NO2.  U(eq) is defined as one third of  the trace of the orthogonalized 
Uij  tensor. 
 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 5199(1) 4518(1) 2813(1) 17(1) 
O(2) 4895(1) 1184(1) 4513(1) 18(1) 
N(1) 3379(2) 2207(1) 3352(1) 15(1) 
C(1) 4351(2) 2261(2) 4137(1) 13(1) 
C(2) 4682(2) 3722(2) 4549(1) 13(1) 
C(3) 6334(2) 4248(2) 4461(1) 16(1) 
C(4) 5094(2) 4880(2) 3823(1) 14(1) 
C(5) 3714(2) 4391(2) 2343(1) 17(1) 
C(6) 2589(2) 3455(2) 2936(1) 14(1) 
C(7) 1256(2) 3013(2) 2280(1) 14(1) 
C(8) 1495(2) 2119(2) 1465(1) 17(1) 
C(9) 275(2) 1737(2) 846(1) 19(1) 
C(10) -1199(2) 2254(2) 1038(1) 20(1) 
C(11) -1454(2) 3140(2) 1847(1) 20(1) 
C(12) -232(2) 3508(2) 2466(1) 17(1) 
C(13) 3788(2) 4106(2) 5474(1) 18(1) 
________________________________________________________________________________  
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Table 5.  Bond lengths [Å] for C13H15NO2. 
____________________________________________________________________________
O(1)-C(4)  1.403(2) 
O(1)-C(5)  1.436(2) 
O(2)-C(1)  1.227(2) 
N(1)-C(1)  1.350(2) 
N(1)-C(6)  1.470(2) 
N(1)-H(1N)  0.85(2) 
C(1)-C(2)  1.511(2) 
C(2)-C(4)  1.506(2) 
C(2)-C(13)  1.508(2) 
C(2)-C(3)  1.518(2) 
C(3)-C(4)  1.496(2) 
C(3)-H(3A)  0.94(2) 
C(3)-H(3B)  0.95(2) 
C(4)-H(4)  1.03(2) 
C(5)-C(6)  1.536(2) 
C(5)-H(5A)  0.97(2) 
C(5)-H(5B)  0.98(2) 
C(6)-C(7)  1.511(2) 
C(6)-H(6)  0.94(2) 
C(7)-C(12)  1.392(2) 
C(7)-C(8)  1.396(2) 
C(8)-C(9)  1.392(2) 
C(8)-H(8)  0.95(2) 
C(9)-C(10)  1.390(2) 
C(9)-H(9)  0.96(2) 
C(10)-C(11)  1.389(2) 
C(10)-H(10)  0.95(2) 
C(11)-C(12)  1.389(2) 
C(11)-H(11)  0.97(2) 
C(12)-H(12)  0.94(2) 
C(13)-H(13A)  0.97(2) 
C(13)-H(13B)  0.95(2) 
C(13)-H(13C)  0.97(2) 
___________________________________________________________________________  
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Table 6.   Bond angles [°] for C13H15NO2. 
_________________________________________________________________________________ 
C(4)-O(1)-C(5) 112.8(1) 
C(1)-N(1)-C(6) 123.8(1) 
C(1)-N(1)-H(1N) 118(1) 
C(6)-N(1)-H(1N) 118(1) 
O(2)-C(1)-N(1) 122.0(1) 
O(2)-C(1)-C(2) 121.9(1) 
N(1)-C(1)-C(2) 116.0(1) 
C(4)-C(2)-C(13) 118.8(1) 
C(4)-C(2)-C(1) 117.8(1) 
C(13)-C(2)-C(1) 115.1(1) 
C(4)-C(2)-C(3) 59.3(1) 
C(13)-C(2)-C(3) 118.0(1) 
C(1)-C(2)-C(3) 116.5(1) 
C(4)-C(3)-C(2) 59.9(1) 
C(4)-C(3)-H(3A) 116(1) 
C(2)-C(3)-H(3A) 118(1) 
C(4)-C(3)-H(3B) 117(1) 
C(2)-C(3)-H(3B) 115(1) 
H(3A)-C(3)-H(3B) 118(2) 
O(1)-C(4)-C(3) 114.3(1) 
O(1)-C(4)-C(2) 117.8(1) 
C(3)-C(4)-C(2) 60.7(1) 
O(1)-C(4)-H(4) 114(1) 
C(3)-C(4)-H(4) 120(1) 
C(2)-C(4)-H(4) 120(1) 
O(1)-C(5)-C(6) 112.8(1) 
O(1)-C(5)-H(5A) 108(1) 
C(6)-C(5)-H(5A) 109(1) 
O(1)-C(5)-H(5B) 108(1) 
C(6)-C(5)-H(5B) 109(1) 
H(5A)-C(5)-H(5B) 111(1) 
N(1)-C(6)-C(7) 110.9(1) 
N(1)-C(6)-C(5) 111.2(1) 
C(7)-C(6)-C(5) 109.8(1) 
N(1)-C(6)-H(6) 107(1) 
C(7)-C(6)-H(6) 108(1) 
C(5)-C(6)-H(6) 110(1) 
C(12)-C(7)-C(8) 118.7(1) 
C(12)-C(7)-C(6) 120.6(1) 
C(8)-C(7)-C(6) 120.7(1) 
C(9)-C(8)-C(7) 120.8(2) 
C(9)-C(8)-H(8) 121(1) 
C(7)-C(8)-H(8) 118(1) 
C(10)-C(9)-C(8) 119.7(2) 
C(10)-C(9)-H(9) 121(1) 
C(8)-C(9)-H(9) 120(1) 
C(11)-C(10)-C(9) 120.1(2) 
C(11)-C(10)-H(10) 116(1) 
C(9)-C(10)-H(10) 124(1) 
C(10)-C(11)-C(12) 119.8(2) 
C(10)-C(11)-H(11) 119(1) 
C(12)-C(11)-H(11) 122(1) 
C(11)-C(12)-C(7) 120.9(2) 
C(11)-C(12)-H(12) 119(1) 
C(7)-C(12)-H(12) 120(1) 
C(2)-C(13)-H(13A) 112(1) 
C(2)-C(13)-H(13B) 112(1) 
H(13A)-C(13)-H(13B) 103(2) 
C(2)-C(13)-H(13C) 110(1) 
H(13A)-C(13)-H(13C) 110(2) 
H(13B)-C(13)-H(13C) 110(2) 
 
_________________________________________________________________________________ 
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Table 7.  Anisotropic displacement parameters  (Å2 x 103) for C13H15NO2.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
_____________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
_____________________________________________________________________________  
O(1) 13(1)  21(1) 16(1)  4(1) 1(1)  -2(1) 
O(2) 17(1)  15(1) 20(1)  3(1) 2(1)  1(1) 
N(1) 19(1)  10(1) 17(1)  0(1) -2(1)  -1(1) 
C(1) 10(1)  15(1) 13(1)  1(1) 4(1)  0(1) 
C(2) 12(1)  13(1) 14(1)  3(1) -1(1)  1(1) 
C(3) 12(1)  17(1) 18(1)  1(1) 0(1)  -1(1) 
C(4) 12(1)  15(1) 17(1)  3(1) 1(1)  -1(1) 
C(5) 16(1)  18(1) 17(1)  3(1) -2(1)  -3(1) 
C(6) 13(1)  13(1) 15(1)  1(1) 2(1)  1(1) 
C(7) 14(1)  12(1) 16(1)  3(1) 2(1)  0(1) 
C(8) 15(1)  16(1) 20(1)  0(1) 1(1)  3(1) 
C(9) 23(1)  15(1) 18(1)  -2(1) -2(1)  -1(1) 
C(10) 18(1)  20(1) 22(1)  5(1) -6(1)  -6(1) 
C(11) 12(1)  24(1) 23(1)  3(1) 2(1)  1(1) 
C(12) 17(1)  18(1) 17(1)  0(1) 3(1)  0(1) 
C(13) 18(1)  19(1) 16(1)  -2(1) 3(1)  -2(1) 
_____________________________________________________________________________ 
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Table 8.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2 x 103) 
for C13H15NO2. 
_____________________________________________________________________________  
 x  y  z  U(eq) 
_____________________________________________________________________________  
H(1N) 3210(20) 1400(20) 3078(14) 20(5) 
H(3A) 7050(20) 3670(20) 4130(14) 20(5) 
H(3B) 6700(20) 4800(20) 5003(13) 20(5) 
H(4) 4710(20) 5902(19) 3950(13) 18(4) 
H(5A) 3870(20) 3970(18) 1696(13) 14(4) 
H(5B) 3272(18) 5343(18) 2286(12) 7(4) 
H(6) 2178(19) 3969(18) 3474(13) 9(4) 
H(8) 2520(20) 1790(20) 1345(14) 20(5) 
H(9) 460(20) 1110(20) 291(15) 28(5) 
H(10) -2080(20) 2043(19) 648(13) 15(5) 
H(11) -2490(20) 3490(20) 1966(16) 29(6) 
H(12) -430(20) 4110(20) 3012(13) 18(5) 
H(13A) 4060(20) 3500(20) 6036(15) 26(5) 
H(13B) 4040(20) 5030(20) 5703(14) 23(5) 
H(13C) 2680(20) 4050(20) 5344(15) 24(5) 
_____________________________________________________________________________  
 
 
Table 9.  Hydrogen bonds for C13H15NO2  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1N)...O(1)#1 0.85(2) 2.55(2) 3.221(2) 137(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  #1:  -x+1, y-1/2, -z+1/2.       
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Table 10. Torsion angles [°] for C13H15NO2. 
________________________________________________________________  
C(6)-N(1)-C(1)-O(2) 174.14(14) 
C(6)-N(1)-C(1)-C(2) -3.6(2) 
O(2)-C(1)-C(2)-C(4) 134.64(15) 
N(1)-C(1)-C(2)-C(4) -47.60(19) 
O(2)-C(1)-C(2)-C(13) -77.30(19) 
N(1)-C(1)-C(2)-C(13) 100.46(16) 
O(2)-C(1)-C(2)-C(3) 67.06(19) 
N(1)-C(1)-C(2)-C(3) -115.18(15) 
C(13)-C(2)-C(3)-C(4) -108.64(16) 
C(1)-C(2)-C(3)-C(4) 108.07(15) 
C(5)-O(1)-C(4)-C(3) 146.49(13) 
C(5)-O(1)-C(4)-C(2) 78.09(16) 
C(2)-C(3)-C(4)-O(1) -109.49(14) 
C(13)-C(2)-C(4)-O(1) -149.00(14) 
C(1)-C(2)-C(4)-O(1) -2.2(2) 
C(3)-C(2)-C(4)-O(1) 103.76(16) 
C(13)-C(2)-C(4)-C(3) 107.24(16) 
C(1)-C(2)-C(4)-C(3) -105.93(15) 
C(4)-O(1)-C(5)-C(6) -49.44(17) 
C(1)-N(1)-C(6)-C(7) -163.39(14) 
C(1)-N(1)-C(6)-C(5) 74.07(19) 
O(1)-C(5)-C(6)-N(1) -40.19(18) 
O(1)-C(5)-C(6)-C(7) -163.35(13) 
N(1)-C(6)-C(7)-C(12) 123.87(15) 
C(5)-C(6)-C(7)-C(12) -112.82(17) 
N(1)-C(6)-C(7)-C(8) -57.22(19) 
C(5)-C(6)-C(7)-C(8) 66.09(18) 
C(12)-C(7)-C(8)-C(9) 0.4(2) 
C(6)-C(7)-C(8)-C(9) -178.51(14) 
C(7)-C(8)-C(9)-C(10) 0.2(2) 
C(8)-C(9)-C(10)-C(11) -0.4(2) 
C(9)-C(10)-C(11)-C(12) -0.1(2) 
C(10)-C(11)-C(12)-C(7) 0.8(2) 
C(8)-C(7)-C(12)-C(11) -0.9(2) 
C(6)-C(7)-C(12)-C(11) 178.01(15) 
________________________________________________________________  
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